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MyoD or Myf5’s requirement for developmental myogenesis has been well established.
However, their roles in adult myogenesis, regeneration after injury, were not precisely known
due to the perinatal lethality of MyoD-null and Myf5-null mice. To circumvent that we created a
conditional floxed allele of MyoD, MyoDcKO, that together with CreER allows temporal control of
MyoD deletion. This combined with other mutant alleles of MyoD and Myf5, as well as
Pax7CreER, allows us to efficiently delete MyoD and Myf5 in satellite cells, the indispensable adult
skeletal muscle stem cell.
Using this system, we show that at least a single allele of MyoD of Myf5 is necessary for
adult myogenesis in vivo and in vitro. No other genetic or cellular factor can compensate for
their loss. Satellite cells that lack both myogenic factors cannot upregulate Myog, a skeletal
muscle differentiation gene, and they cannot fuse to form multinucleated myotubes. We also
show that ~10% of double-null satellite cells differentiate into lipid droplet containing, mature
adipocytes. The remaining cells take retain some myogenic characteristics, but also express
fibroblastic markers. Finally, we reaffirm that MyoD is a more potent driver of adult myogenesis
than Myf5, with satellite cells that contain only a single allele of Myf5 being more open to
adipogenic differentiation, though not to as great of an extent as double-null satellite cells.
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Chapter 1 Introduction:
Skeletal muscle comprises over 40% of a human body by weight. It is required for
mobility and breathing. The parenchymal cells of skeletal muscles are called myofibers and like
cardiac muscle cells, they are striated. However, they are unique in two ways; 1) they can be
among the largest cells in the human body and 2) they are syncytial. Myofibers are post-mitotic;
they cannot replenish their numbers after injury. For that they depend on the adult muscle stem
cell known as the satellite cell. Satellite cells are the predominant adult muscle stem cell,
without which skeletal muscle cannot regenerate. In contrast to large multinucleated myofibers,
satellite cells are small, mononuclear and mitotically quiescent. Upon injury they become
activated, upregulate myogenic genes MyoD and Myf5 and undergo several rounds of
proliferation. This thesis focuses on the roles of MyoD and Myf5 in adult myogenesis and the
fates of satellite cells that lack them. This introduction discusses background information on
developmental and adult myogenesis. Almost all this data is from using mice or isolated mouse
cells as a model system.
1.1 Developmental Myogenesis
An ongoing question in the muscle field is how closely does adult myogenesis
recapitulate developmental myogenesis? Are there significant differences in terms of the roles
of genes? To address that, this thesis will give current knowledge on muscle formation in
development.
1.1.1 Basic Steps of Developmental Myogenesis
Skeletal muscle is ultimately derived from the mesoderm, a component of which, the
paraxial mesoderm, is the source of all skeletal muscle.1 The paraxial mesoderm forms the
cranial paraxial mesoderm, becoming some of the muscle of the head, and it forms the somites.
Somites are epithelial balls of cells that, amongst other tissue, give rise to the skeletal muscle of
1

the trunk and limbs, and some parts of the head musculature. Over time they lose their ball-like
shape and become the sclerotome, syndetome, dermamyotome and myotome.2 The
demamyotome and myotome form myoblasts; these are mononuclear cells that eventually fuse
with each other and give rise to myofibers. The lateral portion of the somites form hypaxial
muscles, while the medial part forms epaxial muscles including the limbs. Developmental
myogenesis is considered to consist of two phases, primary (embryonic) and secondary (fetal)
myogenesis. In primary myogenesis the first myoblasts and myotubes are formed and serve as
a scaffold; this is completed mainly by embryonic day (E) 14.5. Secondary myogenesis, which
creates the majority of myofibers, beings around E14.5 and consists of myoblasts fusing into
primary myofibers and creating new ones adjacent to them as well, finishing around E17.5.3
During this complex ballet of cell migration, proliferation, specification, differentiation, and
fusion; numerous important genes are activated, these include Pax3, Pax7 and the myogenic
regulatory factors (MRFs).
1.1.2 Prominent Genes Involved in Developmental Myogenesis
Before developmental myogenesis occurs, Pax3 and Pax7, two paired homeobox
transcription factors, are expressed in, among other cells, progenitors of skeletal muscle.4
Pax3 is the first to turn on, being seen in the mesoderm and somites, and later the
dermomyotome. While not many direct targets have been found, it does upregulate c-met, an
important muscle gene in development responsible for cell migration, Itm2a, a gene upregulated
in muscle differentiation, and an enhancer of Myf5 and possibly also MyoD, though more on the
those latter two genes later. 5–7 Perhaps most importantly, Pax3 directly influences cell fate.
Control of cell fate and programming are important concepts to note, ones that will come up
many times in this dissertation, and Pax3 is a prime example of a protein influencing cell fate
decisions. Pax3 negatively regulates Foxc2¸and the reverse is true as well.8 While Pax3
protein is important for skeletal muscle development, Foxc2 is important for smooth muscle,
2

vasculature, brown fat, bone and cartilage.9 In the dermomyotome, cells with high Pax3
expression go on to become muscle, while those with high Foxc2 expression become
vasculature. Later in myogenesis, Pax3 controls Fgrf4 and Sprouty expression which influence
myoblast proliferation and differentiation, respectively.10 Upon activation of the MRF Myf5, Pax3
is downregulated in fetal muscle.11 Mutations in Pax3 (Splotch mice) are embryonic lethal and
these mice, among other issues, have abnormal epaxial muscles and no limb musculature. The
latter is due to a failure in cell migration to the limbs.12 It is important to note that early myotome
formation is Pax3 independent, and primary myogenesis occurs without it. Pax3 is necessary
for limb myogenesis and is upstream of the MRFs in that context. Another important upstream
factor is Pax7, a paralog of Pax3.
Like Pax3, developmental expression of Pax7 is not limited to the myogenic linage. With
respect to skeletal muscle, it is first expressed in the central part of the dermomyotome, while
Pax3 is expressed in almost all myogenic progenitors outside of the head. During fetal muscle
development, Pax7 is upregulated in myogenic cells in the limbs, while Pax3 is heavily
downregulated.13,14 Pax7 maintains expression until myogenic differentiation occurs, then it is
downregulated greatly in muscle cells.11 Also, unlike Pax3, Pax7 maintains expression in a
larger subset of cells that become adult muscle stem cells (satellite cells). Pax7 mutant mice
survive through birth with the same number, but smaller myofibers, and in general they are
smaller than wild-type littermates.15 These mice have satellite cells; however, satellite cell
numbers quickly decline in the first few weeks of life. Further defects were seen in adult
myogenesis. This indicates that Pax7 is not necessary for developmental myogenesis, and that
other factors like Pax3 can compensate in its absence.16 Pax3 and Pax7 demonstrate another
important concept that this dissertation addresses; that of genetic redundancy and overlapping
and distinct roles of related genes; a topic that appears several times in this writing. While they
lack limb muscles, Pax3-null mice contain muscle derived from the central dermomyotome,

3

because Pax7 is expressed there and able to partially compensate for the lack of Pax3.
However, it cannot completely fill Pax3’s role. They have partially overlapping roles, but each
has its own distinct functions. In the double Pax3/Pax7 mutant, many cells undergo apoptosis,
and only very few myofibers from the early myotome are present, suggesting that nothing can
compensate for the loss of both of those genes.13 While the Pax genes play important roles in
development, they only set the stage for myogenesis. The MRFs are the true stars of myogenic
determination and differentiation.
1.1.3 MRFs
Experiments in the early 1980’s using heterokaryons (fusions between two cells with
both individual nuclei in a common cytoplasm) of human amniocytes and mouse muscle cells,
as well as chick myocytes and rat neural cell lines showed that the amniocyte and neural nuclei
synthesized human and rat muscle proteins, respectively.17,18 These experiments suggested
the presence of a transactivating factor from the myonuclei that could convert non-muscle nuclei
to myogenic ones. In addition, in experiments where 10T1/2 cells (mouse embryo fibroblasts)
were treated with 5-azacytidine, an inhibitor of DNA methyltransferase that can allow
demethylation to occur, many of those cells underwent a conversion to a myogenic lineage;
some of the experiments were consistent with very few loci being demethylated.19,20 These
discoveries lead Davis, Weintraub and Lassar to search for the underlying genetic cause of
these myogenic conversions. Through subtractive hybridization of 10T1/2 cells and myoblasts,
they discovered particular cDNA, that when transfected into fibroblasts and preadipocyte cell
lines, transdifferentiated them into skeletal muscle.21 This cDNA was from MyoD1 (MyoD),
myogenic determination gene number 1. It was also found to transdifferentiate other cell types
into skeletal muscle.22,23 In the years that followed MyoD’s discovery, three more important
skeletal muscle transcription factors were found, Myf5, MRF4 (Myf6), and Myog.24–27 All of
these genes contain highly conserved basic helix-loop-helix domains.28 They, with very few
4

exceptions, are only expressed in skeletal muscle or its direct progenitors, and all of them can
transdifferentiate certain other cell types to skeletal muscle.
1.1.4 MRFs in Developmental Myogenesis
During primary myogenesis Myf5 is the first MRF to turn on; it appears in the
dermomyotome at E8.0. It also precedes other MRF expression in the limb buds 29. MRF4 is
not far behind, being expressed at E9.0. These Myf5/MRF4+ cells form the myotome. Myog is
expressed in these cells to form the first mononuclear myoblasts. At around E10.5 Pax3/Pax7+
cells from the dermomyotome come in and add to the myotome. MyoD is not expressed until
~E9.5 in the hypaxial myotome, and shortly thereafter in the epaxial as well

30

. MyoD and Myf5-

expressing cells in the hypaxial myotome migrate into the limb for limb muscle formation.
Secondary myogenesis consists of Myf5/MyoD+ myoblasts proliferating, differentiating with
myogenin and re-expression of MRF4 and fusing with each other and existing myofibers.
Specification, determination, and differentiation are important concepts in developmental
biology. Starting from the end, a differentiated cell is the final form of a specialized cell. It is
functional and does work. A cell that is determined is one that is fated to differentiate into a
particular cell type, even if transplanted to another region of the organism. A specified cell is
one that will differentiate into a particular cell type in a neutral environment. However, a
specified cell’s fate is malleable, while a determined cell’s fate is generally not. While Pax3 and
Pax7 are involved in specification, the MRFs are involved in skeletal muscle determination and
differentiation. In addition to the transfection studies, much of the functions of the MRFs were
elucidated via constitutive knockout (KO) models. With one exception, single MRF gene KOs
show minor defects in developmental myogenesis.
MyoD-null mice are viable and are born in the predicted mendelian ratio. However, in
mixed litters with wild type and heterozygotes, 2/3 of the MyoD-null mice die between birth and
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weaning (3 weeks of age). In terms of developmental myogenesis, these mice only feature
minor differences from wild type mice. There is a 2.5-day delay in muscle development of the
limb buds and brachial arches, i.e. epaxial muscles, and Myf5 is upregulated in the
heterozygote and even more in the homozygote.31,32 The increase in Myf5 expression suggests
that Myf5 and MyoD have a level of redundancy.
Myf5-null mice are also viable and feature minor skeletal muscle differences from wild
type mice. Namely, Myog is not turned on until after MyoD’s appearance at E10.5, indicating
that it is downstream of both MyoD and Myf5 activation, and there is a delay in myotome and
hypaxial muscle formation, otherwise skeletal muscle is normal.33,34
Surviving KOs of MRF4 had normal skeletal muscle with a slight reduction in
differentiation muscle genes of neonates, and a large increase in Myog expression.35 Increased
Myog expression in these mice suggests that it and MRF4 have a level of redundancy.
Mice that lack Myog have the most severe phenotype of the single KOs. They die shortly
after birth, have abnormal curves in their spines and ribs, increased brown fat and have
extremely reduced skeletal muscle tissue with very few disorganized myofibers to none in some
regions.36,37 These mice do have many cells including myoblasts in the muscle-forming regions
that express MyoD in similar amounts to wild-type mice at E15.5. However, that expression
does not last past its normal window and these myoblasts do not fuse or differentiate further;
many other muscle genes are downregulated in the skeletal muscle regions of Myog-null
neonates. While Myog-null myoblasts have a severe differentiation defect in vivo, in vitro fetal
myoblasts from those mice can differentiate into multinucleated myotubes. This indicates that
Myog is required for efficient in vivo developmental myogenesis, specifically for differentiation of
myoblasts into multinucleated myofibers, but other genetic factors may substitute for it in
culture.36,37 It is a myogenic differentiation factor.
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Myogenin is not the only published “single” MRF to feature rib defects. The original two
Myf5-KOs as well as two of the three MRF4-null mice featured severe rib defects that in most
cases caused perinatal death. The Myf-5m1 and Myf-5a2 mice lacked the distal portions of ribs
and died shortly after birth. These mutations involved the insertion of a PGK-Neo cassette or
lacZ gene in exon one, respectively.33,34 Of the three published MRF4 mutations, MRF4(Wold),
MRF4(Arnold), and MRF4(Olson) all featured rib abnormalities. MRF4(Olson) mice were the
least severe and the only one with all MRF4-null mice surviving to adulthood; MRF4(Wold)
featured incomplete attachment to the sternum and very few mice living to adulthood, and
MRF4(Arnold) had the same rib phenotype as the Myf5-null mice with complete perinatal
lethality.35,38,39 Myf5 and MRF4 are only 8.7 kb apart in the mouse. What was later discovered
is that in these fatal Myf5 and MRF4 mutations, the inserted selection cassettes or genes
negative affected the expression of the other nearby MRF by disrupting cis regulatory
elements.40,41 The MRF4 mutations, with the exception of MRF4(Olson) abolished Myf5
expression, while the Myf5 mutations negative affected early MRF4 expression. Thus, these
“single” KOs were actually full or partial-double KOs, affecting both Myf5 and MRF4. In the
early 2000s newer null alleles of Myf5 were created that did not negatively affect MRF4
expression.
1.1.5 Compound mutations
In the absence of any one factor, with the exception of Myog, skeletal muscle is largely
normal. This suggest that there is some functional redundancy in the MRFs. While most single
KOs of the MRFs showed very few gross defects in developmental myogenesis, compound
mutants tell a different tale. The first planned double mutation was a MyoD/Myf5-null mouse.
However, researchers used a Myf5-null mouse whose early MRF4 expression was negatively
affected as well, so they actually studied developmental myogenesis in a MyoD/Myf5/partialMRF4 triple KO (tKO).42 The tKO mice were born but lacked skeletal muscle and died shortly
7

after birth. These mice also lacked myoblasts and skeletal muscle-specific mRNAs. Increased
adipose and connective tissue filled the place of skeletal muscle, some of which were derived
from presumptive myoblasts.43 The investigators also looked at differing allelic combinations of
MyoD and Myf5(early MRF4) finding that amongst the two, having one allele of MyoD or Myf5 is
sufficient for developmental myogenesis, though mice with one allele of Myf5 and lacking early
MRF4 were smaller with ~35-55% fewer myofibers.
A true constitutive double KO (dKO) mouse was generated by combining the original
MyoD-null mouse with a new Myf5-null allele, Myf5loxP/loxP.41 This minimally disruptive null-allele
was generated through excising only the transactivation domain of Myf5, leaving the majority of
the Myf5-locus and wild-type-like MRF4 expression intact. Pax3+ cells migrate into the limbs of
these dKO mice, though they do not form muscle. However, the researchers found that MRF4
can determine skeletal muscle fate in the absence of MyoD and Myf5, as indicated by Myog and
MyHC protein in the embryo. Regardless, developmental myogenesis was incomplete and
these true MyoD/Myf5-null mice were born with almost no skeletal muscle. Therefore, MyoD
and Myf5 have overlapping roles in determining skeletal muscle fate, and MRF4 can act as a
determination factor, but not as efficiently as MyoD or Myf5. They also demonstrated that MyoD
expression is only delayed in the Myf5/MRF4-null mice, indicating that both are genetically
upstream of it. Interestingly, like the Myog-null samples, in vitro these dKO embryonic myoblasts
were able to form myotubes, suggesting that MRF4 can drive myogenesis in culture better than
it can in vivo.
Over the years other dKO combinations were examined in order to find more potential
genetic redundancy. MyoD/Myog or Myf5/Myog dKO mice are similar to Myog-null mice in that
muscle does not form in vivo, but it does in vitro.44 This suggests that MRF4 can act as a
differentiation factor. MRF4/myogenin mutants had a similar phenotype to myogenin-null mice,
sparse myofibers in vivo, with MyoD potentially acting as a differentiation factor in vitro.45 To
8

sum up the developmental KO work, Pax3 and Pax7 can specify cells to the myogenic fate.
MyoD and MRF4 can function both as determination factors and also as differentiation factors.
Myf5 functions only as a determination factor, and Myog only as a differentiation factor. See
Table 1 for a summary
1.1.6 DNA Binding and Molecular Functions of the MRFs
A major question in the skeletal muscle field, and in developmental biology in general is
how do master regulators like the MRFs cause these large cascades that commit cells to
specific lineages and differentiate them. This has been somewhat elucidated using molecular
biology with respect to the MRFs. In fact, much of the molecular functions of the MRFs has
been researched via induced MRF transcription in vitro and with C2C12 cells, an immortalized
mouse skeletal muscle cell line; all of which may not completely recapitulate developmental or
adult myogenesis. A simplistic model is that MyoD and the other MRFs bind to the enhancers
and promoters of skeletal muscle genes to activate transcription of those genes, committing
cells to the myogenic lineage and differentiating them. And indeed they do that.46 However,
just like the central dogma of molecular biology is a simplification, so too is this. Early studies of
MyoD found that it and the other MRFs can form homodimers to bind promoters and enhancers
of skeletal muscle genes to help initiate transcription. Though, when they form heterodimers by
binding with E-proteins HEB, E12, or E47, they have a much higher affinity of binding to the
genome.47 Structurally, the basic portion of the MRFs are required for binding DNA and
activation, and the HLH region is necessary for dimerization. Specifically an alanine and
threonine in the basic domains of the MRFs are necessary for myogenic induction in all muscle
bHLH proteins from worms to humans.48 MRF heterodimers bind to E-box sequences
(CANNTG).49 It was later found that MyoD has a “private” E-box sequence, including a flanking
sequence of VCASCTG, where V ≠ T and S = G or C.50
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However, even with the “private” E-boxes, there are potentially millions of locations on
the genome where the MRFs can bind, and ChIP-seq data show that MyoD and Myf5 bind to
thousands of places on the genome, not only at skeletal muscle genes, but also many other
locations.51,52 Further complicating cell programming is the fact that other master regulators,
e.g. NeuroD2 a master regulator for neurons, can bind a shared (with respect to MyoD)
CAGCTG E-box motif.53 Binding at shared sites is associated with regional epigenetic
modifications, namely histone acetylation, and binding of the transcription factor’s individual
private sites is more associated with gene transcription. Generating a mutant of MyoD that had
the DNA-binding specificity of NeuroD2 showed that this mutant could bind both NeuroD2 sites
and a subset of MyoD-specific sites activating both neuronal and myogenic genes, suggesting
that even though MyoD and NueroD2 are not that similar outside of their bHLH domains,
binding location and affinity gives these master regulators the ability to commit cells to specific
lineages.54
While the MRFs can transdifferentiate many cell types into skeletal muscle, there are
certain cells that are resistant to that, e.g. forced MyoD expression cannot change P19 cells, an
embryonic carcinoma cell line, into muscle, while NeuroD2 can convert them into neurons.55
Though, MyoD can convert mouse embryonic fibroblasts (MEFs) into skeletal muscle, while
NeuroD2 cannot convert them into neurons. Researchers showed that binding accessibility and
chromatin structure in those cell lines were important, i.e. more NeuroD2 private sites were
available for binding in P19 cells than in MEFs.53 However, it is not known exactly how these
cells become specified for this lineages.
To complicate things even further, there repressor of myogenesis; proteins like Id2 that
can heterodimerize with E-proteins and proteins like Snail1 that bind to E-boxes which rob
MyoD of its binding partner and site, respectively.56 Building something like a genetic regulatory
network by taking all of this into account for skeletal myogenesis remains an elusive task.
10

When it comes to the individual MRFs, there are many similarities between them. For
instance, MyoD and Myf5 have very similar bHLH domains but differing amino- and carboxylterminal domains. Both proteins bind to the same loci and induce histone acetylation via
interactions with histone acetyltransferases, however, MyoD better recruits Pol II and induces
transcription particularly well at muscle genes.57,58 MyoD and Myf5 tend to activate proliferation
genes as well as muscle differentiation genes, with MyoD being a better activator of
differentiation genes, though not as good as Myog. Myog can bind to the same loci as MyoD,
but does not induce chromatin remodeling, instead relying on the other MRFs as pioneering
factors in order to induce transcription.59,60 While the MRFs do induce many skeletal muscle
genes, they cannot do it alone and often interact with other essential transcription factors for
muscle differentiation; some examples are the myocyte enhancer factor 2 family of genes
(Mef2), as well as other cooperative coactivators like Pbx and Sp1.61,62
Much of the regulation of the MRFs, particularly in development, is through their
enhancers that help specify temporal and spatial expression. MyoD expression is mostly
regulated through its two enhancers, the core enhancer and the distal regulatory region, with the
former being more involved in myoblast determination and the later in differentiation, though
more most likely exist, as deletion of the known enhancers does not ablate MyoD
expression.30,63 Myf5, Six1/4, Pitx2 and Foxo3, have been shown to be necessary for MyoD
activation; MyoD also has the ability to auto-regulate.
Myf5 and MRF4 have many enhancers that specify temporal expression.40 The earliest
activation of Myf5 is through Wnt and Shh signaling via Myf5’s early epaxial enhancer. Later
Pax3 and Six1/4 work together to regulate Myf5.64 MRF4 and Myf5’s physical proximity has
also lead to the discovery of transcription balance sequences (TRABS). These TRABS are
involved in equilibrium states between enhancers and promoters and specify MRF4 and Myf5
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expression. Myog is mainly regulated by a 4kb sequence upstream of it by MyoD in
combination with FoxO3 and other transcription factors.65,66
1.2 Postnatal Myogenesis and Satellite Cells
Developmental myogenesis mostly originates from the somite. It is complete by E17.5.
After that additional myofibers are no longer created.67 However, there is tremendous growth of
myofiber size after birth, as well as the regeneration of myofibers after injury. This growth and
regeneration is dependent upon the adult muscle stem cell known as the satellite cell.
1.2.1 Satellite Cells
Satellite cells were first described 57 years ago in frogs by Alexander Mauro and
independently by Bernard Katz in the same month via electron microscopy of myofibers.68,69
They were named satellite cells due to their location, on the periphery of myofibers. Since then,
they have been found in many other species like humans and mice; similar cells have even
been found recently in drosophila and zebrafish.70,71 At the time of their discovery it was known
that skeletal muscle had quite a capacity for regeneration, but the cellular and genetic
mechanisms behind it were unclear, and nothing was known about satellite cell origin or
function. Mauro even mentions that with regards to muscle regeneration, “[m]ost cytologists
lean toward the interpretation that surviving nuclei in the damaged multinucleate muscle cell
give rise to single cells by ‘gathering up’ cytoplasm from the sarcoplasm of the muscle cell”.68
Though he noted that cardiac muscle, also striated, which lacks regenerative abilities, also lacks
satellite cells. Over the years much has been elucidated about satellite cell function,
heterogeneity, and mechanism of action. However, much remains to be explored.
A scientific history of satellite cells in a review by Scharner and Zammit tells that
scientists have known about skeletal muscle regeneration since the mid-19th century.72
However, most thought the damaged myofibers themselves were responsible for muscle
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healing. It was not until the 1950’s and 60’s that it was discovered that myofibers were postmitotic and the regeneration of skeletal muscle in many organisms was due to myoblast cell
fusion. Further experiments, including transplantations of single myofibers with satellite cells,
up through the 1970’s finally proved that satellite cells were mainly responsible for muscle
regeneration and postnatal muscle growth. In fact, transplantation of labeled, single satellite
cells can give rise to both myofibers and satellite cells in the recipient mouse, indicating that
satellite cells are bona fide adult muscle stem cells, as they can give rise to differentiated tissue
as well as repopulate the satellite cell niche.73 However, it would take until the 21st century to
demonstrate that satellite cells were indispensable for muscle regeneration.
1.2.2 Satellite Cells as Stem Cells
Stem cells can self-renew and give rise to differentiated cell types. The predominant
evidence that satellite cells are muscle stem cells is the following: they can become
differentiated multinuclear muscle cells. Culturing satellite cells gives rise to multinucleated
myotubes in low serum conditions.74 In vivo it has been shown that labeled satellite cells also
give rise to labeled myotubes after injury or during homeostasis.73,75 Satellite cells can also give
rise to themselves in vivo, meaning that they repopulate the satellite cell niche and can
participate in future rounds of adult myogenesis. In fact, satellite cells are so good at
regenerating skeletal muscle, that mice can sustain upwards of 35 cycles of injury and still form
abundant normal myofibers.76 And satellite cells are so potent that the transplantation of a
labeled single satellite cell can contribute to muscle regeneration and replenishment of
quiescent satellite cells in their niche.73 Not only are satellite cells adult muscle stem cells, they
are also indispensable for adult myogenesis. Two labs ablated satellite cells in adult mice and
found that in their absence, muscle regeneration is non-existent.77,78
1.2.3 Satellite Cells During Development
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The developmental origins of satellite cells are not completely clear. Through chick-quail
transplantation studies it was found that trunk and limb satellite cells originate from somites and
the dermomyotome.79–81 Head musculature satellite cells come from cranial mesoderm.82
Though it is not known how satellite cell progenitors differ from developmental myogenic cells,
i.e. cells that directly become skeletal muscle. Eventually these satellite cell progenitors
become closely associated with myofibers and around E16.5 to E18.5 a basal lamina forms
around them and myofibers.83 This forms the satellite cell niche, i.e. satellite cells lay outside
the plasma lemma of myofibers, but beneath the basal lamina. These perinatal satellite cells
are very active and numerous, composing up to 35% of sublaminal nuclei in some muscles.84
They are responsible for postnatal myofiber growth and they do this by continuing to proliferate
and by fusing with myofibers until about 2-4 weeks after birth when mostly only quiescent
satellite cells remain (those in Go). These quiescent satellite cells account for only 4-7% of
sublaminal nuclei at this stage in most body muscles.67 The mechanisms by which satellite cells
stop proliferating and become quiescent during postnatal growth are not completely understood.
Genetically during development trunk and limb satellite cell progenitors express Pax3
and Pax7; all satellite cells of the body maintain Pax7 expression, while only a subset in the
trunk and forelimbs maintain Pax3 expression.15,85 Regardless of anatomical location, during
development virtually all satellite cells express MyoD and MRF4, and 90% express Myf5.86–88
However, these results are based upon inducible reporter expression which are dependent
upon expression of Cre knocked into the MRF locus.
1.2.4 Cre-loxP
Many hypotheses and advancements in developmental biology have been because of
Cre-loxP technology. Discovered in the E. coli bacteriophage P1, the Cre-loxP system can be
used in eukaryotic cells to delete selected sequences of DNA.89 Two elements are required for
this recombination: Cre recombinase and two loxP sites. loxP sites are palindromic 34-bp
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sequences of DNA that consist of 13-bp inverted repeats separated by an 8-bp sequence. Cre
recombinase recognizes two loxP sites, and depending on their orientation, can excise the DNA
between them, leaving only a single chimeric loxP site. Two of the biggest uses of this
technology in developmental biology are lineage tracing and the nullification of a gene in certain
cell types. Previously, many lineage tracing experiments relied upon injecting dyes into cells, or
with cell transplantations, either interspecies, or through labeled cells. However, both of those
methods have severe limitations, injectable dyes can diffuse or become dilute upon multiple cell
divisions, and transplanted cells do not always behave like endogenous cells. Cre-loxP in
conjunction with an inducible reporter can circumvent this. An example of an inducible reporter
is the R26NG allele created by the Goldhamer lab.90 R26NG features a strong constitutive
promoter followed by a floxed PGK-Neo stop cassette and finally eGFP knocked into the
Rose26 locus. The Rosa26 locus is transcriptionally active in most mouse tissues in
development and in the adult.91,92 Therefore, in MyoDiCre/+; R26NG/+ mice, any cell that
expresses or has progenitors that expressed MyoD will be GFP+, because Cre recombinase
has been knocked into the first exon of MyoD and is under the control of the endogenous MyoD
promoter. This technology has furthered lineage tracing experiments and allowed for the
previously mentioned results of satellite cell progenitors expressing MyoD, Myf5, and MRF4.
However, a very important caveat to note is that reporter expression only indicates that the Cre
locus is transcriptionally active, NOT that there is or would be functional protein product of the
endogenous gene. That said, almost all satellite cells have transcriptional activity at the MyoD
and MRF4 loci, and 90% of them at the Myf5 locus during development, and satellite cells are
present in the absence of any individual MRF listed. Another important result from Cre-based
lineage tracing studies (in addition to knocking-in reporters at the MRF loci) was determining the
transcriptional fidelity of the MRFs. All of the MRFs are almost exclusively expressed in skeletal
muscle or it progenitors.87,88,93 However, Myf5 also has current expression in the adult brain,
and historic expression in some white fat depots.94,95 The combination of the fidelity of MRF
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expression to skeletal muscle, and that satellite cells developmentally express three of the
MRFs suggests that satellite cells are primed for commitment to the myogenic lineage.
In addition to recombination upon Cre expression, fusing Cre with a mutated human
estrogen receptor creates CreER. CreER allows temporal control over recombination, because
CreER cannot access the nucleus until the administration of tamoxifen or 4-OH tamoxifen to an
animal.96,97 Using CreER can give both spatial, based on the promoter which it is under, and
temporal, based on when one administers tamoxifen, control. This allows for a larger variety of
experimental design and gives researchers the ability to delete genes in an adult organism,
particularly genes whose deletion would be embryonic lethal.
1.3 Adult Myogenesis
After about 4-6 weeks of postnatal growth, satellite cells decrease in number and
become mostly mitotically quiescent. During normal myofiber lifespans, satellite cells can
become active and can contribute to muscle homeostasis, the extent of which is dependent on
specific muscle and myofiber type.75 However, where satellite cells really shine is in adult
myogenesis, muscle regeneration. A brief summary: myofibers become necrotic and
degenerate upon injury. Many infiltrating cells like macrophages and neutrophils remove debris
from the damaged site. While this is happening satellite cells become activated, they
upregulate MyoD and Myf5 and undergo several rounds of proliferation. They then come to a
fate decision, the majority of them upregulate Myog and other muscle differentiation genes and
fuse with each other to create new myofibers. A small subset downregulates MyoD and Myf5,
maintains Pax7 expression and returns to quiescence and the satellite cell niche, thus
replenishing their numbers for future rounds of regeneration. It has been shown that while other
cells can contribute to muscle fibers, satellite cells are absolutely essential for adult
myogenesis, ablation of them results in complete loss of regenerated muscle.77 Most mouse
studies of regeneration involve injuring the tibialis anterior muscle of a mouse with a chemical,
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toxin, or physical injury and assessing the regenerative processes through histological, and
molecular genetic techniques.98 It should be noted that upwards of 80-90% of satellite cells die
from these injuries as well, suggesting that satellite cells have enormous proliferation
capabilities.99,100
1.3.1 Satellite Cell Quiescence and Activation
Quiescent satellite cells are in a reversible Go state, they are mitotically non-active, but
they do express markers that can be used to identify and isolate them, including Pax7 (which in
adult mouse muscle is only expressed in satellite cells, both quiescent and activated) mcadherin, α7-integrin, V-CAM1, and CD34, amongst many others.15,101–104 However, most of
those markers are not unique to satellite cells in skeletal muscle. There are also many genes
expressed in quiescent satellite cells that help maintain and return to that state; genes like p27,
Suv4-20h1, Notch, and Spry1; the loss of any of those promotes precocious differentiation of
satellite cells and impairs the maintenance of or return to quiescence.105–108 Quiescent satellite
cells are also primed for activation. Myf5 expression has been found in at least 90% of
quiescent satellite cells88 This mRNA is sequestered in mRNP granules that are disrupted and
that mRNA can be quickly translated into protein upon injury.109 However, another group claims
to have detected actual Myf5 protein in quiescent satellite cells.110
Satellite cell activation requires signals and mitogens that can come from injured muscle
and other cells. These signals cause satellite cells to become active, enter the cell cycle, divide,
and also chemotax.111,112 These mitogens include growth factors like hepatocyte growth factor,
platelet-derived growth factor, vascular endothelial growth factor, as well as factors like Ang II
and nitric oxide.113–117 These factors can directly interact with receptors on the surface of
satellite cells or indirectly through the surface of the basal lamina (if it is still intact after injury)
and the extracelluar matrix (ECM).118 It is important to note that damage to part of a muscle
fiber activates all the satellite cells along that fiber, regardless of their proximity to the injured
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area, though there is still debate on whether satellite cells can travel between fibers.119–121
Interestingly, it was recently found that when one limb of a mouse is injured, satellite cells in the
contralateral limb undergo a sort of priming via HGF signaling; this has been dubbed Galert.122
This state features a larger satellite cell size, a faster time to division compared to quiescent
cells, but not as fast as activated cells, and increased transcriptional activity, but no MRF protein
expression.
Upon activation and commitment to the cell cycle, satellite cells increase in size, contain
more cytoplasm and have less heterochromatin.123 One of the most prominent and defining
changes is the upregulation of MyoD and Myf5. Initial upregulation of MyoD and Myf5 occurs 26 after injury, while the vast majority of satellite cells express either MyoD or Myf5 24 hr after
injury, and both MRFs by 48 hr. Culturing of satellite cells shows that ~100% of them express
MyoD 24 hr after isolation.124–126 There are several rounds of massive proliferation, and then
Pax7 is downregulated, while MyoD maintains expression and Myog is upregulated in the
majority of the cells in order to differentiate them.127 These cells go on to further express
muscle differentiation genes like myosin heavy chains, fuse with each other and existing
myofibers to repair the skeletal muscle.128 Recently two necessary fusion proteins were
discovered, Myomaker and Myomixer (also known as Minion and Myomerger), as well as a
negative regulator Rspo1.129–132 Remarkably, all this activation, proliferation, differentiation,
fusion and return to quiescence is essentially completed within ~14 days after relatively mild
injuries to mouse hind limb muscle.
1.3.2 MRFs+ During Adult Myogenesis
A major question in the myogenesis field is how much adult myogenesis recapitulates or
differs from developmental myogenesis. One way of looking at this is examining the roles of the
MRFs in adult myogenesis. Similar gene knockout studies have been conducted in muscle
regeneration with the following results. Much like developmental myogenesis, mice that lack
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MyoD or Myf5 mice feature minor defects in adult myogenesis. MyoD-null mice contain more
satellite cells than wild-type mice and have a delay in regeneration after injury.133–137 Though,
full regeneration does eventually take place. MyoD-null satellite cells are also deficient in
myotube formation in vitro, forming nowhere near the number of myotubes compared to
wildtype cells. It was found that MyoD-null satellite cells have lower expression of musclespecific genes and apoptotic genes as well as upregulation of stem cell markers and antiapoptotic genes.133,138 Myf5-null mice have little to no difference to wildtype mice in terms of
regeneration time. Though they do undergo precocious differentiation and have a slight
impairment in proliferation in early stage cultures.100,137
While MRF4 has the greatest expression of the MRFs in adult myofibers and is
upregulated in their nuclei during injury, it is not expressed during any part of satellite cell
quiescence, activation, early differentiation or fusion; no regeneration defects were reported in
MRF4-null mice.139,140 In mice where Myog was deleted in all cells after birth via an inducible
Cre-loxP system, it was found that it is not necessary for postnatal myogenesis.141 Mice were
smaller than wildtype littermates, but they grew, and their satellite cells were able to form
multinucleated myotubes in culture, though during differentiation they had increased levels of
the three other MRFs compared to wildtype mice.142 Myog was also found to be dispensable in
mdx mice; mdx mice are a model of muscular dystrophy which features repeated skeletal
muscle degeneration and regeneration.143
In addition to the MRFs, it was found that both constitutive and induced during adulthood
deletion of Pax7 negatively affects muscle regeneration. Constitutive Pax7-null mice have
satellite cells, but their numbers decline greatly over a period of a few weeks, with most mice
dying by 3 weeks of age.13,15 A Pax7-null mouse was subsequently created on another
background, 129Sv/J, where some of them survived to adulthood.144 As these mice aged they
suffered from myofiber loss and muscle wasting. These mice also have severe defects after
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injury with few surviving fibers showing signs of regeneration. There were also many
adipocytes and fibrotic tissue infiltrating the muscle one month after injury. Though, isolated
satellite cells from these mutant mice were capable of differentiating into myotubes culture. In
order to investigate if current Pax7 expression is necessary for adult myogenesis, labs used
CreER to delete Pax7 in adult mouse satellite cells.145,146 The injured mice showed severe
defects in regeneration, including increased fat deposits and fibrosis, as well as inhibition of
proliferation in satellite cells. Satellite cells from these mice downregulated MRF expression in
culture compared to control cells.
1.3.3 Satellite Cell Heterogeneity and “Multipotency”
Satellite cell heterogeneity is a contentious issue in the muscle field. Almost all satellite
cells in all muscles of the body express Pax7.15 However, expression of many other markers is
not 100%, e.g. Pax3+ satellite cells are rarely found in mouse hindlimb and head, but are 50%
of forelimb satellite cells; ~85% of satellite cells express m-cadherin or CD34, and perhaps
~10% express Sca-1.13,101,147 More recent studies have taken advantage of high-throughput
technologies and found many more different markers and factors in the satellite cell
population.3,148
A 2007 paper found that 90% of satellite cells progenitors express Myf5 during
development, as well as have current Myf5 expression.88 This paper claims that the 90% of
Myf5+ satellite cells preferentially proliferate and form muscle, while the 10% of cells that have
never expressed Myf5 are the true satellite cell stem cell, and they can asymmetrically divide to
give Myf5+ and Myf5- satellite cells. However, another paper states that the true satellite cell
stem are those that have highest 10% of Pax7 expression.149 These cells have a lower
metabolic status, are slow to enter mitosis, and when they do divide, they divide asymmetrically
with template DNA strands going to daughter cells that maintain their “stemness”. Though, it is
not clear if these studies are referring to the same 10% of “stem” satellite cells. A less
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contentious issue is muscle specific satellite cell behavior. Extraocular muscle satellite cells are
larger, more active and perhaps more numerous on a per-fiber basis than their limb
counterparts; many also express Pitx2.150 Satellite cells of the head also do not express Pax7
during development, but rather afterwards.82 Studies also suggest that satellite cells from
different fiber types are functionally different.128,151 Though satellite cells transplantations from
and to different muscle types or origins are successful and can contribute to muscle
regeneration in their new location.151,152
An even more controversial issue is potential satellite cell multipotency. Research from
the 90’s and early 2000’s showed that culturing myogenic cells like C2C12 cells and satellite
cells with BMP2 can induce those cells to express osteogenic markers like alkaline phosphatase
and secrete osteocalcin, and downregulate myogenic markers.153–155 An article from 2001
suggested that satellite cells could give rise to mature osteocytes and adipoctyes as well as
myoblasts in vitro when cultured in adipogenic- or osteogenic-inducing media containing
BMPs.156 However, the results of that paper were most likely due to impure cultures; their
isolation methods did not select only for satellite cells, but rather also other stem cells in skeletal
muscle. A later paper using a specific muscle reporter system (MyoDicre with a floxed
fluorescent reporter), demonstrated that satellite cells only give rise to myoblasts and myotubes,
and that even MyoD or Myf5-null satellite cells behave the same as wildtype in that regard.157 It
should be noted that when satellite cells are cultured in an adipogenic inducing medium, they
can accumulate lipid droplets, but do not undergo terminal adipogenic differentiation.158 In vivo
under hyperglycemic conditions, muscle fibers can accumulate lipid droplets, but they do not
become mature adipocytes.159,160
More recent studies have claimed that 0.1% of satellite cells can spontaneously
differentiate into mature brown adipocytes in culture, and that this can happen in vivo under cold
exposure.161 This is caused by a lack of microRNA-133 binding to the 3’URT of Prdm16, a
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transcription factor important in brown fat determination that will convert satellite cells to brown
adipocytes in the absence of miR-133. Finally, it would be remiss of me not to mention
miRNAs, lncRNAs, and other methods of satellite cell regulation and myogenesis. However,
this introduction is long enough as it is, so I invite the curious reader to read the latest review by
Mok et al.162
This introduction has laid the background to the following questions:
1) Do MyoD and Myf5 play the same roles in adult myogenesis that they do in
developmental myogenesis, or are there alternative pathways that can compensate
for them?
2) Is historical expression of MyoD, Myf5, and MRF4 sufficient for satellite cell
determination, or is protein product after injury required?
3) What is the fate of satellite cells that lack MyoD and Myf5?
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Table 1. MRF knockout results
Gene(s)

Developmental Myogenesis

MyoD

Myf5 upregulated. Delayed Myog
expression and delayed hypaxial
muscle formation. Otherwise
normal muscle

Myf5

Myotome formation delayed,
epaxial muscle formation
delayed, mice lacked dorsal tail
muscles

MRF4

Myog

MyoD/Myf5

MyoD/MRF4

Normal muscle formation,
decreased amount of eMyHC,
Myog upregulated
Myoblasts and sparse fibers in
vivo, myotubes formed in vitro,
MRF4 upregulated
Myotome delayed, sparse
myofibers, lacks skeletal muscle,
presumptive myoblasts
differentiate into brown fat,
cartilage and bone. MRF4
responsible for what muscle
forms
Sparse muscle fibers, centrally
localized nuclei, myoblasts
present, in vitro myotubes form.
Myog at normal levels

Adult Myogenesis
Elevated number of
satellite cells in adult
mice. Delayed
regeneration. Sparse
myotube formation in
vitro
Mostly normal
regeneration
depending on KO
design, delayed initial
proliferation in vitro.
Knock-down
increased myofiber
hypertrophy
myogenin-null; mdx
mice form myotubes
in vivo

Source(s)

31,133,163–165

33,41,100,126,166

35,38,39,140,167–169

36,37,44,141,143,170

41–43,166

???????

45

N/A
44

MyoD/Myog

See Myog-null

N/A

Myf5/Myog/
(MRF4)

See Myog-null

N/A

Myog/MRF4

See Myog-null

N/A

44

45

Myf5/MRF4

MyoD/Myf5/
MRF4
MyoD/MRF4/
Myog

Myotome delayed, delayed
epaxial muscle formation,
delayed trunk muscle. MyoD
expression delayed
No myoblasts or myofibers.
Skeletal muscle location filled
with adipose and connective
tissue. Myotubes form in vitro.
Contain normal amount of
myoblasts but cannot form
myotubes in vivo or in vitro.

34,39,41,164,171,172

N/A

163,164,173

N/A
174

NA
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Chapter 2: Either MyoD or Myf5 is required for adult myogenesis
2.1 Abstract:
The requirement of either MyoD or Myf5 for developmental myogenesis has been well
studied, though their roles in adult myogenesis are not completely clear. For the first time we
present evidence that at least a single allele MyoD or Myf5 is necessary for adult myogenesis.
Using a tamoxifen dependent Cre-loxP system we delete MyoD in Myf5-null satellite cells in
adult mice; this results in double knockout (dKO) satellite cells. We find that adult myogenesis
is completely hindered in these mice. Furthermore, these mutant satellite cells have some
satellite cell/myoblast properties, however, they do not express myogenic differentiation markers
like Myog or MyHC proteins. Satellite cells with a single allele of MyoD behave like control cells,
while those with a single allele of Myf5 behave more like dKO satellite cells.
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2.2 Introduction
With the exception of Myog, single knockouts of the myogenic regulatory factors (MRFs)
exhibit mild defects in both developmental and adult myogenesis (regeneration after injury), that
is, myogenesis is essentially complete in these mice.100,134,168,175 Compound MRF knockout
experiments elucidated the roles of the MRFs in myogenic determination and differentiation.
The necessity of MyoD or Myf5 for developmental myogenesis was first established 25 years
ago.42 Without at least one of those factors, myoblasts cannot differentiate and fuse into multinucleated myofibers, and mice die perinatally, almost completely devoid of skeletal muscle.
Mice that lack MyoD, Myf5 and MRF4 do not even have myoblasts in vivo.41 Instead, these
presumptive myoblasts become mostly connective tissue and brown fat.43 However, cells that
lack MyoD and Myf5 can become multinucleated myotubes in vitro. And those that lack Myog
and MRF4 can as well. These studies showed that MyoD, Myf5 and to a lesser extent MRF4
are determination factors, they commit cells to the myogenic fate, while Myog, MRF4, and MyoD
act as differentiation factors, turning on other skeletal muscle genes and furthering a cell’s
change into a multinucleated myotube. These studies also demonstrated the genetic
redundancy of the MRFs, they have overlapping, but not identical roles.
Forced expression of the MRFs in many non-muscle cells can reprogram them into
skeletal muscle.21,22,24–26 The MRFs are master regulatory transcription factors whose protein
can initiate the myogenic program. The vast majority of satellite cell progenitors express MyoD,
Myf5, and MRF4 during development.86–88 However, these studies only indicate that those loci
are transcriptionally active, not that MRF protein is being made. Though, MRF expression is,
with a few exceptions, conserved to the myogenic lineage.
A key question in the skeletal muscle field is how closely adult myogenesis recapitulates
developmental myogenesis. Do the MRFs play the same roles in both? Specifically, are MyoD
and Myf5 necessary for adult myogenesis, like they are for developmental, or are there
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alternative genetic pathways? Also, given that there are other myogenic cells in the skeletal
muscle niche, are there alternative cellular pathways for efficient myogenesis when satellite
cells lack MyoD and Myf5?116 With the high fidelity of MRF expression in skeletal muscle, is
developmental expression of MyoD and MRF4 enough to commit satellite cells to the myogenic
lineage, or is current MyoD or Myf5 expression required?
To answer these questions, and to generate adult mice that lack MyoD and Myf5, we
created a conditional floxed allele of MyoD, MyoDcKO, that upon Cre-mediated recombination,
excises the coding sequence of MyoD. When this allele is paired with Pax7CreER, it becomes an
inducible system.176 In this system we can control when MyoD is deleted via administration of
tamoxifen and ensure that it is only deleted in satellite cells and their progeny. This is due to
CreER being under the control of Pax7, which is only expressed in satellite cells in adult skeletal
muscle.15 This model system allows us to create satellite cells that are null for MyoD and Myf5,
both in vivo and in vitro.
Using this system, we found that mice, whose satellite cells lack MyoD and Myf5 cannot
undergo adult myogenesis in vivo or in vitro. Protein expression of one of those factors after
injury is necessary for regeneration. Satellite cells that have a single allele of either MyoD or
Myf5 can undergo adult myogenesis, with MyoD being a much more potent regulator. No other
proteins can substitute for MyoD or Myf5 in adult myogenesis, not even the other MRFs. We
also show that other cell types do not substitute for mutant satellite cells. Normal satellite cells
are required for efficient regeneration after injury.
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2.3 Methods and Materials:
Mouse Breeding and Genotyping
All mouse handling, breeding, and treatments were done in accordance with our IACUC
protocol. All mouse lines were maintained by breeding on an enriched FvB background. The
control mouse (Pax7CreER/+; MyoDcKO/+; Myf5loxP/+; R26NG/+) [dHET] contains a single wild type
allele of both MRFs and is essentially wild type in both adult and embryonic myogenesis.42
Myf5loxP is a null allele that does not affect MRF4 expression, and was donated by the
Tajbakhsh lab.41 MyoDneo is a null allele containing a PGK-Neo cassette knocked into the first
exon of MyoD, and was donated by the Rudnicki lab.31 Pax7CreER is an IRES system that allows
for expression of both CreERT2 and Pax7; it was donated by the Kardon lab.77 The
experimental samples are as follows:
dKO: Pax7CreER/+; MyoDcKO/Neo; Myf5loxP/loxP; R26NG/+
Myf5-single allele [Myf5-SA]: Pax7CreER/+; MyoDcKO/Neo; Myf5loxP/+; R26NG/+
MyoD-Single allele [MyoD-SA]: Pax7CreER/+; MyoDcKO/+; Myf5loxP/loxP; R26NG/+
Occasionally MyoDNeo/+ was used in place of MyoDcKO/+ in the dHET and MyoD-SA mice, and
Pax7CreER/CreER, or R26NG/NG were used instead of the heterozygotes. This was done to reduce
breeding times. There were differences noted in leakiness, see section 2.4, but otherwise mice
were healthy and viable. See Table 2.1 for a list of PCR primers, product size, and conditions
used for genotyping.
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Table 2.1 PCR Information

Allele

Pax7CreER
Pax7+

Myf5loxP/+

MyoDNeo
MyoDcKO
MyoD+
R26NG
R26+

Forward Primer

Reverse Primer

5’GCTGCTGTTGATTACC
TGGC-3’
5’GCTGCTGTTGATTACC
TGGC-3’

5’CAAAAGACGGCAATATGGT
G-3’
5’AGGCCACGATACAGAGAAG
G-3’

5’GGTGTCTCCTCTCTGC
TGAATCCAGGTAT-3’

5’AGGTGCACGCACGTGCTCC
TCACTGTCTGA-3’

5’TGGATGTGGAATGTGT
GCGAG-3’
5’AGGCTGGGTAGTGCT
GGGTAA-3'
5’AGGCTGGGTAGTGCT
GGGTAA-3'
5’GATCAGCAGCCTCTGT
TCCACA-3’
5’AAAGTCGCTCTGAGTT
GTTAT-3’

5’TCACTGTAGTAGGCGGTGT
CGTAG-3’
5’CGCTGAACTTGTGGCCGTT
TAC-3'
5’CGCTGAACTTGTGGCCGTT
TAC-3'
5’CGCTGAACTTGTGGCCGTT
TAC-3’
5’GGAGCGGGAGAAATGGATA
TG-3’

Product
Size
(bp)

Annea
ling
Temp
(°C)

Cycles

235

52

35

400

52

35

loxP
(349),
+
(225)

57

35

429

57

35

223

60

35

434

60

35

264

58

35

603

53

35

Fluorescence Activated Cell Sorting (FACS)
Satellite cells were isolated as described previously with some modifications.177,178 Total
mouse hind limb muscles were minced for 7 min and digested with 0.1% (w/v) collagenase type
II (Gibco, 17101-015) and 2.5 units/mL Dispase II (Gibco, 17105-041) in DMEM for 1 hr with
gentle trituration every 15 min. The digestion was terminated by the addition of 20% FBS in
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DMEM and the samples were passed through 100 μm and 70 μm cell strainers. Cells were
subjected to a red blood cell-lysis and were incubated in 10% FBS in DPBS (Gibco, #14190250) for 15 min. For RT-qPCR and cell culture experiments, cells were washed and
resuspended in 2% FBS, filtered through a 40 µm filter, and a 1:20 dilution of a 100 µg/mL
propidium iodide solution was added for live/dead gating. Cells were sorted on a BD FACSAria
II based on a hierarchy of live/dead, forward and side scatter and gated to include cells positive
for GFP (see Fig 2.2). In order to analyze the recombination efficiency at the R26NG allele, cells
were stained after the incubation in 10% FBS with Alexa Fluor 647-conjugated anti-α7-integrin
(1:1000, gift from Dr. Fabio Rossi), biotinylated anti-VCAM-1 antibody (1:100, eBioscience, 131061), PE-conjugated anti-CD31 antibody (1:800, eBioscience, 12-0311), PE-conjugated antiCD45 antibody (1:500, eBioscience, 12-0451), and PE-conjugated anti-Sca1 (1:800,
eBioscience, 12-5981) on ice for 30 min. Subsequently, cells were stained with BV421conjugated streptavidin (1:100 Biolegend, 405226), resuspended in 2% FBS and prepared as
above before analyzing on the instrument. See Appendix A for a more detailed and updated
protocol.
MACS Enrichment
Satellite cells were initially processed as described in the FACS method. However,
instead of a 10% FBS block, samples were incubated with antibodies conjugated to magnetic
microbeads after incubation in MACS-Buffer (0.5% BSA, 2 mM EDTA in PBS). Cells were
incubated in anti-CD31 microbeads (1:10, Miltenyi, 130-097-418) and anti-C45 microbeads
(1:20, Miltenyi, 130-052-301) for 15 min at 4°C. Samples were washed and run through 70 µM
cell streainers into Miltenyi LS columns (130-042-401) in the presence of a magnetic field. The
flow-through was captured and then incubated in anti-α7-Integrin microbeads (1:5, Miltenyi,
130-104-261) for 15 min at 4°C and run through Miltenyi MS columns (130-042-201) in the
presence of a magnetic field. Columns were removed from the field and flushed, collecting the
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CD31-/CD45-/α7-Integrin+ enriched cells. Cells were washed and then plated as mentioned
previously.
Satellite Cell Cultures
Cells were used at passage number of 4 or less. All FACS-isolated cells were plated in
growth medium [GM: 20% FBS (Hyclone, SH30071.03), 2.5 ng/mL basic-FGF (Life
Technologies, PHG0264), and 1x Penicillin-Streptomycin in DMEM] on 35 mm tissue culture
plates coated with 1 mg/mL Matrigel (Corning, 356231). In order to minimize differentiation in
GM, cells were plated at a low density, fed every 1 to 2 days, and were passed at a confluency
of <50% until fixation. To assess differentiation capacity, cells were maintained in GM in 35 mm
tissue culture dishes until reaching approximately 70% confluency (5-6 days) and then were
passed into 8-well chamber slides (Ibidi, 80826) or larger dishes in GM until reaching >70%
confluency (2-3 days). Cells were then switched to differentiation medium [DM: 10% Horse
Serum, and 1x Penicillin-Streptomycin in DMEM] and fed every 3 days until fixation. Cultured
cells were fixed for 5 min in 4% PFA (Electron Microscopy Sciences, 15700)/PBS after 1, 3, 7,
14, 21 or 28 days in growth medium or after 3, 7, 14, 21, and 28 days in differentiation medium,
rinsed in PBS and PBS-T (0.1% Triton X-100 in PBS), and processed for immunofluorescence.
EdU studies were performed with Click-iT Plus EdU Alexa Fluor 647 Imaging kit (ThermoFisher,
C10640). Cells were grown and passed after 5 days at a density of ~2.0x103 cells/cm2. Cells
were then grown an additional 2 days (7 total days after the sort); they were incubated with 10
uM of EdU for 4 hr and washed and fixed afterwards, per the kit’s manual. All samples were
done in biological triplicate.
Cells for fusion and differentiation indices were enriched via magnetic-activated cell
sorting (MACS) with Miltenyi’s manual cell separator (see MACS). Cells were directly plated at
high density into 8-well chamber slides and grown for 2-3 days until reaching >70% confluency.
They were then switched to DM for 3 days and then fixed and stained as described. All samples
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were done in biological triplicate. Fusion index = (# of nuclei in multinucleated MyHC+ &GFP+
cells/total # of nuclei in GFP+ cells). Differentiation index = (# of nuclei in MyHC+ & GFP+
cells/Total # of nuclei in GFP+ cells)
Tamoxifen and Cardiotoxin Treatment
Tamoxifen (Toronto Research Chemical, T006000) was dissolved in corn oil at a
concentration of 50 mg/mL. Unless otherwise noted, all experimental mice were between 8-13
weeks of age and were administered tamoxifen at a dose of 10 mg via oral-gavage for 5
consecutive days. Muscle injury was induced at least 3 days after the last tamoxifen dose by
injecting 50 μl of 10 μM Naja mossambica mossanbica cardiotoxin (Sigma-Aldrich, C9759) in
PBS into both tibialis anterior muscles (TA) and 100 uL into both gastrocnemius muscles. For
RNA-seq experiments, mice were fed tamoxifen chow (500 mg/kg, Envigo, TD.130858) for ~1
month, and 3 days later were processed as described below.
Immunofluorescence
Cultures were fixed in 4% PFA/PBS for 15 min at room temperature and then washed in
PBS. After fixation and washing, satellite cell cultures were blocked in PBS containing 10%
goat serum, 2% bovine serum albumin (Sigma-Aldrich, A2153) and 0.2% Triton X-100 for 45
min at room temperature. Cultures were then incubated with primary antibodies overnight at
4°C in blocking solution, washed 3X in PBS/0.5% Triton X-100 (PBT) and incubated in
secondary antibodies at room temperature for 1.5 hr in blocking solution. After washing in PBT
as above, cultures were incubated in 0.1 µg/mL DAPI to visualize nuclei. Primary antibodies
were used at the following dilutions: mouse anti-chicken PAX7 (1:10 of hybridoma supernatant);
MF20 (undiluted hybridoma supernatant); mouse anti-rat myogenin (F5D, undiluted hybridoma
supernatant); mouse anti-human MYOD 5.8A (1:250); rabbit anti-desmin (1:500). The following
secondary antibodies were used (1:500, Life Technologies): Alexa Fluor 555-conjugated goat
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anti-mouse IgG (A-21424); Alexa Fluor 568-conjugated goat anti-mouse IgG (A-11004); Alexa
Fluor 568-conjugated goat anti-rabbit IgG (A11036).
RNA Isolation and RT-qPCR
Experimental and control mice were given tamoxifen as described above and left
uninjured. For TLDA card analysis, cells were FACS-isolated and grown as described above.
Growth media samples were passed 1-2 times and kept in GM for 7 days until RNA isolation.
Differentiation media samples were passed once and grown until ~70% confluent, then media
was switched to DM and cells continued to be cultured for 7 days, for a total of time of 12-13
days in culture. RLT lysis buffer (Qiagen, 79216) was directly added to the culture dishes.
Samples were then processed with QIAshredder columns (Qiagen, 79654) and RNA isolated
with the RNeasy Mini Kit (Qiagen 74104). RNA quality and quantity were assayed with an
Agilent RNA 6000 Pico Kit (Agilent, 5067-1513) on an Agilent 2100 Bioanalyzer. All RNA
Integrity Numbers were greater than 6.0. 125 ng of RNA was reverse transcribed with an iScript
Advanced cDNA Synthesis Kit (BioRad, 172-5038). Samples were loaded on a custom TaqMan
Low Density Array (TLDA) card (Applied Biosystems, 4342259) containing 96 assays (see
Supplemental Table 2.1) and run on an Applied Biosystems 7900HT Fast Real-Time PCR
System. Each condition contained 2 biological replicates. Bmpr2 was used as the reference
gene for all samples, as it had the lowest variance in Ct values between conditions, averages
with standard deviations given here: GM: dKO: 26.89 ± 0.50, Het: 26.73 ± 0.72, DM: dKO: 26.75
± 0.49, Het: 26.51 ± 0.49. Genes with Ct values > 30 were not included in data analysis. Fold
differences were calculated by the Livak Method.179 Student’s t-test was used to determine
statistical significance between genotypes. p < 0.05 was considered statistically significant.
For RNA analysis of freshly-isolated dKO and dHet cells, experimental and control mice
were given tamoxifen as described above and either left uninjured or were injected with 100 µL
of 10 µM cardiotoxin in PBS into their TA and gastrocnemius muscles of both legs. In order to
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minimize prep time as well as to not bias our collection based on cell surface markers, satellite
cells (uninjured, 3 dpi and 12 dpi) and their progeny, were isolated as GFP+ cells via FACS as
described above. Greater than 10,000 cells were collected directly in RLT lysis buffer. Samples
were then processed with QIAshredder columns and RNA isolated with the RNeasy Micro Kit.
RNA quality and quantity were assayed as described. All RNA Integrity Numbers were greater
than 8. Either 1.7 ng (for uninjured samples) or 10 ng (for injured samples) of RNA were
reverse transcribed with an iScript Advanced cDNA Synthesis Kit. Samples were pre-amplified
for 12 cycles using SsoAdvanced PreAmp Supermix (BioRad, 1725160) and TaqMan assays
run on a BioRad CFX96 qPCR system (see Supplemental Table 2.2). Each time point contained
3 biological replicates and each biological replicate was run in triplicate for every gene.
Samples were analyzed using CFX Manager software. To minimize variability, the average Ct of
the reference genes Gapdh and Eif1a was used in the ΔCt calculations, averages with standard
deviations given here: Uninjured: dKO: 24.26 ± 0.47; dHet: 23.25 ± 0.51; 3 dpi: dKO: 21.05 ±
0.17; dHet: 20.79 ± 0.48; 12 dpi: dKO: 24.58 ± 0.48; dHet: 24.5 ± 0.30. Due to variation in
expression of reference genes between samples, only comparisons within a specific time point
should be made. Genes with Ct values > 30 were not included in data analysis. Data was
analyzed as above.
RNA-Sequencing
RNA was isolated via FACS as described above, following the same protocol and
uninjured and injury timepoints as well, though cells were collected in 10% FBS in PBS. RLT
lysis buffer was added to the sample tubes after spinning them down and aspirating the
solution. In order to collect enough RNA for sequencing, four and two mice were pooled for
each dKO and dHET uninjured timepoint, respectively. All other timepoints used one
mouse/timepoint. All RINs were > 8.8. Library preparation and sequencing was performed by
Bo Reese and Li Lu at the Center for Genome Innovation at the University of Connecticut. 12
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RNA samples were prepared for RNA-Seq using the Illumina TruSeq Stranded mRNA sample
preparation kit, Set A. The samples were sequenced on an Illumina NextSeq 500, averaging
~130 million paired-end reads/sample. Reads were mapped to the mouse mm10 genome
(NCBI Build 37) using STAR.180 The aligned reads were counted with featureCounts and
differentially expressed genes were identified using DESeq2.181,182 Due to the mixed use of
male and female mice, anything mapped to the X or Y chromosomes were deleted before
performing differential gene expression. A chosen threshold for differentially expressed genes
was adjusted p-value < 0.05, and fold change greater than 1.5. Gene ontology and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed in Advaitabio
(www.advaitabio.com). See appendix C for a more detailed protocol.
Imaging
Whole mount fluorescence images were captured on a Leica MZFLIII stereomicroscope
(Spot RT3 digital Camera), and images of cultured cells were captured on either a Nikon TMS
(phase: Nikon Coolpix 950 digital camera) or a Nikon Eclipse TE2000-U inverted microscope
(fluorescence: QImaging Retiga EXi digital camera) microscope. Minor adjustments in
brightness, midtone, color and contrast, which were applied to the entire image, were made in
Photoshop.
2.4 Results:
Deletion of MyoD and Labeling of dKO Satellite Cells is Highly Efficient
Because mice that are constitutively null for MyoD and Myf5 die perinatally, the
Goldhamer lab created a floxed allele of MyoD (MyoDcKO) (Fig 2.1). This conditional allele is
fully functional and was used in conjunction with a tamoxifen inducible Cre-loxP system to
delete MyoD in mice that already have one constitutively null allele of MyoD and are already
homozygous-null for Myf5. Mice with the dKO genotype are born in predicted mendelian ratios
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(n=300) and are fertile. In addition, we used CreER under the control of Pax7 (Pax7CreER) so
that in the experimental dKO mouse, after tamoxifen administration, only satellite cells lack both
MyoD and Myf5.31,77 While the MyoDcKO allele contains GFP under the control of the
endogenous MyoD promoter, the expression of GFP is too weak to detect without antibody
staining; thus for lineage tracing, we used the R26NG reporter allele, which labels cells with GFP
after Cre-mediated recombination and gives a robust and strong GFP signal.90 Because this is
a new inducible system, we tested recombination efficiency at both loxP-containing alleles.
Mice between 8-13 weeks of age received daily oral gavage doses of 10 mg of tamoxifen
dissolved in corn oil over a period of 5 days. Uninjured mice of varying genotypes were
sacrificed and analyzed via flow cytometry three days after the last dose of tamoxifen, showing
a very high level of recombination as indicated by α7-integrin+/VCAM1+/CD31-/CD45-/Sca-1
staining (Fig 2.2). A period of three days was chosen to give sufficient time for the mice to
metabolize tamoxifen to its active form, for CreER to excise floxed DNA, and to generate or stop
the generation of mRNA and protein, depending on the allele. We also examined the leakiness
of recombination, i.e. recombination in the absence of tamoxifen. There we found that
Pax7CreER/CreER homozygotes had more recombination at the R26NG allele than heterozygotes,
but that recombination was low (Fig 2.3). However, we did notice the occasional presence of
GFP+ fibers in uninjured mice given tamoxifen (Fig 2.1). This could be due to either
recombined satellite cells fusing during the tamoxifen dosing period, or earlier leaky
recombination during development or postnatally.
While the recombination efficiency at the R26NG allele was high, recombination at the
MyoDcKO allele is independent of that. In order to assay that, we took several approaches. Most
of the methods involved isolating GFP+ cells. In the first we cultured GFP+ dKO satellite cells
for 72 hr in growth media, a timepoint where the vast majority of satellite cells become active
and express MyoD protein.124 After which we fixed and stained the cells for MyoD protein (Fig
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2.3). While almost all dHET satellite cells were MyoD+, only 6.4% of dKO cells were. Going a
level deeper we assayed for MyoD expression at the mRNA level. Looking at mRNA isolated
from uninjured and injured mice shows Ct values > 30 for MyoD in the the dKO samples; this is
considered above our range of detection. RNA-seq samples also showed low levels of MyoD
transcripts. DESeq2 normalized counts from dKO mice are very low compared to dHET
samples. Finally, we assayed the recombination of MyoD at the genetic level. We used primers
designed to detect the DNA from the intact and recombined alleles by using ddPCR on FACSisolated cells. However, results were mixed, most likely due to the method not being fully
optimized (Supplemental Fig. 2.1). That said, ddPCR has great potential to determine
recombination efficiency at the genetic level. Additionally, we examined MyoDcKO leakiness by
sorting satellite cells from dKO mice that were not given tamoxifen and found that a minority of
them had leaky recombination as indicated by lack of MyoD protein (Supplemental Fig 2.2).
dKO Satellite Cells are Initially Very Similar to dHET Satellite Cells in vitro, but Change
Greatly over Time
After we verified the high levels of recombination in our mouse system, we assayed the
dKO satellite cells in culture to test their myogenic potential. Cultured satellite cells are often
used to study adult myogenesis, because they can proliferate and form myotubes in vitro. We
found that at early timepoints, the dKO cells were very similar to dHET cells. In terms of their
morphology they were both small, round and refractive. In terms of satellite cell markers, both
the dKO and dHET expressed the unique satellite cell marker Pax7 as well as Desmin, a marker
of activated satellite cells and myoblasts, in approximately equal numbers. Quiescent dKO cells
isolated from uninjured muscle have similar amounts of satellite cell surface makers α7-integrin
and V-Cam1 as assayed by flow cytometry (Fig 2.2). This is not a surprise, as most labs report
no MyoD or Myf5 protein in quiescent satellite cells, so their absence would presumably not
have a great effect on quiescent dKO cell behavior. However, satellite cells greatly upregulate
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MyoD in culture and proliferate, and while dKO cells proliferate, they have a lower rate
compared to dHET satellite cells at 7 days after isolation (Fig 2.7). In addition to the lower
proliferation rate in GM, the dKO satellite cells undergo a drastic change in morphology between
3 and 7 days post sort in culture. They become fibroblastic in shape and much larger than the
dHET cells, while dHET satellite cells are more likely to maintain their original shape in low
confluent and growth conditions. If kept in growth media, the dKO cells begin to lose Pax7 and
Desmin protein expression in some of their cells over a period of 3 weeks (Fig 2.4). These
changes show that dKO satellite cells are initially very similar to dHET cells, but they begin to
change in culture, most likely due to the absence of MyoD.
Satellite Cells Lacking MyoD and Myf5 Cannot Undergo Myogenic Differentiation
Even though dKO satellite cells differ from dHET cells after prolonged time in growth
conditions, they still may be able to undergo their myogenic programming, differentiate and fuse
together to form multinucleated myotubes. When switched to low serum medium or upon high
confluency, wild type satellite cells will differentiate by expressing skeletal muscle differentiation
gene Myog and then MyHC protein. The differentiating cells fuse with each other to form
multinucleated myotubes. We tested the myogenic capacity of dKO cells by switching confluent
cultures of them to DM and determined the extent of differentiation and cell fusion by calculating
the differentiation and fusion indices. While the dHET cells had high rates of differentiation and
fusion, the dKO cells did not differentiate or fuse at all (Fig 2.5). We cultured the cells for up to
28 days in differentiation medium with no change in fusion or myogenic differentiation. In case
there was something happening to the cells in prolonged culture, we tested cells sorted shortly
after isolation, as well as those cultured for a week before switching to low-serum media. The
only cells that did undergo myogenesis in dKO cultures, were those that were unrecombined at
the MyoDcKO allele, as indicated by MyoD staining. While dKO cells cannot under myogenesis
themselves, they could perhaps be induced to differentiate and fuse if near normal satellite
37

cells. To that end we co-cultured GFP-labeled dKO and unlabeled wildtype satellite cells in
several ratios. We found very few GFP+ and MyHC+ multinucleated myotubes, indicating that
dKO satellite cells are not fusagenic.
Staining reveals that dKO satellite cells do not express protein of the myogenic
differentiation markers Myog and MyHC. While Myog is an early muscle differentiation gene,
and can turn on many other muscle genes, in its absence MRF4 can serve as muscle
differentiation gene and active other skeletal muscle genes.44 Myogenic differentiation involves
many genes, and it is possible that they can be upregulated in the absence of MyoD and Myf5,
but not be sufficient to engage the entire myogenic program, thus not forming myotubes. For
that, we wanted to expand our marker set, so we cultured dKO and dHET cells in GM for 7 days
as well as in DM for 7 days, which is ample time for myotubes to form in dHET cultures. We
then isolated the RNA and ran the cDNA on custom TaqMan Low Density Array (TLDA) cards
that contained 94 genes of different lineages, including myogenic markers. Not only do dKO
cells not differentiate or fuse, they do not express other myogenic differentiation markers in
culture like Myh4, Myh7, and Mef2c (Fig 2.5).
What we found in culture, was recapitulated in vivo. Masa Yamamoto, a research
professor in the Goldhamer lab, performed cardiotoxin injury experiments of dHET and dKO
mice and found that similar to the culture work, adult myogenesis does not occur in the dKO
animals (Supplemental Fig 2.3). The injured dKO muscles are small, with few to no myofibers,
a lot of fibrotic tissue, and many lipid-droplet containing adipocytes. He looked at greater than
31 days after injury and found no signs of muscle regeneration in dKO mice. As a reference,
regeneration is essentially complete in dHET mice by 14 days after injury. It is possible that
dKO satellite cells die after cardiotoxin injury. However, fluorescence microscopy reveals that
dKO satellite cells survive the cardiotoxin injection and proliferate after injury. Immunostaining
and RT-qPCR of FACS-isolated satellite cells of uninjured and 3 and 12 days post injury (dpi)
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confirmed the lack of Myog expression after injury (Figure 2.6). Additionally, RNA-seq data
using the same timepoints as the RT-qPCR experiments showed much lower expression of
many skeletal muscle differentiation genes after injury in the isolated dKO satellite cells
(Supplemental Table 2). These genes were selected based on commonly found genes in the
skeletal muscle literature. Thus, we show that no other genes can substitute for MyoD and
Myf5 in adult myogenesis.
MyoD-SA cells behave like dHET cells, while Myf5-SA cells behave like dKO cells
Given the breeding of our dKO mice, we were also able to generate many specimens
that contained either a single allele of MyoD or Myf5 in their satellite cells. While there are
mentions of them being generated in the literature as far back as 1992, these are novel mice
with respect to experiments in adult myogenesis.42 They serve as a way to test the efficacy of a
single allele MyoD or Myf5 in driving adult myogenesis. We found that in vitro MyoD-SA cells
have similar rates of proliferation, differentiation and fusion compared to dHET cells. In vivo,
they have similar regeneration times as well. However, Myf5-SA satellite cells initially start very
similar to dHET cells, but, like dKO cells, they undergo drastic changes to morphology and take
much longer to undergo myogenesis in culture, with the majority of cells not completely
differentiating and fusing to form myotubes. Interestingly and unlike dKO cells, Myf5-SA
satellite cells can activate Myog, with many cells showing Myog protein via immunostaining.
However, Myf5-SA satellite cells take a long time to form multinucleated myotubes and they are
sparse in vitro (Fig 2.7). In vivo, Myf5-SA mice are delayed in regeneration, but they still
express Myog and form a comparable number of myofibers compared to MyoD-SA and dHET
mice (Supplemental Fig 2.3, 2.4).
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Figure 2.1 Design of MyoDcKO and R26NG alleles. (A) The conditional MyoD allele (also known
as MyoDL2G) contains two loxP sites, one after the 5’UTR, and the other downstream of the
3’UTR (white boxes). The coding sequence (grey box) is excised upon Cre-mediated
recombination. The allele was designed to express GFP under the control of the MyoD
promoter after recombination, but it was not detected. (B) Therefore, mice were paired with the
R26NG allele, which upon Cre-mediated recombination expresses GFP under the control of a
constitutive CAG-promoter. (C) Whole-mount TA of mouse given tamoxifen regiment, with
GFP+ satellite cells (examples at arrows), and a GFP+ fiber (out of focus, yellow arrow).

40

Figure 2.2 FACS isolation and analysis strategies. Representative FACS plots comparing
dHET and dKO populations are shown. Satellite cells were lineage labeled using Pax7CreER and
the Cre-dependent reporter, R26NG. (A) Satellite cells were first gated based on a hierarchy of
live/dead (not shown), forward and side scatter, and doublet discrimination. (B, C)
Subsequently, cells were analyzed/isolated based on GFP fluorescence alone (B), or with the
satellite cell markers, α7-integrin and VCAM-1 (++), after negative selection for CD31, CD45,
Sca-1 (C) [Lin-]. The vast majority of GFP+ cells of both control and dKO populations
expressed both α7-integrin and VCAM-1, showing the fidelity of GFP labeling (B). However, to
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avoid selection bias against a minority population that does not express both α7-integrin and
VCAM-1, satellite cells for cell culture and RNA analyses were isolated based on GFP
fluorescence alone (B).
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Figure 2.3 High recombination efficiency at both R26NG and MyoDcKO alleles. (A) R26NG
recombination efficiency as determine by flow cytometry (see Fig 2.2). 91.7 ± 4.0% of CD31CD45-Sca-1-/VCAM-1+α7-integrin+ satellite cells isolated from total ind limb muscles after
tamoxifen regiment were GFP+ (n = 10). 0.9 ± 0.6% of Pax7CreER/+, R26NG/+ (CreER/+, n=6)
satellite cells were GFP+ without tamoxifen treatment. Recombination due to leaky activity of
the Cre driver increased to 7.7 ± 3.8% in mice homozygous for Pax7CreER (CreER/CreER, n=5).
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(B) Culture of dKO satellite cells showing MyoD+ cell (arrow). (C) Quantification of FACSisolated cells for MyoD protein by IF. Cells were cultured for 72 hr and assayed for MyoD
protein. Almost all dHET cells (n=5) were MyoD+, while only 6.4 ± 4.6% of dKOs were (n = 4).
Error bars in A and C represent standard deviation. (D) DESeq2 normalized counts of MyoD
from RNA-seq samples. Red line drawn at 2000 counts, (n=2 per genotype per timepoint).
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Figure 2.4. Cultured dKO cells initially are similar to dHET cells. Cultured dKO cells adopt
a fibroblast-like appearance, but they continue to express Pax7 and Desmin (DES). (A-D)
Phase images of dKO and dHET cells after 3 and 7 days in culture. (E-L) IF of Pax7 in dHET
(E, F, I, and J), and dKO (G, H, K, and L) satellite cells after culturing for 3 (E-H) or 21 days (IL). Some of the dKO cells lose their Pax7+ in GM, arrows. Comparison of DES expression in
dHET (M, N, Q, and R) and dKO (O, P, S, and T) cells 3 and 14 days in GM. dKO cells lacking
detectable DES were common by day 14 (T), arrows. Scale bars represent 50 µm. Exposure
time listed to show differences in signal intensity.
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Figure 2.5. Cultured dKO satellite cells cannot undergo myogenesis. (A-H) Cultured dKO
satellite cells fail to fuse or express Myog (MYOG) or MyHC after 21 days in DM. (I-L) Coculturing of equivalent numbers of wild-type and GFP+ dKO cells for 14 days in DM did not
rescue fusion of differentiation capacity of dKO cells. Arrowheads identify representative fibers,
which are GFP- and MyHC+. Scale bars represent 50 µm (A-H), or 100 µm (I-L). (M) TLDA
card analysis of myogenic differentiation genes between dKO and dHET cells after either 7 days
in GM or 7 days in DM. NA represents Ct values for dKO samples > 30.
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Figure 2.6. dKO satellite cells do not express muscle differentiation genes in vivo or in
vitro. (A) Heatmap of DESeq2 normalized counts featuring representative muscle differentiation
genes from dHET and dKO satellite cells FACS-isolated 3 and 12 days post injury (dpi). Upper
bar represent Z-scores representing the number of standard-deviations the expression of that
gene is different from the mean. (B) RT-qPCR of the same timepoints showing lack of MyoD
and Myog expression in dKO satellite cells. ΔCT values were calculated using the average Ct
values of the internal controls Gapdh and Eif1a, which were highly consistent between
genotypes within a given stage. Average Ct values were as follows: 3 dpi, 20.92, 12 dpi, 24.54.
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Each data point represents the average value of three biological samples and three technical
replicates for each sample. Error bars represent standard deviations. Ct values > 30 were
considered N.D., not detected.
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Figure 2.7 MyoD-SA and Myf5-SA satellite cells behave like dHET and dKO satellite cells,
respectively. (A-D) Phase images of FACS-isolated MyoD-SA and Myf5-SA cells after 2 and 7
days in culture. While MyoD-SA cultures contain many multinucleated myotubes after 3 days in
DM (E), Myf5-SA contain very few myotubes, arrows (F). (G-J) However, both MyoD-SA (G, H)
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and Myf5-SA (I, J) satellite cells express Myog protein, examples of Myog- cells at arrowheads.
(K) MACS-isolated satellite cells plated at a high density were induced to differentiate after
reaching near-confluence. Fusion and differentiation indices were calculated as described in
the methods section. Myf5-SA satellite cells exhibited markedly reduced capacity for fusion and
differentiation. Values for the Myf5-Sa satellite cells are slightly over-estimated due to the
presence of a small number of MyoD-unrecombined cells in the cultures. Data represent
technical duplicates for each of the three biological replicates. Error bars represents ± standard
deviation. (L) Satellite cells were FACS-isolated, plated at low density in growth medium and
EdU incorporation quantified. Proliferation of dKO satellite cells was significantly reduced
compared to dHET cells. Asterisk represent p <0.05, n=3. Scale bars represent 50 µm (E-J).
2.5 Discussion
The results presented here demonstrate for the first time that satellite cells that lack
MyoD and Myf5 cannot undergo myogenesis in vivo or in vitro. We also show that the novel
MyoDcKO allele has high levels of recombination in a dKO mouse model, and this allele is
potentially suitable for studies that require deleting MyoD at specific timepoints. Finally, our
results indicate and corroborate reports that MyoD protein is a more potent driver of adult
myogenesis than Myf5.
The vast majority of wildtype satellite cells progenitors express three of the four MRFs,
MyoD, Myf5, and MRF4 during development, and expression of these factors is almost
completely limited to skeletal muscle progenitors and myofibers.86–88 That suggests that satellite
cells are committed to the myogenic lineage. And indeed, wildtype satellite cells only form
skeletal muscle.157 However, our dKO mice are not able to express functional Myf5 and only
have one function allele of MyoD during development. Regardless, it is interesting to note that
developmental expression of MRF4 and a single allele of MyoD does not commit dKO satellite
cells to the myogenic lineage. This could be due to the loci being only transcriptionally active
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and no actual functional MRF4 or MyoD protein being made in these satellite cell progenitors. It
is also possible that, since these mutant alleles feature Cre knocked into the MRF locus, that
changes the transcriptional regulation of them and causes non-endogenous transcription,
maybe short leaky transcriptional activity that is long enough to generate Cre to recombine the
reporter allele. Regardless, the fact that these loci are transcriptionally active at all and the fact
that the MRFs are mostly confined to skeletal muscle and its progenitors, suggests that satellite
cells are primed for myogenic commitment, including dKO satellite cells. But as we show here,
being primed for myogenic commitment is not sufficient, active expression of MyoD or Myf5
protein is necessary for adult myogenesis.
The absolute requirement of MyoD or Myf5 for adult myogenesis is not a completely
surprising result. Studies from the early 1990’s and 2000’s have shown the necessity of having
at least one of those MRFs for developmental myogenesis.41,42 However, the perinatal lethality
of constitutive MyoD-null and Myf5-null mice prevented other researchers from performing the
experiments we have done regarding adult myogenesis. Our novel system has allowed us to
show that MyoD and Myf5 are determination factors in adult myogenesis, no other genetic factor
can substitute for them with regards to forcing satellite cells down the myogenic pathway. They
play a similar role in developmental myogenesis with Myf5 and MyoD protein turning on many
myogenic genes. However, an important difference is that during developmental myogenesis
MRF4 can act as a determination factor, though it is not very effective in that role in vivo and
cannot sustain complete myogenesis; animals lacking MyoD and Myf5 contain sparse myofibers
at birth.41 It is important to note that MRF4 expression did not increase in our experiments as
indicated in the RNA-seq data, and it was not detected in qRT-PCR experiments, suggesting
that it does not respond to the absence of MyoD and Myf5. It is possible that MRF4 is regulated
differently in embryonic cells, and it could be prevented in being upregulated and acting as a
differentiation factor itself or able to turn on Myog in dKO satellite cells in vivo and in vitro. It is
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possible that MyoD and Myf5 are able to change the chromatin landscape enough for MRF4 to
be expressed in mature myofibers, whereas it would be prevented from being expressed in
activated satellite cells. Researching MRF4 and its enhancers’ chromatin landscape could give
a mechanism for this, particularly since MRF4 is strongly expressed in myofibers and has a role
in muscle hypertrophy.169
Data from staining and RNA analyses suggests that the block in adult myogenesis in
dKO cells is that Myog cannot turn on. Only MyoD or Myf5 protein can upregulate Myog in
satellite cells and begin skeletal muscle differentiation. This is supported by data from a 2016
paper from the Tapscott lab.57 They show that MyoD and Myf5 can bind to the 5’ region of
Myog and initiate transcription of it. Once Myog is upregulated, it binds and initiates
transcription at other skeletal muscle differentiation genes furthering the formation of
multinucleated myotubes.59,60 However, Myog itself is not necessary for differentiation in
satellite cells. Myog-null satellite cells can still undergo myogenesis, with MyoD, Myf5 and
MRF4 all being upregulated during adult myogenesis in these mice.142 This suggests that
another MRF can compensate for its loss, and indeed MyoD can bind to similar regions of the
genome as Myog.59 However, in our dKO cells, this compensation cannot happen.
Interestingly, MRF4 again cannot come to the rescue during adult myogenesis, thus giving it a
different role from its developmental determination and differentiation factor role. The four MRFs
are thought to have come from evolutionary gene duplication events.183 Speculating on this, it is
possible that the redundancy of MRFs with respect to myogenesis allowed mutations of them
throughout the years to change their functions, e.g. MRF4 is not featured in adult myogenesis.
This could be because it would be very unlikely to have an organism with deleterious mutations
in adult myogenic-necessary genes MyoD and Myf5 survive to adulthood, thus putting less
pressure on MRF4 to participate, and freeing it up for different roles.
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Myogenic differentiation is not the only things dKO satellite cells lack, they are also not
fusagenic. The co-culturing experiments showed very little contribution of labeled dKO cells to
multinucleated MyHC+ myofibers. While we cannot be completely certain of it, those cells that
did contribute are most likely not recombined at the MyoDcKO allele. Every isolation of dKO
satellite cells contained a small number of MyoD+ cells. A 1997 paper claimed that Myog-null
myoblasts were able to fuse with wildtype myoblasts in vivo in chimeric mice.184 However, our
preliminary transplantation experiments of labeled dKO satellite cells into nude mice also
showed a lack of myogenic differentiation and fusion, but results were equivocal, and it needs to
be repeated with another reporter system to see the extent that donor nuclei are fusing with host
myotubes, because the GFP in our reporter is not nuclear localized and will spread through the
entire fiber’s cytoplasm when a few GFP+ cells fuse with non-GFP+ cell. RNA-seq analysis
supports a lack of fusion, as dKO satellite cells had very little expression of myomaker and
myomixer (also known as myomerger and minion), two necessary myogenic fusion
genes.129,130,185 Inducing fusion protein expression in dKO cells might cause them to further
myogenic programming, given that satellite cells are primed for myogenesis. and should be
done. However, these need to be pure dKO cultures, as fusions of non-muscle cells with
myogenic cells indicate MyoD can transactivate myogenic programming in non-muscle
nuclei.17,18
A single allele of MyoD or Myf5 is sufficient for regeneration in vivo and the formation of
myotubes in vitro. However, our results show that a single allele MyoD is a more potent driver
of adult myogenesis than Myf5. This corroborates a recent paper showing that while MyoD and
Myf5 both bind to the same locations and induce comparable levels of acetylation, MyoD more
effectively recruits Pol II for transcription.57 This would explain the delay of adult myogenesis in
vivo, as Myog protein as detected by immunofluorescence is delayed. However, this does not
explain why in Myf5-SA cultures the delay and lack of formation of myotubes is so severe,

53

especially because numerous Myf5-SA satellite cells had detectable myogenin protein by 3
days in confluent culture in DM, and myotube formation did not usually occur until greater than
14 days in culture and was sparse when it did occur. This suggests that non-autonomous
factors are responsible for more efficient in vivo adult myogenesis of Myf5-SA mice. These
could be fibro-adipogenic precursors (FAPs), which have been shown to have a positive effect
in regeneration, Wnt and Notch signaling, or P38 MAPK signaling.131,176,186,187 Further
experiments are necessary to determine what supports Myf5’s more efficient driving of adult
myogenesis in vivo compared to in vitro.
It is interesting to note that no other myogenic cell type in skeletal muscle rescued adult
myogenesis in vivo. Other resident myogenic stem cells include mesoangioblasts, the so-called
side population cells, particular types of pericytes and PICs, CD133+ cells, Twist2-dependent
cells, and myoendothelial cells.188,189 This result confirms other reports that either ablated
satellite cells or mutated them and found a lack of muscle regeneration after injury. 77,145,146 It is
possible that these other resident myogenic cells undergo a Pax7-expressing transition period
when undergoing myogenesis and thus excise MyoD in the presence of tamoxifen. However,
the majority of these cells do not express Pax7, and the minority that would most likely not be
exposed to tamoxifen, especially since skeletal muscle does not accumulate tamoxifen as much
as other tissues.190,191 To be certain of this, experiments with longer times after the last
tamoxifen administration need to be done.
In addition to what was previously mentioned above, further experiments should be
performed on different muscle groups, particularly those of the head. Most muscles of the head
have a different developmental origin than those of the body.192 Extraocular muscles would be
very interesting to look at, because their satellite cells tend to be more active and have different
genetic signatures compared to satellite cells of the body.150 Given that so much recent work
has been done in miRNA in satellite cells, it might be worthwhile to examine how they differ in
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dKO satellite cells to determine what is dependent on MyoD and Myf5. Chromatin remodeling is
another potential area, as the difference between dKO and dHET satellite cells could show
exactly where MyoD and Myf5 are working in a more endogenous system than cell culture.
Supplemental Methods
ddPCR
Digital droplet PCR (ddPCR) was performed on ~1,000-5,000 FACS-isolated
cells/sample. DNA was extracted using and following the Qiagen QIAamp DNA Micro Kit
(56304) protocol. Bio-Rad’s ddPCR Supermix protocol (186-3042) was used in conjunction with
customized TaqMan probes to detect MyoD-WT DNA (FAM) and a CNV-Assay [Apob] (BioRad, 10042961, unique Assay ID: dMmuCNS407594696) probe (Hex). Samples were run on a
QX200 and analyzed with QuantaSoft software. Percent recombination was calculated as
follows: (1-[(MyoD-WT signal)/(CNV-Assay Signal)]) X100 = %MyoD recombined.
4-OH Tamoxifen Cultures
Satellite cells from dKO and dHET mice not given tamoxifen were isolated via FACS and
cultured as described above. A range of concentrations of Z-4-OH tamoxifen (Sigma, H7904)
diluted in ethanol was used to test MyoDcKO recombination in culture by feeding daily for three
days. Cells were fixed and stained for MyoD to assay what percent of dKO cells were MyoD+
and/or GFP+.
In vivo work was done by Masakazu Yamamoto. See Yamamoto et al, 2018 for methods
135

.
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Supplemental Figure 2.1 Recombination of MyoDcKO allele of RNA-seq samples assayed
by ddPCR. 1-5,000 FACS-isolated dHET and dKO satellite cells were analyzed by ddPCR with
a custom MyoD-WT TaqMan assay that amplifies the end of exon 1 and beginning of intron 1 of
MyoD, as well as a TaqMan assay that amplifies a region of Apob. (A) The 1D amplitude of
MyoD-WT events per sample. (B) The 1D amplitude of Abob events per sample. (C) The ratio of
MyoD-WT events to Apob events, the error bars represent Poisson 95% confidence intervals.
Values for dKO Uninjured samples seem high based on culture and mRNA data. More work
needs to be done to optimize this method.
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Supplemental Figure 2.2 Recombination and leakiness of MyoDcKO. FACS-isolated satellite
cells from dHET and dKO NOT given tamoxifen were cultured in GM with increasing levels of 4OH tamoxifen for 72 hours. 24 hr later Cultures were fixed and assayed for GFP+ and MyoD+.
(A and B) Example of dKO given 0.01 µM of 4-OH tamoxifen. Arrowheads point to
GFP+/MyoD- cells. (C) Recombination efficiency of R26NG and MyoDcKO alleles in culture, note
that upwards of ~20% of dKO satellite cells not given any form of tamoxifen were MyoD- after
96 hr in culture. Black bars indicate MyoD-results, green bars indicate GFP-results. Error bars
represent standard deviation. n = 2 for 0, 0.01, 0.1, 1 (MyoD), 2 (GFP), and 5 (GFP) µM. n = 4
for GFP 1 µM. n = 1 for 2 and 5 µM MyoD.
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Supplemental Figure 2.3 Whole-Mount and histological analyses of skeletal muscle
regeneration [Taken from Yamamoto et al, 2018].
(A-D) Whole-mount images of 11 dpi TA muscles. Experimental mice carried the Cre-dependent
GFP reporter, R26NG. Fluorescence images of muscles in A and C are shown in B and D,
respectively. GFP+ satellite cells in uninjured muscles are not visible at this magnification and
exposure (B, D; top). The exposure times to capture the GFP images were 126 ms (B) and 892
ms (D). Scale bars represent 1 mm (A-D). (E-L) Histological analyses at 11 dpi (E-H) and 31 dpi
(I-L). Sections were stained with H&E (E-K) or Oil-Red-O (L). The same section is shown in (K)
and (L). Satellite cells carrying at least one intact allele of MyoD or Myf5 supported
regeneration, although regeneration was delayed and regenerated fibers had a substantially
smaller cross-sectional area in Myf5-SA muscle compared to mice carrying at least one intact
MyoD allele (E-G, I, J). dKO muscle was filled with adipocytes (black asterisks) and apparent
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fibrotic tissue (white asterisks) (H, K, L). Scale bars represent 50 μm. (M-O) Lineage-labeled
dKO cells populated the injured TA muscle, forming disorganized accumulations of
mononuclear cells. The boxed area in (M) is magnified in (N). Occasional, minute fibers (derived
from unrecombined satellite cells) are evident in (O) (arrows). (P) By comparison, Myf5-SA mice
exhibited the typical architecture of regenerated muscle at 31 dpi. Scale bars represent 100 μm.

Supplemental Figure 2.4 dKO satellite cells cannot differentiate in vivo. [Taken from
Yamamoto et al, 2018] (A-L) Expression of Myog in injured muscle is dependent on MyoD or
Myf5. Myog (MYOG)-positive, lineage-labeled, mononuclear cells were readily detected by
immunofluorescence at 3 days post-injury (dpi) in MyoD-SA satellite cells (A, B), but not in
Myf5-SA cells (E, F). At 6 dpi, both MyoD-SA (C, D) and Myf5-SA (G, H) satellite cells
expressed Myog. Myog was not detectable in dKO satellite cells at either 3 or 6 dpi (I-L).
Arrowheads, examples of Myog+ cells. Scale bars represent 10 µm.
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Supplemental Table 2.1
TaqMan Assays used in RT-qPCR Analysis (TLDA Card and individual primers)
Gene
Symbol
18S

TaqMan Assay Cat.
Number
Hs99999901_s1

Gene
Symbol
Ly6a

TaqMan Assay Cat.
Number
Mm00726565_s1

Abcg2

Mm00496364_m1

Mcam

Mm00522397_m1

Acan

Mm00545807_m1

Mdfi

Mm00521983_m1

Acta2

Mm01546133_m1

Mef2c

Mm01340839_m1

Acvr1

Mm00431645_m1

Meox2

Mm00801881_m1

Adipor1

Mm01291334_mH

Met

Mm00434924_m1

Alpl

Mm00475834_m1

Msc

Mm00447887_m1

Anpep

Mm00476227_m1

Mstn

Mm00440328_m1

Bglap2

Mm03413826_mH

Msx1

Mm00440330_m1

Bmp2

Mm01340178_m1

Mustn1

Mm00663760_g1

Bmp4

Mm00432087_m1

Myf5

Mm00435125_m1

Bmpr2

Mm03023976_m1

Myf6

Mm00435126_m1

CD34

Mm00519283_m1

Myh2

Mm01332564_m1

CD44

Mm01277163_m1

Myh4

Mm01332541_m1

Cdh15

Mm00483191_m1

Myh7

Mm00600555_m1

Cdh5

Mm00486938_m1

Myod1

Mm00440387_m1

Cebpa

Mm01265914_s1

Myog

Mm00446194_m1

Cebpb

Mm00843434_s1

Ncam1

Mm03053534_s1

Chrd

Mm00438203_m1

Nog

Mm01297833_s1

Cidea

Mm00432554_m1

Notch

Mm00435245_m1

Col1a1

Mm00801666_g1

Nt5e

Mm00501910_m1
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Col2a1

Mm01309565_m1

Numb

Mm00477927_m1

Col3a1

Mm0125476_m1

Pax3

Mm00435493_m1

Cspg4

Mm00507256_m1

Pax7

Mm00834082_m1

Ctgf

Mm01192932_g1

Pdgfra

Mm01211694_m1

Ctnnb1

Mm00483039_m1

Pdgfrb

Mm01262489_m1

Cxcr4

Mm01292123_m1

Pecam1

Mm00476702_m1

Desmin

Mm00802455_m1

Peg3

Mm00493299_s1

Dlk1

Mm00494477_m1

Pou5f1

Mm03053917_g1

Eif1a

Mm00456651_m1

Pparg

Mm00440945_m1

Elovl3

Mm00468164_m1

Prdm16

Mm00712556_m1

Fabp4

Mm00445880_m1

Prom1

Mm00477115_m1

Fn

Mm01256744_m1

Ptprc

Mm01293577_m1

Foxk1

Mm00440301_m1

Retn

Mm00445641_m1

Frzb

Mm00441378_m1

Runx2

Mm00501580_m1

Gapdh

Mm99999915_g1

Sdc4

Mm00488527_m1

Gli1

Mm00494645_m1

Serpina3k

Mm03058186_m1

Gli3

Mm00492345_m1

Shh

Mm00436528_m1

Grem1

Mm01277437_s1

Smo

Mm01162710_m1

Gsr

Mm00833903_m1

Sox9

Mm00448840_m1

Id1

Mm00775963_g1

Srf

Mm00491032_m1

Id2

Mm00711781_m1

Tagln

Mm00441660_m1

Ihh

Mm01259021_m1

Tek

Mm00443254_m1

Il4ra

Mm01259021_m1

Thy1

Mm00493681_m1

Itga7

Mm00434400_m1

Timp1

Mm00441818_m1

Itgam

Mm00434455_m1

Twist1

Mm00442036_m1
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Itgb1

Mm01253227_m1

Ucp1

Mm01244861_m1

Kdr

Mm00440111_m1

Vcam1

Mm01320970_m1

Klf4

Mm00516104_m1

Vwf

Mm00550376_m1

Lbr

Mm00522574_m1

Wnt3a

Mm00437337_m1

Lpl

Mm00434770_m1

Supplemental Table 2.2 TLDA card ΔCt values

Gene
18S
Abcg2
Acan
Acta2
Acvr1
Adipor1
Alpl
Anpep (Cd13)
Bglap2
Bmp2
Bmp4
Bmpr2
Cd34
Cd44
Cdh15 (M-Cad)
Cdh5
Cebpa
Cebpb
Chrd
Cidea
Col1a1
Col2a1
Cspg4
Ctnnb1 (β-cat)
Cxcr4
Dlk1
Eif1a
Elovl3
Fabp4 (Ap2)
Foxk1
Frzb
Gapdh
Gli1

dHet GM ΔCt
n/a
0.41 ± 0.2
N.D.
-5.41 ± 0.79
N.A.
-0.28 ± 0.76
N.D.
3.12 ± 0.58
N.D.
N.D.
N.D.
N.D.
-3.51 ± 0.36
-1.93 ± 0.36
N.D.
0 ± 0.29
N.D.
N.D.
N.D.
-1.32 ± 0.97
N.D.
2.73 ± 1.19
-2.23 ± 0.81
2.14 ± 0.38
N.D.
-0.96 ± 1.62
N.D.
N.D.
2.22 ± 0.47
N.D.
-6.66 ± 0.50
N.D.

dKO GM ΔCt
n/a
-0.13 ± 0.20
N.D.
-6.85 ± 0.21
N.A.
-1.54 ± 0.32
N.D.
0.8 ± 0.03
N.D.
N.D.
0.31 ± 1.73
-0.92 ± 0.38
-5.01 ± 0.79
N.D.
N.D.
-2.11 ± 1.00
1.51 ± 0.41
N.D.
N.D.
-5.52 ± 0.01
N.D.
1.62 ± 1.33
-2.76 ± 0.28
N.D.
N.D.
-2.73 ± 2.62
N.D.
-2.5 ± 1.84
0.97 ± 0.34
N.D.
-7.14 ± 0.40
N.D.

dHet DM ΔCt
n/a
2.34 ± 0.11
N.D.
-3.72 ± 0.16
-0.09 ± 0.3
0.49 ± 0.49
N.D.
2.65 ± 0.77
N.D.
N.D.
N.D.
1.18 ± 0.06
-3.36 ± 0.66
-0.46 ± 0.19
N.D.
1.43 ± 0.61
N.D.
N.D.
N.D.
2.03 ± 0.19
N.D.
N.D.
-1.94 ± 0.54
2.61 ± 0.23
N.D.
0.04 ± 0.88
N.D.
N.D.
N.D.
N.D.
-5.50 ± 0.27
N.D.

dKO DM ΔCt
n/a
2.5 ± 0.52
N.D.
-4.94 ± 1.1
0.23 ± 0.32
0.73 ± 0.15
N.D.
0.37 ± 0.46
N.D.
N.D.
-1.07 ± 0.07
1.53 ± 0.31
-0.53 ± 0.02
N.D.
N.D.
-2.03 ± 0.19
3.23 ± 0.44
N.D.
N.D.
-3.49 ± 0.05
N.D.
N.D.
-1.28 ± 0.35
N.D.
N.D.
-0.69 ± 2.12
N.D.
-2.12 ± 1.96
N.D.
N.D.
-4.66 ± 0.34
N.D.
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Gli3
Grem1
Gsr
Id1
Id2
Ihh
Il4ra
Itga7
Itgam
Itgb1
Kdr
Klf4
Lbr
Lpl
Ly6a (Sca1)
Mcam
Mdfi
Mef2c
Meox2
Met (c-Met)
Msc
Mstn
Msx1
Mustn1
Myf5
Myf6 (Mrf4)
Myh2
Myh4
Myh7
Myod1
Myog
Ncam1
Nog
Notch1
Nt5e
Numb
Pax3
Pax7
Pdgfra
Pdgfrb
Pecam1 (Cd31)
Peg3 (Pw1)
Pou5f1 (Oct4)
Pparg
Prdm16
Prom1
Ptprc
Retn
Runx2

1.28 ± 0.57
1.40 ± 0.16
3.26 ± 1.32
-1.56 ± 0.64
-0.72 ± 0.05
N.D.
1.65 ± 0.23
-2.24 ± 0.21
N.D.
-3.79 ± 0.53
N.D.
2.32 ± 0.64
0.32 ± 0.14
-0.90 ± 0.37
0.43 ± 1.28
1.69 ± 0.43
N.D.
-0.58 ± 0.58
N.D.
-0.82 ± 0.13
N.D.
1.86 ± 1.26
N.D.
-2.42 ± 0.16
-0.54 ± 0.01
1.42 ± 0.24
N.D.
2.6 ± 0.16
-3.15 ± 0.54
-1.42 ± 1.65
-5.44 ± 0.82
-2.75 ± 0.73
N.D.
3.15 ± 1.28
3.04 ± 1.43
2.15 ± 0.51
N.D.
2.28 ± 0.42
N.D.
2.95 ± 0.39
N.D.
-3.24 ± 0.66
N.D.
1.90 ± 0.10
N.D.
N.D.
N.D.
N.D.
1.74 ± 0.57

0.42 ± 0.23
-5.12 ± 0.06
1.48 ± 2.34
-1.96 ± 0.84
-1.3 ± 0.93
N.D.
-2.39 ± 0.39
-0.66 ± 0.53
N.D.
-4.49 ± 0.58
N.D.
-0.04 ± 0.32
-0.41 ± 0.85
-3.2 ± 1.27
-6.55 ± 1.27
0.53 ± 0.80
N.D.
N.D.
N.D.
0.24 ± 0.10
N.D.
N.D.
N.D.
-1.06 ± 1.13
-1.52 ± 0.44
2.75 ± 0.78
N.D.
N.D.
N.D.
N.D.
N.D.
-0.55 ± 0.24
N.D.
3.06 ± 1.75
2.14 ± 0.61
0.56 ± 0.08
N.D.
2.44 ± 0.29
-0.48 ± 0.03
-1.31 ± 0.65
N.D.
0.83 ± 1.03
N.D.
-0.46 ± 0.69
N.D.
N.D.
N.D.
N.D.
-0.12 ± 0.38

1.93 ± 0.66
0.14 ± 0.62
N.D.
-1.11 ± 0.57
0.3 ± 0.19
N.D.
0.87 ± 0.58
-1.25 ± 0.01
N.D.
-2.56 ± 0.42
N.D.
2.35 ± 0.16
1.2 ± 0.48
-0.91 ± 0.58
-0.86 ± 1.04
N.D.
N.D.
1.95 ± 0
N.D.
-0.7 ± 0.1
N.D.
2.54 ± 0.84
N.D.
1.06 ± 0.09
-0.23 ± 0.06
N.D.
N.D.
N.D.
0.34 ± 1.04
-0.72 ± 0.54
-3.89 ± 0.77
-2.31 ± 0.13
N.D.
N.D.
N.A.
N.D.
N.D.
1.05 ± 0.26
N.D.
N.D.
N.D.
-2.68 ± 0.07
N.D.
1.93 ± 0.53
N.D.
N.D.
N.D.
N.D.
2.41 ± 0.3

2.44 ± 0.20
-1.81 ± 1.00
N.D.
1.58 ± 0.97
N.D.
N.D.
-0.44 ± 0.43
2.18 ± 0.94
N.D.
-2.79 ± 0.32
N.D.
0.8 ± 0.63
2.86 ± 0.17
-3.61 ± 0.19
-6.31 ± 0.65
N.D.
N.D.
N.D.
3.16 ± 1.11
N.D.
N.D.
N.D.
N.D.
0.65 ± 0.7
-0.26 ± 1.2
N.D.
N.D.
N.D.
N.D.
N.D.
1.29 ± 0.32
-1.24 ± 0.42
N.D.
N.D.
2.52 ± 0.11
N.D.
N.D.
2.51 ± 0.42
-0.29 ± 0.61
-0.87 ± 0.09
N.D.
1.72 ± 0.95
N.D.
3.31 ± 0.51
N.D.
N.D.
N.D.
N.D.
N.D.
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Sdc4
Serpina3k
Shh
Smo
Sox9
Srf
Tagln (Sm22a)
Tek
Thy1
Twist1
Ucp1
Vcam1
Vwf
Wnt3a

-3.89 ± 0.51
N.D.
N.D.
-0.32 ± 0.47
1.98 ±0.36
-0.36 ± 0.68
-3.13 ± 0.04
N.D.
N.D.
N.D.
N.D.
0.06 ± 1.03
N.D.
N.D.

-5.83 ± 0.03
N.D.
N.D.
-1.17 ± 0.05
0.01 ± 1.04
-0.78 ± 1.35
-5.02 ± 0.45
N.D.
0.33 ± 0.01
-0.57 ± 0.13
N.D.
-0.38 ± 0.02
N.D.
N.D.

-3.37 ± 0.71
N.D.
N.D.
0.15 ± 0.49
1.77 ± 0.23
0.35 ± 0.46
-0.39 ± 0.17
N.D.
N.D.
N.D.
N.D.
0.55 ± 0.31
N.D.
N.D.

-2.88 ± 0.16
N.D.
N.D.
0.19 ± 0.46
2.22 ± 0.32
1.26 ± 0.31
-3.6 ± 0.62
N.D.
N.D.
0.81 ± 0.24
N.D.
0.41 ± 1.86
N.D.
N.D.

Table S2.2. Genes assayed and ΔCt values for TLDA card samples. ΔCt values were
calculated using Bmpr2 as the reference gene, which had the greatest consistency in Ct values
and lowest standard deviation between genotypes (Ct = 26.72 ± 0.45). N.D., not detected (A Ct
value > 30 was used as the cut-off). n/a: amplification curve was suboptimal and data was
excluded. GM, growth medium. DM, differentiation medium. Each value is derived from
biological duplicates.
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Supplemental Table 2.3 Myogenic differentiation genes 3 and 12 dpi
3 dpi
Gene

Acta1
Cdh15
Chrna1
Chrnd
Ckm
Myh1
Myh2
Myh3
Myh4
Myh7
Myh8
Myl1
Myl2
Myl4
Mylpf
Mymk
Mymx
Myod1
Myog
Pygm
Ryr1
Ryr3
Tnni1
Tnnt2
Trim63

12 dpi

Fold

Adjusted

Change

p-value

-148.9
-10.9
-76.5
-224.8
-5.5
-42.1
-1.2
-3452.4
-4.1
-7.1
-195.2
-149.6
-1.0
-32.8
-109.9
-614.4
-1294.0
-17.6
-7488.7
-2.4
-36.1
-18.6
-143.6
-89.4
-4.9

8.41E-258
3.72E-17
2.27E-77
4.73E-100
0.000154
2.60E-41
0.547336
1.65E-134
0.002597
0.005948
5.05E-24
5.18E-85
0.910175
1.55E-75
1.81E-160
3.46E-11
8.31E-15
3.29E-77
2.65E-54
0.001986
2.74E-64
2.48E-11
2.99E-88
7.95E-114
0.003136

Gene

Acta1
Cdh15
Chrna1
Chrnd
Ckm
Myh1
Myh2
Myh3
Myh4
Myh7
Myh8
Myl1
Myl2
Myl4
Mylpf
Mymk
Mymx
Myod1
Myog
Pygm
Ryr1
Ryr3
Tnni1
Tnnt2
Trim63

Fold

Adjusted

Change

p-value

-26.4
-4.7
-4.2
-9.7
-28.1
-1.1
-4.0
-1.4
-21.7
-18.9
-2.5
-23.5
-13.9
-1.9
-20.0
-57.8
-22.1
-7.6
-107.9
-1.5
-18.4
-1.1
-22.7
-36.5
-1.6

3.27E-25
4.54E-06
2.10E-06
2.36E-09
5.41E-19
0.689588
0.005183
0.181734
1.19E-14
2.01E-06
0.000854
1.16E-16
1.29E-10
0.003948
6.98E-07
5.47E-35
5.53E-08
4.05E-11
1.12E-45
0.074251
2.45E-25
0.61185
1.43E-23
8.33E-27
0.085775

Table S2.3. A representative selection of fold changes for dKO vs dHET satellite cells as
calculated by DESeq2 and adjusted p-values (Benjamini-Hochberg) of myogenic differentiation
genes corresponding to Figure 2.6A. Genes in bolded orange are not significant meaning their
adj. p value > 0.05.
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Chapter 3: Satellite Cells that Lack MyoD and Myf5 Change their Fate to Adipogenic and
Fibrogenic Lineages.
3.1 Abstract:
Satellite cells that lack functional MyoD and Myf5 cannot undergo adult myogenesis in
vivo or in vitro. They do not upregulate muscle differentiation genes and do not become
multinucleated myotubes. However, these presumptive myoblasts do not die, but rather
maintain some myogenic traits, including satellite cell markers and, most strikingly, comparable
Myf5 expression to control cells. They also transdifferentiate into fibroblast-like cells, with a
significant minority becoming mature adipocytes both in vitro and in vivo. Additionally, RNA-seq
analysis of muscle regeneration reveals potential novel candidates involved in adult myogenesis
in vivo.
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3.2 Introduction
Cell fate is a key concept in developmental biology. C. H. Waddington proposed a model
of cell development as a landscape of canals.193 A ball (representing a cell) sits at the top of the
landscape; it is totipotent and can become any specialized mature cell. As the ball moves down
the landscape, it falls into canals and becomes less and less multipotent, in general. Eventually
it can become a mature differentiated cell that can no longer become other cell types. This
applies as equally to satellite cells as it does to other cells of the body. Early studies of muscle
regeneration were uncertain if myotubes could dedifferentiate to heal injury and form satellite
cells.72 Later experiments clarified that satellite cells were responsible for muscle regeneration
after injury. However, given that there are multiple adult cell types in skeletal muscle, e.g. fat
and fibroblasts, it was still thought that satellite cells could be multipotent, particularly in culture.
Early isolation of satellite cells was difficult, often giving impure cultures that potentially
contained many mixed cells, like mesenchymal stem cells, a multipotent cell type that can
differentiate into mature adipocytes and osteoblasts.156 This lead to claims of satellite cell
multipotency. Discoveries of satellite cell surface markers and technological advances like Cremediated cell labeling proved these claims wrong. A more recent study using a inducible
reporter system that only labels skeletal muscle and satellite cells showed that satellite cells do
not spontaneously adopt fates other than skeletal muscle.157 Other studies have shown that
there are numerous stem cell in skeletal muscle that can give rise to the different cell types
skeletal muscle, particularly in the in aged and diseased states, were fibrotic tissue and fat can
dominate the skeletal muscle environment.194
Even though satellite cells do not normally form other cell types, they can be induced to
express different cell type markers. Exposure of satellite cells to bone morphogenetic protein 2
(BMP2) or BMP4 can induce osteogenic differentiation markers, and decrease myogenic
markers.153–155 Also, exposing satellite cells to serum from older mice can lead to a more
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fibroblastic/aged phenotype.195,196 Those changes pale in comparison to what a more recent
paper found. A 2013 study claimed that a few satellite cells can spontaneously become brown
adipocytes in vitro, and in vivo when mice are exposed to prolonged cold temperatures, due to
dysregulation of a microRNA.161
While wildtype satellite cells maintain their commitment to myogenesis in most healthy
adult conditions, mutated presumptive myoblasts can adopt different fates. During
development, myogenic precursors that lack both MyoD and Myf5 become mature bone, brown
adipocytes, and connective tissue.43 C2C12 cells (an immortalized mouse muscle cell line) that
lack MyoD can become brown adipocytes.197 Our results both corroborate previous research
and show new findings. MyoD+/-; Myf5-/- Satellite cells behave like wildtype, they are committed
to the myogenic lineage. MyoD-/-; Myf5+/- satellite cells are mostly committed to myogenesis in
vivo, but poorly differentiate in culture, and can become adipocytes. dKO satellite cells cannot
make muscle, with ~10% adopting an adipogenic fate, and the remaining maintaining myogenic
features, but also taking on characteristics of fibroblasts, both in morphology and in gene
expression, in vitro and in vivo.
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3.3 Methods and Materials:
Mouse Breeding and Genotyping
All mouse handling, breeding, and treatments were done in accordance with our IACUC
protocol. All mouse lines were maintained by breeding on an enriched FvB background. The
control mouse (Pax7CreER/+; MyoDcKO/+; Myf5loxP/+; R26NG/+) [dHET] contains a single wild type
allele of both MRFs and is essentially wild type in both adult and embryonic myogenesis.42
Myf5loxP is a null allele that does not affect MRF4 expression, and was donated by the
Tajbakhsh lab.41 MyoDneo is a null allele containing a PGK-Neo cassette knocked into the first
exon of MyoD, and was donated by the Rudnicki lab.31 Pax7CreER is an IRES system that allows
for expression of both CreERT2 and Pax7; it was donated by the Kardon lab.77 The
experimental samples are as follows:
dKO: Pax7CreER/+; MyoDcKO/Neo; Myf5loxP/loxP; R26NG/+
Myf5-single allele [Myf5-SA]: Pax7CreER/+; MyoDcKO/Neo; Myf5loxP/+; R26NG/+
MyoD-Single allele [MyoD-SA]: Pax7CreER/+; MyoDcKO/+; Myf5loxP/loxP; R26NG/+
Occasionally MyoDNeo/+ was used in place of MyoDcKO/+ in the dHET and MyoD-SA mice, and
Pax7CreER/CreER, or R26NG/NG were used instead of the heterozygotes. This was done to reduce
breeding times. There were differences noted in leakiness, see section 2.4, but otherwise mice
were healthy and viable. See Table 2.1 for a list of PCR primers, product size, and conditions
used for genotyping.
Fluorescence Activated Cell Sorting (FACS)
Satellite cells were isolated as described previously with some modifications.177,178 Total
mouse hind limb muscles were minced for 7 min and digested with 0.1% (w/v) collagenase type
II (Gibco, 17101-015) and 2.5 units/mL Dispase II (Gibco, 17105-041) in DMEM for 1 hr with
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gentle trituration every 15 min. The digestion was terminated by the addition of 20% FBS in
DMEM and the samples were passed through 100 μm and 70 μm cell strainers. Cells were
subjected to a red blood cell-lysis and were incubated in 10% FBS in DPBS (Gibco, #14190250) for 15 min. For RNA and cell culture experiments, cells were washed and resuspended in
2% FBS, filtered through a 35 µm cell strainer, and a 1:20 dilution of a 100 µg/mL propidium
iodide solution was added for live/dead gating. Cells were sorted with a BD FACSAria II based
on a hierarchy of live/dead, forward and side scatter and gated to include cells positive for GFP
(see Fig 2.2).
Satellite Cell Cultures
Cells were used at passage number of 4 or less. All FACS-isolated cells were plated in
growth medium [GM: 20% FBS (Hyclone, SH30071.03), 2.5 ng/mL basic-FGF (Life
Technologies, PHG0264), and 1x Penicillin-Streptomycin in DMEM] on 35 mm tissue culture
plates coated with 1 mg/mL Matrigel (Corning, 356231). In order to minimize differentiation in
GM, cells were plated at a low density, fed every 1 to 2 days, and were passed at a confluency
of <50% until fixation. To assess differentiation capacity, cells were maintained in GM in 35 mm
tissue culture dishes until reaching approximately 70% confluency (5-6 days) and then were
passed into larger dishes in GM until reaching >70% confluency (2-3 days). Cells were then
switched to differentiation medium [DM: 10% Horse Serum, and 1x Penicillin-Streptomycin in
DMEM] and fed every 3 days until fixation. Cultured cells were fixed for 5 min in 4% PFA
(Electron Microscopy Sciences, 15700)/PBS after 1, 3, 7, 14, 21 or 28 days in growth medium
or after 3, 7, 14, 21, and 28 days in differentiation medium, rinsed in PBS and PBS-T (0.1%
Triton X-100 in PBS), and processed for immunofluorescence.
To test the plasticity of experimental satellite cells they were cultured in adipogenicinducing media. Adipogenic media (10% FBS, 500 µM 3-isobutyl-1-methylxanthine [Sigma
I5879], 1 µM dexamethasone [Sigma D4902], 10 µg/mL human recombinant insulin [Sigma
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91077C], and 1% Pen/strep in DMEM) was fed to cultures 3-4 days after isolation. Cultures
were fed every 3 days and fixed 14 and 21 days after isolation.
Tamoxifen and Cardiotoxin Treatment
Tamoxifen (Toronto Research Chemical, T006000) was dissolved in corn oil at a
concentration of 50 mg/mL. Unless otherwise noted, all experimental mice were between 8-13
weeks of age and were administered tamoxifen at a dose of 10 mg via oral-gavage for 5
consecutive days. Muscle injury was induced at least 3 days after the last tamoxifen dose by
injecting 50 μl of 10 μM Naja mossambica mossanbica cardiotoxin (Sigma-Aldrich, C9759) in
PBS into both tibialis anterior muscles (TA) and 100 uL into both gastrocnemius muscles. For
RNA-seq experiments, mice were fed tamoxifen chow (500 mg/kg, Envigo, TD.130858) for ~1
month, and 3 days later were processed as described below.
Immunofluorescence
Cultures were fixed in 4% PFA/PBS for 15 min at room temperature and then washed in
PBS. After fixation and washing, satellite cell cultures were blocked in PBS containing 10%
goat serum, 2% bovine serum albumin (Sigma-Aldrich, A2153) and 0.2% Triton X-100 for 45
min at room temperature. Cultures were then incubated with primary antibodies overnight at
4°C in blocking solution, washed 3X in PBS/0.5% Triton X-100 (PBT) and incubated in
secondary antibodies at room temperature for 1.5 hr in blocking solution. After washing in PBT
as above, cultures were incubated in 0.1 µg/mL DAPI to visualize nuclei. Primary antibodies
were used at the following dilutions: mouse anti-chicken PAX7 (1:10 of hybridoma supernatant);
MF20 (undiluted hybridoma supernatant); mouse anti-rat myogenin (F5D, undiluted hybridoma
supernatant); mouse anti-human MYOD 5.8A (1:250); rabbit anti-desmin (1:500), and anti-rabbit
perilipin (1:400, Sigma-Aldrich, P1817). The following secondary antibodies were used (1:500,
Life Technologies): Alexa Fluor 555-conjugated goat anti-mouse IgG (A-21424); Alexa Fluor
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568-conjugated goat anti-mouse IgG (A-11004); Alexa Fluor 568-conjugated goat anti-rabbit
IgG (A11036).
RNA Isolation and RT-qPCR
Experimental and control mice were given tamoxifen as described above and left
uninjured. For TLDA card analysis, cells were FACS-isolated and grown as described above.
Growth media samples were passed 1-2 times and kept in GM for 7 days until RNA isolation.
Differentiation media samples were passed once and grown until ~70% confluent, then media
was switched to DM and cells continued to be cultured for 7 days, for a total of time of 12-13
days in culture. RLT lysis buffer (Qiagen, 79216) was directly added to the culture dishes.
Samples were then processed with QIAshredder columns (Qiagen, 79654) and RNA isolated
with the RNeasy Mini Kit (Qiagen 74104). RNA quality and quantity were assayed with an
Agilent RNA 6000 Pico Kit (Agilent, 5067-1513) on an Agilent 2100 Bioanalyzer. All RNA
Integrity Numbers were greater than 6.0. 125 ng of RNA was reverse transcribed with an iScript
Advanced cDNA Synthesis Kit (BioRad, 172-5038). Samples were loaded on a custom TaqMan
Low Density Array (TLDA) card (Applied Biosystems, 4342259) containing 96 assays (see
Supplemental Table 2.1) and run on an Applied Biosystems 7900HT Fast Real-Time PCR
System. Each condition contained 2 biological replicates. Bmpr2 was used as the reference
gene for all samples, as it had the lowest variance in Ct values between conditions, averages
with standard deviations given here: GM: dKO: 26.89 ± 0.50, Het: 26.73 ± 0.72, DM: dKO: 26.75
± 0.49, Het: 26.51 ± 0.49. Genes with Ct values > 30 were not included in data analysis. Fold
differences were calculated by the Livak Method.179 Student’s t-test was used to determine
statistical significance between genotypes. p < 0.05 was considered statistically significant.
For RNA analysis of freshly-isolated dKO and dHet cells, experimental and control mice
were given tamoxifen as described above and either left uninjured or were injected with 100 µL
of 10 µM cardiotoxin in PBS into their TA and gastrocnemius muscles of both legs. In order to
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minimize prep time as well as to not bias our collection based on cell surface markers, satellite
cells (uninjured, 3 dpi and 12 dpi) and their progeny, were isolated as GFP+ cells via FACS as
described above. Greater than 10,000 cells were collected directly in RLT lysis buffer. Samples
were then processed with QIAshredder columns and RNA isolated with the RNeasy Micro Kit.
RNA quality and quantity were assayed as described. All RNA Integrity Numbers were greater
than 8. Either 1.7 ng (for uninjured samples) or 10 ng (for injured samples) of RNA were
reverse transcribed with an iScript Advanced cDNA Synthesis Kit. Samples were pre-amplified
for 12 cycles using SsoAdvanced PreAmp Supermix (BioRad, 1725160) and TaqMan assays
run on a BioRad CFX96 qPCR system (see Table S1, Supplemental Experimental Procedures).
Each time point contained 3 biological replicates and each biological replicate was run in
triplicate for every gene. Samples were analyzed using CFX Manager software. To minimize
variability, the average Ct of the reference genes Gapdh and Eif1a was used in the ΔCt
calculations, averages with standard deviations given here: Uninjured: dKO: 24.26 ± 0.47; dHet:
23.25 ± 0.51; 3 dpi: dKO: 21.05 ± 0.17; dHet: 20.79 ± 0.48; 12 dpi: dKO: 24.58 ± 0.48; dHet:
24.5 ± 0.30. Due to variation in expression of reference genes between samples, only
comparisons within a specific time point should be made. Genes with Ct values > 30 were not
included in data analysis. Data was analyzed as above.
RNA-Sequencing
RNA was isolated via FACS as described above, following the same protocol and
uninjured and injury timepoints as well, though cells were collected in 10% FBS in PBS. RLT
lysis buffer was added to the sample tubes after spinning them down and aspirating the
solution. In order to collect enough RNA for sequencing, four and two mice were pooled for
each dKO and dHET uninjured timepoint, respectively. All other timepoints used one
mouse/timepoint. All RINs were > 8.8. Library preparation and sequencing was performed by
Bo Reese and Li Lu at the Center for Genome Innovation at the University of Connecticut. 12
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RNA samples were prepared for RNA-Seq using the Illumina TruSeq Stranded mRNA sample
preparation kit, Set A. The samples were sequenced on an Illumina NextSeq 500, averaging
~130 million paired-end reads/sample. Reads were mapped to the mouse mm10 genome
(NCBI Build 37) using STAR.180 The aligned reads were counted with featureCounts and
differentially expressed genes were identified using DESeq2.181,182 Due to the mixed use of
male and female mice, anything mapped to the X or Y chromosomes were deleted before
performing differential gene expression analysis. A chosen threshold for differentially expressed
genes was adjusted p-value < 0.05, and fold change greater than 1.5. Gene ontology and
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed in
Advaitabio (www.advaitabio.com). For determination of direct targets of MyoD ChiP-seq and
RNA-seq data were both inputted into BETA (binding and expression target analysis)
[cistrome.org/ap/].198 ChIP-seq data accession numbers for Gene Expression Omnibus are
GEO:GSE75370 and GSE56131.51,52 See appendix C for a more detailed protocol.
Imaging
Whole mount fluorescence images were captured on a Leica MZFLIII stereomicroscope
(Spot RT3 digital Camera), and images of cultured cells were captured on either a Nikon TMS
(phase: Nikon Coolpix 950 digital camera) or a Nikon Eclipse TE2000-U inverted microscope
(fluorescence: QImaging Retiga EXi digital camera) microscope. Minor adjustments in
brightness, midtone, color and contrast, which were applied to the entire image, were made in
Photoshop.
3.4 Results:
dKO Satellite Cells Maintain Some Myogenic Traits
While dKO satellite cells cannot undergo myogenesis, the block being in the expression
of Myog, they do have some myogenic characteristics. In FACS-isolated cultured cells of
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uninjured mice, the vast majority of dKO cells maintain Pax7 protein expression in GM and DM.
This contrasts with dHET cells, the majority of which in DM and under confluent conditions
express Myog, abolish Pax7 expression, and fuse with each other. Though, in culture there are
some mononuclear Pax7+ “reserve cells” that do not undergo differentiation (Fig 3.1). dKO
cells also express Desmin, a marker of activated myoblasts, though with time in culture Desmin
expression becomes much more variable. Two markers are really not sufficient to determine
cell identity, so we expanded the marker set in vitro via 94 gene custom TLDA cards. Data from
cells cultured 7 days in GM and 7 days in DM, respectively, show that while dKO cells generally
do not express myogenic differentiation genes like Myog and Myh4 (Fig 2.5), they do have
similar expression of some satellite cell and early myoblast markers like Ncam1, Vcam1, Itga7,
Foxk1, and even have more expression of CD34 and Sdc4 in GM. As the cells progress in
culture, they lose some of that marker expression with respect to dHET cells, e.g. Ncam1 and
Itga7.
qRT-PCR and RNA-seq experiments allow us to see that a similar phenomenon occurs
in vivo. Many early myoblast and satellite cell markers are not significantly different between
FACS-isolated dKO and dHET cells at the uninjured, 3 dpi, and 12 dpi timepoints. See
supplemental table 3.1 for fold changes at each timepoint. What is most striking, is that at all
time points both in vivo and in vitro there is comparable expression of Myf5 between dHET and
dKO cells. Myf5 is a myogenic determination factor seen almost exclusively in skeletal muscle
precursors and skeletal muscle differentiating cells. This combined with Pax7 expression
indicates that dKO satellite cells may be trying to execute the myogenic program, but they
cannot complete it. It must be noted that this Myf5-null allele is almost completely intact; it only
lacks the endogenous transactivation domain, and it cannot complete adult myogenesis.41
While dKO cells do express many satellite cell markers, most of those genes are not exclusive
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to satellite cells and myoblasts and can be found in other lineages. dKO satellite cells can also
form other cell types.
A Minority of dKO Satellite Cells Form Mature Adipocytes
dKO satellite cells continue to have some myogenic and satellite cell characteristics, but
they also adopt other fates. When dKO satellite cells are grown until confluent and switched to
DM, approximately 10% of them (n = 3) became mature, perilipin+ adipocytes (Figure 3.2).
These cells were never seen in low confluent conditions or in GM, regardless of the confluency.
TLDA card analysis of cultured cells in 7 days of GM and 7 days in DM, respectively, show a
significant increase in adipogenic markers like Pparγ, and Fabp4. The same is true for dKO
satellite cells in vivo, but only after injury, where approximately 7% of GFP+ dKO cells are
perilipin+ at 6 dpi (Supplemental Fig 3.2). RNA-seq analysis of FACS-isolated cells supported
the adipogenic conversion. However, while we could collect preadipocytes, we could not collect
mature adipocytes, due to their large size and lipid content they were lost during sample
processing. Using RNA-seq data we conducted gene ontology analysis of uninjured, 3 dpi, and
12 dpi dKO and dHET satellite cells, only 3 dpi dKO cells generally upregulated fat
differentiation genes as indicated by gene ontology analysis (GO #0045444, 0045598,
0045600).
This lead us to question whether dKO satellite cells were multipotent, or perhaps there
were a subset of cells predisposed to becoming mature adipocytes. In order to investigate that,
single dKO cells were sorted into individual wells of 96-well plates. They were grown until
confluent in areas of the wells and switched to DM. Approximately 3.3% of all dKO colony
forming wells (n = 2, 242 wells) contained a mix of fibroblastic cells and adipocytes. The
majority of wells had only fibroblast-like cells.
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Interestingly, dKO cells were more open to fate change than control cells. When
cultured in adipogenic-promoting media, the number of lipid-droplet containing dKO cells
drastically increase, while no adipocytes are seen in the control cultures. It was also shown that
the lipid-droplet containing dKO cells no longer had detectable Pax7 protein, further
demonstrating a complete fate switch.
The Majority of dKO Satellite Cells are Fibroblastic
While ~10% of dKO satellite cells become mature adipocytes in vitro, and other satellite
cells maintain some semblance of myogenic programming, the question remains what else, if
anything, do they become? By morphology dKO cells in prolonged cultures appear fibroblastic,
they are multipolar and unlike dHET satellite cells, they can stick to glass, a feature of
fibroblasts, but not satellite cells.199,200 dKO cells also upregulate some fibroblastic genes in
both GM and DM culture, like Col1a1, Il4ra and Pdgfrα (Fig 3.3). Similarly, in vivio after injury
there is a large amount of fibrotic tissue, as evidenced by Picrosirius red staining which stains
collagen (Supplemental Fig 3.3). Many of the fibrotic-like cells in the injured area are GFP+,
suggesting that they are contributing to the fibrosis of the injured muscle.
Isolating these cells from uninjured and injured muscle and performing RNA-seq gives
us a wider set of fibrogenic markers to assay. We found that, as opposed to adipogenic
markers which are detected only at 3 dpi, dKO satellite cells express fibrogenic genes and
processes at all timepoints assayed as calculated by gene ontology analysis. A major source of
fibrosis in skeletal muscle is from fibro/adipogenic progenitors (FAPs).201 These mesenchymal
stem cells can give rise to both mature adipocytes and fibrogenic cells. A 2011 paper by
Uezumi et al listed upregulated genes in FAPs as compared to satellite cells by microarray.201
When we compare gene expression between our control and mutant satellite cells to these
FAPs, we find more similarities between FAPs and dKO cells than FAPs and dHET cells. The
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time point with the greatest number of genes in common was 3 dpi. This further suggests that
dKO cells are becoming fibrogenic.
Quizzically, uninjured dKO satellite cells express fibrotic genes greater than dHET cells.
This suggests that they could contribute to fibrosis over time in uninjured muscle. However,
when we generate dKO satellite cells in mice, age them and leave them uninjured, we see no
evidence of increased fibrosis over dHET mice based on Pircosirius red staining (Supplemental
Fig 3.3). This suggests that while fibrotic expression is different between the dKO and dHET
cells, they might not be creating any functional protein in the uninjured state.
MyoD-SA and Myf5-SA Cells are More like dHET and dKO Cells, Respectively.
Similar to what was found in chapter 2, MyoD-SA satellite cells are similar to dHET cells
(Figure 3.4). They express Desmin and Pax7 protein in all cells in GM and downregulate Pax7
in differentiating cells. They do not undergo differentiation into mature adipocytes, even in
adipogenic-inducing media, and they do not form fibroblastic cells either, in vitro or in vivo.
Myf5-SA satellite cells are similar to dKO, in that in low-serum conditions a small minority can
become mature adipocytes, and those numbers greatly increase in inducing media. They also
lose Desmin and Pax7 protein expression in GM over time. However, Myf5-SA satellite cells do
not become adipocytes in vivo¸ and Myf5-SA mice have only a delay in regeneration after injury,
not a complete failure like dKO cells.
RNA-seq Reveals More about MyoD and Myf5’s Roles in Adult Myogenesis
Before I begin this section, I want to note some caveats about the RNA-seq data. I had
to pool 4 and 2 mice together for the uninjured samples, as the RNA amount from an individual
mouse was not sufficient for the library prep kit. Perhaps as a result of that, the biological
replicates for the uninjured dHET samples are the least correlated among all the samples
(Supplemental Fig 3.4). Also, due to the difficulties and low odds of generating dKO mice, there
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were a mix of male and female mice used. In order to control for that I deleted counts from any
genes that mapped to the X and Y chromosomes. This does not completely correct for that,
and actually leaves out important functional genes on the X chromosome, e.g. dystrophin.
Regardless, much can still be learned from this analysis, and the raw data includes it and can
be used for future analyses.
RNA-seq analyses can reveal a lot about the underlying biology and lead to novel genes
involved in biological processes, e.g. Myomaker (formally known as Tmem8c) a necessary
fusion protein for myogenesis was recently discovered because it had a similar expression
profile to MyoD and Myog.202 Our RNA-seq data shows the largest number of differentially
expressed genes at 3 dpi, directly when dHET cells are undergoing adult myogenesis, though
there are large numbers of differentially expressed genes at the uninjured state, showing large
changes to the transcriptome already (Fig. 3.5). Looking at the top 20 significantly differentially
expressed genes at each timepoint, shows that at 3 dpi, the vast majority of genes differentially
expressed are skeletal muscle differentiation genes, which are upregulated in the dHET.
Though, looking at those lists shows that many of the genes upregulated in the dKO, and even
some in the dHET are not well annotated and further analysis could lead to more key myogenic
genes. For example, Wisp2 (CCN5) is greatly upregulated in the uninjured dKO samples. It is
a part of the Wnt inducible signaling pathway and its overexpression was recently implicated as
opposing cell proliferation and promoting differentiation in fibroblasts.203 However, its effects on
myoblasts or satellite cells are not well understood, and it could be having a similar effect.204
While the individual significantly up- and downregulated genes are of interest, it is
difficult to go through them all one by one. To better analyze broad changes in pathways or
cellular markers we performed gene ontology and KEGG pathway analyses on our results. The
differential gene expression data sets were uploaded to AdvaitaBio, a company that specializes
in gene ontology and pathway analysis, among other things. Using an adjusted p-value < 0.05
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and a fold change of >1.5, gene ontology and KEGG pathway analyses were performed.
Looking at the GO terms with the lowest p-values (Elim-pruning corrected), as well as KEGG
pathway analysis (FDR-corrected) shows many collagen and extracellular matrix terms
upregulated at all timepoints, further supporting the fibrogenic conversion of dKO satellite cells.
Interestingly, cell division genes (GO #0051301) are greatly downregulated in the dKO uninjred
timepoint. This is not a surprise, as it has been found that MyoD-null satellite cells tend to be
slow to enter the cell cycle and have fewer cell divisions.205
Finding Putative Direct Targets of MyoD
In addition to differential expression analysis, this RNA-seq data in combination with
published ChIP-seq data can allow us to determine potentially novel direct targets of MyoD.
Many changes occur in satellite cells as they become activated and undergo myogenesis, e.g.
proliferation, and differentiation. However, while some direct targets of MyoD have been
identified, many genes are merely suggested to be directly upregulated, but this is not
definitively known.206,207 MyoD is considered a transcriptional activator, so it is of interest to
identify potential direct targets of MyoD in endogenous satellite cells. One way researchers do
this is via ChIP-seq, which finds places where a transcription factor like MyoD binds to the
genome. However, previous ChIP-seq reports show that MyoD binds to many thousands of
locations on the genome.51,52 Not all binding sites found in these experiments are functional.
Additionally, differential expression analysis via RNA-seq of a transcription factor’s KOs and
wildtype samples cannot ascertain direct targets of the transcription factor, due to potential
downstream effects of a direct target.
To determine which significantly upregulated genes are direct targets of MyoD, we used
a program called BETA (binding and expression target analysis). BETA combines transcription
factor ChIP-seq data with gene expression data in order to determine potential direct target
genes.198 BETA considers all genes 100 kb within binding peaks as potential targets and uses a
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monotonically decreasing function based on distance between the binding site and a gene’s
transcription start site to calculate a score. BETA factors in both differential expression levels
and regulatory potential of factor binding to calculate a rank product, which can be treated like a
p-value. The lower the rank product, the more likely the gene is a direct target of the
transcription factor. Genes with more binding potential and more differential expression are
more likely to be scored as direct targets.
Our differential expression analysis of dKO satellite cells and dHET satellite cells
indicate that in the dHET samples with adjusted p-values < 0.05, 664 and 1,398 genes were
upregulated in the uninjured and 3 dpi timepoints, respectively, that is these genes were
upregulated in the dHET compared to the dKO. If we look at genes upregulated > 2-fold, those
numbers become 315 and 654 genes for the uninjured and 3 dpi samples, respectively. ChIPseq data input was from cultured proliferating satellite cells and MyoD-null and Myf5-null mouse
embryonic fibroblasts that were then transduced with MyoD and differentiated. We did not
analyze the 12 dpi samples, as regeneration is mostly complete in those mice, and their MyoD
mRNA levels were the lowest among the dHET genotypes.
The top 50 results based on rank product of the BETA analyses are shown in tables 3.1
and 3.2. There are 201 and 490 putative direct targets of MyoD based on expression and ChIPseq data for the uninjured and 3 dpi mice, respectively. A large portion of these are known
skeletal muscle differentiation genes, e.g. Acta1, Myog, Mymk, and Ttn, and some proliferation
genes like Mycl. However, there are a few gene whose functions are not well defined, like
6430548M08Rik, and Pnmal2. It could be worthwhile to knockout or knockdown these genes to
determine their effects on myogenesis.
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Figure 3.1. dKO satellite cells express some early myogenic genes, but they decrease
variably over time. (A-D) Immunofluorescence analysis of Pax7 expression of dHET and dKO
cells in DM. (A and B) Cultured dHET satellite cells in DM downregulated Pax7 in myotubes
(arrowheads) and maintained in some mononuclear “reserve” cells (arrows), while the majority
of dKO (C and D) cells maintain Pax7 protein expression, with some losing it as shown by the
arrow. (E-H) Immunofluorescence analysis of Desmin shows continued expression in dHET
cells (E and F), with variable expression in dKO cells (G and H), arrows show loss of Desmin in
dKO cells. Scale bars represent 50 µm. (I) TLDA card analysis of satellite cell and early
myogenic markers in GM and DM. Genes in green are upregulated in dKO cells, red indicates
downregulation, and black is no significant difference (NS) between genotypes. NA indicates
the genes in either the dHET or dKO were above the Ct value cutoff (>30), in up- and
downregulated genes, respectively. (J-L) qRT-PCR results of myogenic genes from FACSisolated cells at uninjured (J), 3 dpi (K), and 12 dpi (L) timepoints. ΔCt values were calculated
using the average Ct values of the internal controls, Gapdh and Eif1a, which were highly
consistent between genotypes within a given stage. Average Ct values were as follows:
uninjured, 23.75; 3 dpi 20.92, 12 dpi, 24.54. Each data point represents the average value of
three biological samples and three technical replicates for each sample. Error bars represent
standard deviations. p < 0.05 was considered significant (asterisks). N.D. indicates Ct value >
30. (M) DESeq2 normalized counts of the MRFs in FACS-isolated satellite cells. Note that the
dHET samples are all much more highly expressed than the dKO samples, with the exceptions
of Myf5 and MRF4. (N) Heatmap of normalized counts of satellite cell and early myogenic
genes from FACS-isolated cells.
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Figure 3.2. dKO satellite cells can become mature adipocytes. (A-D) dKO satellite cells
show a propensity for adipogenic differentiation. dKO cells were cultured in GM for 7 days and
switched to DM for 13 (A and B) or 21 (C and D) days. Examples of lipid droplet containing,
perilipin+ (PLIN1) cells at arrows (A and B). Insert in (B), is a phase contrast image of boxed
lipid-filled cell in (A and B). Pax7 is downregulated in adipogenic cells, example at arrow (C and
D). (E) TLDA card fold change shows increased adipogenic genes in dKO cells in both GM and
DM, NA indicates dHET Ct values > 30. (F) Example of differentially expressed annotated genes
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from 3 dpi RNA-seq samples using GO analysis, positive regulation of fat cell differentiation
(GO# 0045600). (G-J) FACS-isolated cells were grown to confluence and incubated in
myogenic and adipogenic inducing media for 5-6 days. dKO (G and H) cells showed increased
adipogenic differentiation, dHET (I and J) remained committed to the myogenic lineage. Scale
bars represent 50 µm (A-D), or 100 µm (G,I).
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Figure 3.3. Fibrogenic genes are upregulated in dKO satellite cells (A) Cultured satellite
cells grown in both GM and DM were analyzed on TLDA cards with dKO cells showing an
upregulation in fibrotic genes, NA indicates dHET Ct values > 30. (B-D) qRT-PCR results of
fibrotic genes from FACS-isolated cells at uninjured (B), 3 dpi (C), and 12 dpi (D) timepoints,
see Figure 3.2 for ΔCt calculations. (E) Common upregulated genes between FAPs and FACSisolated dKO or dHET satellite cells. Either 2-fold or 4-fold upregulated genes (adjusted p <
0.05) in dKO and dHET cells were compared to a list of 380 genes found to be preferentially
upregulated (at least 4-fold) in FAPs. (F) Example of differentially expressed annotated fibrotic
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genes from 3 dpi RNA-seq samples using GO analysis, proteinaceous extracellular matrix (GO#
0005578).
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Figure 3.4. MyoD-SA satellite cells are committed to the myogenic lineage, Myf5-SA cells
are not. (A-D) Immunofluorescence analysis of Pax7 expression of MyoD-SA and Myf5-SA cells
in GM 7 days post sort. (A and B) Similar to dHET cells, cultured MyoD-SA satellite cells
downregulate Pax7 in myotubes (arrowheads) and maintain it in non-differentiating
mononuclear cells (arrows), while the majority of Myf5-SA (C and D) cells maintain Pax7
expression. (E-H) Immunofluorescence analysis of Desmin shows robust expression in MyoDSA cells (E and F), with variable expression in Myf5-SA cells (G and H), arrows show loss of
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Desmin in Myf5-SA cells. (I and J) A minority of Myf5-SA satellite cells become mature
adipocytes, shown here 12 days in DM. (K and L) MyoD-SA satellite cells are committed to
myogenesis even in adipogenic media (K). The number of mature adipoctyes increases in
Myf5-SA satellite cells cultures in adipogenic media (L). Scale bars represent 100 µm (A-H),
and 50 µm (I,J).
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Figure 3.5 RNA-seq analysis and top differentially regulated genes. (A-C) Volcano plots of
DESeq2 results of uninjured, 3 dpi, and 12 dpi dKO vs dHET samples. Red dots signify genes
up or downregulated > 2 fold with adjusted p-values < 0.05, dashed and dotted black lines
indicate fold change of greater than 2. (D) Table listing number of significant (adjusted p-value
< 0.05) up and downregulated genes at each timepoint. (E-G). Top 20 differentially regulated
genes DESeq2 normalized counts by adjusted p-value at each timepoint.
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Figure 3.6 Gene ontology and KEGG pathway results. (A-C) Tables of significant GO terms
for each timepoint using Elim Pruning corrected p-values. (D-F) Advaitabio KEGG Pathway
Summary Plot, red dots are significant (FDR-corrected p-value < 0.05), x-axis represents -log10
of p-value of over represented analysis (ORA), y-axis represents -log10 of p-value of
perturbation analysis as described in Draghici et. al 2007, and Donato et al. 2013.208,209 (H)
Genes up (red boxes) and downregulated (blue boxes) at 3 dpi for GO #0005604, basement
membrane. (I) Genes up and downregulated at uninjured timepoint for GO #0051301, cell
division.

Table 3.1 Putative Direct Targets of MyoD from Uninjured Samples

Gene
Cd82
Myod1
Chrna1
Traf3ip3
Jsrp1
Aif1l
Itga7
Ckap2
Nol4
Rtn2
Gal
Ank1
Popdc2
Mymk
Myh8
Smarcd3
Bves
Kcnn3
Myog
Ccdc162
Pitx3
Cdh15
Musk
Cenpf

refseqID
NM_001271462
NM_010866
NM_007389
NM_153137
NM_028001
NM_145144
NM_008398
NM_001004140
NM_199024
NM_001025364
NM_010253
NM_031158
NM_022318
NM_025376
NM_177369
NM_025891
NM_024285
NM_080466
NM_031189
NM_001177571
NM_008852
NM_007662
NM_010944
NM_001081363

Avg Rank
Product
1.33E-06
1.33E-05
1.59E-05
3.87E-05
5.12E-05
5.20E-05
1.00E-04
1.35E-04
1.76E-04
1.82E-04
1.84E-04
1.88E-04
1.96E-04
2.05E-04
2.30E-04
2.45E-04
2.48E-04
2.57E-04
2.75E-04
2.83E-04
2.95E-04
3.23E-04
3.24E-04
4.44E-04

log2 Fold
Change
1.7
3.9
6.3
2.9
4.2
1.9
2.1
3.5
2.2
1.9
2.1
2.5
2.4
4
6.3
1.8
2.9
1.7
6.4
2.6
3.8
2.2
1.9
3.9

padj
9.24E-11
6.09E-49
2.53E-35
5.74E-12
3.60E-30
1.54E-06
5.74E-12
7.23E-15
6.55E-11
1.72E-11
4.46E-06
1.20E-24
2.52E-09
4.37E-04
1.24E-18
3.71E-11
4.91E-17
1.14E-08
3.87E-06
1.23E-03
9.11E-11
7.80E-09
8.58E-06
4.94E-10
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Dok7
Pnmal2
Rapsn
Uhrf1
Lmnb2
Iffo1
Spc24
Lix1
Wbscr17
Ppp1r14b
Ppfia4
Troap
Acta2
Mycl
Cep55
Prc1
Smug1
Anxa6
Lrrfip1
Mcm2
Myh3
Pias2
Gm4737
Trim55
Lrrc17

NM_172708
NM_001099636
NM_009023
NM_010931
NM_010722
NM_001039669
NM_026282
NM_025681
NM_145218
NM_008889
NM_001144855
NM_001162506
NM_007392
NM_008506
NM_028293
NM_145150
NM_027885
NM_001110211
NM_008515
NM_008564
NM_001099635
NM_008602
NM_001304528
NM_001081281
NM_028977

4.77E-04
5.14E-04
5.42E-04
5.46E-04
5.79E-04
6.00E-04
6.81E-04
7.30E-04
7.48E-04
8.00E-04
8.20E-04
8.29E-04
8.42E-04
8.69E-04
8.76E-04
9.65E-04
9.72E-04
9.99E-04
1.07E-03
1.07E-03
1.07E-03
1.10E-03
1.13E-03
1.18E-03
1.20E-03

3.2
2
1.5
2.6
2.2
1.5
2.9
2.7
1.5
1.1
1.1
3.8
1.3
1.2
2.7
3.2
1.5
1.2
1.1
2.2
3.4
1.1
4.8
3.5
1.2

1.11E-05
8.37E-04
4.03E-08
3.96E-09
2.66E-06
1.49E-03
1.76E-05
7.73E-08
4.33E-09
7.50E-06
4.49E-02
7.09E-10
6.12E-07
3.84E-02
1.73E-06
1.23E-08
4.87E-04
3.13E-05
4.90E-04
2.26E-07
1.01E-04
2.78E-06
5.97E-09
8.62E-07
7.87E-03

Genes identified as putative direct targets of MyoD combining ChIP-seq and RNA-seq data via
BETA. Avg Rank Product from BETA can be interpreted similar to p-values for BETA results.
Log2 Fold Change (positive indicates greater expression the dHET) and p-adj are from RNAseq differential gene expression data.

Table 3.2 Putative Direct Targets of MyoD from 3 dpi Samples

Gene
Acta1
Cd82
Aif1l
Atp2a1

refseqID
NM_001272041
NM_001271462
NM_145144
NM_007504

Avg Rank
Product
7.46E-07
6.98E-06
1.21E-05
1.77E-05

log2 Fold
Change
7.2
1.9
3.9
7.4

padj
8.41E-258
3.90E-23
1.51E-84
3.63E-190
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Mylpf
Myh3
Srl
Tnnt2
Pnmal2
Synpo2l
6430548M08Rik
Ttn
Chrng
Myom2
Lrrn1
Myog
Chrnd
Myl1
Sertad4
Tnni1
Smyd1
Chrna1
Klhl41
E2f2
Sft2d2
Mycl
Ppfia4
Mymk
Mb
Tnnt3
Myod1
St3gal5
Dok7
Stac3
Arpp21
AI467606
Cacng1
Jsrp1
Gal
Rbm24
Myl4
Cpa4
St8sia2
Iffo1
Des
Pdlim3
Ankrd1
Mymx
Trim72

NM_016754
NM_001099635
NM_175347
NM_001130178
NM_001099636
NM_175132
NM_001163760
NM_028004
NM_009604
NM_008664
NM_008516
NM_031189
NM_021600
NM_021285
NM_001177794
NM_021467
NM_001160127
NM_007389
NM_001081087
NM_177733
NM_145512
NM_008506
NM_001144855
NM_025376
NM_001164048
NM_001163668
NM_010866
NM_011375
NM_172708
NM_177707
NM_001177617
NM_178901
NM_007582
NM_028001
NM_010253
NM_001081425
NM_010858
NM_027926
NM_009181
NM_001039669
NM_010043
NM_016798
NM_013468
NM_001177469
NM_001079932

3.14E-05
3.97E-05
4.30E-05
5.18E-05
5.27E-05
5.47E-05
8.57E-05
9.95E-05
1.03E-04
1.08E-04
1.19E-04
1.20E-04
1.26E-04
1.34E-04
1.53E-04
1.55E-04
1.56E-04
1.62E-04
1.68E-04
1.82E-04
1.87E-04
2.31E-04
2.41E-04
2.54E-04
2.55E-04
2.74E-04
2.75E-04
2.76E-04
2.79E-04
2.83E-04
2.96E-04
3.05E-04
3.06E-04
3.19E-04
3.20E-04
3.45E-04
3.75E-04
3.84E-04
3.95E-04
4.07E-04
4.56E-04
4.69E-04
5.10E-04
5.12E-04
5.26E-04

6.8
11.8
5.0
6.5
5.1
7.3
2.9
9.3
8.5
6.1
7.5
12.9
7.8
7.2
1.8
7.2
6.7
6.3
7.2
4.6
1.8
5.3
3.5
9.3
2.6
4.3
4.1
1.3
5.8
4.2
6.7
4.2
4.5
8.0
6.5
5.8
5.0
6.1
3.8
1.9
1.4
4.0
2.1
10.3
3.5

1.81E-160
1.65E-134
1.04E-123
7.95E-114
2.47E-79
2.45E-132
8.56E-47
7.50E-117
3.85E-104
3.27E-122
1.86E-157
2.65E-54
4.73E-100
5.18E-85
1.95E-22
2.99E-88
1.32E-79
2.27E-77
3.01E-59
1.75E-65
1.60E-14
3.71E-27
3.74E-20
3.46E-11
1.88E-05
2.95E-64
3.29E-77
2.33E-09
9.62E-35
1.27E-43
1.05E-113
1.12E-53
9.63E-63
6.42E-65
1.06E-11
2.44E-61
1.55E-75
2.40E-29
5.30E-76
1.11E-15
5.75E-16
4.75E-52
4.05E-28
8.31E-15
9.89E-20
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Genes identified as putative direct targets of MyoD combining ChIP-seq and RNA-seq data via
BETA. Avg Rank Product from BETA can be interpreted similar to p-values for BETA results.
Log2 Fold Change (positive indicates greater expression the dHET) and p-adj are from RNAseq differential gene expression data.
3.5 Discussion
While dHET satellite cells can only differentiate into myotubes in vitro and in vivo, at
least at a population level dKO satellite cells are multipotent; a minority of them can become
mature adipocytes, the majority retain myogenic elements and have some fibroblastic
characteristics.
The clear fate change to adipogenic cells is not without precedent. Two 2013 papers
found that a very small percent of wildtype satellite cells can become brown adipocytes with
prolonged exposure to cold, and a more recent paper claimed that MyoD-null satellite cells were
more apt to become brown fat in adipogenic conditions.161,197,210 However, when we assayed for
brown fat makers, we did not see any upregulation of brown fat mRNA like Ucp1, Cidea, or
Elovl3, or staining of them in vitro. In vivo, the GFP+ fat looks like white fat, i.e. the lipid
droplets are large as opposed to brown fat’s smaller multilocular droplets. It must be noted, that
due to technical limitations, we were not able to assay the mRNA of them in vivo, as we could
not collect mature GFP+ adipocytes via FACS. Interestingly, at 3 dpi, a timepoint before mature
fat is seen, Prdm16 is upregulated in the dKO mouse. Prdm16 is a brown adipose
determination factor, whose overexpression can cause some cells, including satellite cells, to
take on brown fat characteristics, and even become mature brown adipocytes.211,212 A 2017
paper showed that MyoD-null satellite cells express lower levels of miR-133, a micro-RNA that
targets Prdm16 mRNA and prevents that transcription factor from executing brown adipocyte
programming, claiming that MyoD is a negative regulator of brown adipocyte development. 197 It
is not known how much Myf5 can regulate brown adipocyte development, though, looking at our
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results, it appears that it is at least somewhat effective, seeing that dKO cultures contained
more fat than Myf5-SA ones, and that dKO mice were the only ones to have GFP+ fat after
injury. This could be another case where Myf5 is not as potent as MyoD, or it could be that
Myf5 expression is in general lower in these Myf5-SA cells than MyoD’s expression in dHET
and MyoD-SA cells. As more miRNAs are discovered to have a role in myogenesis, more work
needs to be done to examine miRNA differences between the dKO and dHET satellite cells,
because of their potential roles to play in adult myogenesis.
While there has been debate about satellite cell heterogeneity in the literature, it is
unclear whether a subset of dKO satellite cells are more likely to become fat, if it is stochastic,
or responsive to the environment. Transdifferentiation of dKO cells is susceptible to
environmental signals as seen in adipogenic-inducing cultures, but clonal analysis showed that
single cells could give rise to both mature adipocytes and fibroblastic-cells. Of course, it may be
that such multipotent dKO satellite cells are a subpopulation. GFP+ adipocytes in dKO mice
were found to be clustered in the injured area. This could be due to either clonal expansion or a
response to cytokines from infiltrating cell types like immune cells. Further investigation is
warranted to determine if a more susceptible subpopulation exists, and what Myf5’s role is, if
any, in preventing the browning of satellite cells. Single cell RNA-seq or even just qRT-PCR
with the proper markers could determine if there are subpopulations with greater propensities to
adipogenesis. It could be interesting to perform a glycerol injection into dKO mice, as that is
known to induce lipid droplets in skeletal muscle and determine if there are more GFP+
adipocytes. The increased fat could also allow us to perform metabolic studies, as brown and
white fat behave differently with regards to thermogenesis.
The maintenance of myogenic characteristics in dKO satellite cells is not completely
surprising. These cells could be simply primed for myogenesis with respect to chromatin
structure and current expression of quiescent satellite cell genes. We did find many
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differentially expressed genes during the uninjured timepoint, but we cannot be certain that
those results would hold true in endogenous satellite cells. The act of isolating cells is a form of
injury and can be very traumatic to the cells themselves. During development satellite cells
express three of the four MRFs, as well as have current expression of Pax7 protein. Pax7 is a
pioneering transcription factor, whose expression can initiate the myogenic program in
pluripotent stem cells, and in conjunction with MyoD and Mef2b can reprogram adult fibroblasts
into muscle progenitors.213,214 Pax7 also remodels the chromatic landscape to one more
conducive to muscle. Satellite cells without functional MyoD and Myf5 cannot fully execute the
myogenic program, but they appear to try as indicated by maintaining some early myogenic and
satellite cell markers, particularly Myf5, whose mRNA is seen predominately in skeletal muscle
and its progenitors. Interestingly, Myf5 expression is increased during development in MyoDnull mice.31 RNA-seq analysis showed higher Myf5 expression at all time points, though qRTPCR results only show a significant increase at 12 dpi. Also, data from other changing cell fate
experiments, particularly to other cell types can be incomplete with respect to chromatinremodeling.215 Given that Pax7 expression was absent in the mature adipocytes, it is possible
that Pax7 protein protects dKO satellite cells from becoming fat and causes the maintenance of
myogenic characteristics. Pax7 is considered a pioneering transcription factor, whose
expression can remodel the chromatin landscape. It is possible that upon being downregulated,
it can no longer prevent/reverse changes to chromatin that make dKO cells become mature
adipocytes. Attempts were made to silence Pax7 via siRNA mediated knockdown but were not
successful and need to be repeated in another way. Another method might be to delete Pax7 in
early cultures to see if more dKO cells become fat or even more fibrogenic.
An alternative hypothesis for the maintenance of myogenic characteristics is that
deletion of MyoD is not 100% efficient. However, looking at the low levels of MyoD mRNA, the
few MyoD+ cells in culture shortly after isolation, the lack of myotube formation in vitro and in
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vivo, and the data that shows incredibly downregulated muscle differentiation genes, including
Myog, strongly suggests that MyoD is efficiently deleted in dKO satellite cells. It is possible that
if we waited longer after deletion of MyoD, then dKO satellite cells would be even less like
satellite cells in terms of marker expression. Interestingly, some reports state that
Increased fibrosis is a hallmark of failed muscle regeneration. It can be seen in
diseased states like muscular dystrophy, and also when Pax7 is deleted in satellite cells, or
when satellite cells themselves are ablated.77,146 It is also seen in aged skeletal muscle, though
not to the extent of the previous examples.196 The source of the increased fibrosis in these
situations is usually from fibroblasts and FAPs. The increase in fibrotic gene expression in our
samples is similar to aged satellite cells, which are more fibrotic, but unlike dKO satellite cells,
they can still form skeletal muscle.216,217 The causes are also different, dKO cells lack MyoD
and Myf5, while it has been proposed that increased Wnt signaling, and older bone marrow cells
and immune systems, among other things, negatively affect satellite cells in older mice.216
Interestingly, dKO cells most resemble FAPs at 3 dpi, most likely because the Uezumi et al.
microarray data is from mdx mice which constantly undergo bouts of muscle regeneration. In
that milieu FAPs would be more active, our 3 dpi is in the heart of muscle regeneration which
would be similar to that. More interesting experiments would be to determine if dKO satellite
cells actually perform the same functions as fibroblasts, e.g. do they actually secrete
extracellular matrix proteins, or do they only express the mRNA of those genes?
Finally, a lot of data was generated via RNA-seq. Unsurprisingly, many of the putative
direct targets of MyoD protein and many of the differentially expressed genes are known
skeletal muscle genes. However, there is still room for discovery. The two recently
characterized fusion proteins were discovered from previously predicted and detected
genes.202,218 Some candidate genes that show up in our lists are: Pnmal2, and
6430548M08Rik. An ambitious early stage graduate student could do well by looking at the top
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differentially expressed genes at each timepoint to find those that are not well annotated. They
may play important and novel roles in myogenesis. Of course, any genes of interest should be
validated by well-designed qRT-PCR experiments. Another set of experiments to look at is
early activation of dKO satellite cells. It is not surprising that satellite cells are activated as part
of isolation, it is a violent experience for cells that involves processing over a period of 4 hours.
There has been a recent paper on how to isolate or analyze truly quiescence satellite cells, and
this could be interesting to look at to see satellite cells before activation, as they found that over
2,800 genes can be upregulated and over 4,800 genes downregulated during FACS-isolation of
non-fixed satellite cells.219 Repeating the uninjured RNA-seq experiment using their procedures
could be interesting. It would allow us to see the difference between early activation of dKO and
dHET satellite cells, as well as MyoD-SA and Myf5-SA. What precise roles do MyoD and Myf5
play in that? Fixing the cells may also prevent what is seen in the dHET samples, as they have
the largest difference in sample correlation. An example of that is how Myog expression is so
different between the two replicates.
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Supplemental Figure 3.1 dKO satellite cells express makers of myogenic commitment
after muscle injury [Taken from Yamamoto et al, 2018] (A-F) Pax7 immunofluorescence of
transverse cryosections of the TA muscle 31 days after cardiotoxin-induced muscle injury.
Pax7+ cells (examples at yellow arrowheads) carrying a wild-type allele of MyoD (A, D) or Myf5
(B, E) were associated with regenerated fibers, identified by their central nucleation (examples
at arrows). Pax7+ dKO cells were numerous at 31 days post-injury (dpi) (C, F). Apparent Pax7
protein levels were reduced in dKO satellite cells compared to MyoD-SA and Myf5-SA cells.
Exposure times were identical between genotypes. The GFP signal was captured before the
antigen retrieval step for Pax7 immunofluorescence, which resulted in slight shift of cell position
between (A-C) and (D-F). All mice were heterozygous for Pax7CreER and homozygous for R26NG.
Scale bars represent 10 μm
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Supplemental Figure 3.2
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Supplemental Figure 3.2 dKO satellite cells can adopt an adipogenic fate following
muscle injury [Taken from Yamamoto et al, 2018]. (A-H) Immunofluorescence localization of
Pax7 and perilipin on transverse cryosections of TA muscles collected 6 days following
cardiotoxin-induced injury. Some dKO satellite cells gave rise to GFP+perilipin+ adipocytes (E,
F, H; examples at white arrowheads), whereas MyoD-SA satellite cells did not adopt an
adipogenic fate (A, B, D). Representative PAX7+ cells are shown with yellow arrowheads. Note
that adipocytes were Pax7-negative (C, D, G, H). GFP images were captured after Pax7
immunofluorescence processing, which required antigen retrieval and resulted in a substantially
reduced GFP signal, especially in myofibers (A, B). Arrows in (E), (F), and (H), represent
examples of GFP-negative, PERILIPIN+ adipocytes, the majority of which are expected to be of
non-satellite cell origin. Scale bars represent 25 μm (A, E)
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Supplemental Figure 3.3 dKO satellite cells only adopt fibrotic fate only after injury in
vivo [Taken from Yamamoto et al, 2018]. (A-D) Picrosirius red staining of TA crosssections at
11 dpi. The extent of COLLAGEN-rich fibrotic tissue is dramatically increased in dKO muscle.
(E) Schematic representation of tamoxifen/cardiotoxin administration schedule. Muscles were
analyzed between 16- and 19-months-of-age. (F-H) Merged images of gastrocnemius
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cryosections stained for Pax7 (green; arrowheads), laminin (red) and DAPI (blue). Comparable
numbers of Pax7-positive mononuclear cells were observed in MyoD-SA, Myf5-SA and dKO
muscles. (I-L) Cross sections of injured Myf5-SA (I, K) or dKO (J, L) TA muscles 11 days after
cardiotoxin injection. Sections were stained with Picrosirius Red to detect collagen
accumulations (I, J) or represent merged GFP/DAPI images (K, L). The exposure time to
capture the GFP signal was three times longer in panel (L) than (K). Rare small nascent fibers
are labeled with arrowheads in (J) and (L). (M-O) Cryosections of uninjured TA muscles stained
with Picrosirius Red. Muscle structure and the quantity of interstitial connective tissue was
comparable between MyoD-SA, Myf5-SA, and dKO muscles. (P-R) Low magnification images
of uninjured gastrocnemius muscles imaged for GFP and DAPI. Lineage-labeled, GFP+
myofibers (yellow arrowheads) were observed in MyoD-SA and Myf5-SA muscles, but not in
dKO muscles. Scale bars represent 50 μm (A-D, M-O, K, L) 25 µm (F-J), and 200 µm (P-R).
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Supplemental Figure 3.4 RNA-seq sample information. (A) Sample information for mice
used in RNA-seq analysis including RNA integrity number (RIN). The uninjured timepoint had
lower RNA quantity and samples needed to be pooled for library prep. (B) Hierarchical
clustering heatmap of samples. This shows the correlation of gene expression for all pairwise
combination of samples. Most biological replicates have >0.995 with the exception of the
uninjured dHET samples.
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Supplemental Table 3.1 Satellite cell marker expression from RNA-seq
Uninjured

3 dpi

Gene

Fold
Change

Cd34

2.2

12 dpi

padj

Gene

Fold
Change

Sdc4

2.3

Cd34

2.2

Myf5

2.3

padj
2.89E13
5.28E08
6.33E06

Tenm4

2.9

Calcr
Vcam1

3.2
1.5

Myod1

-15.1

Itga7

-4.2

Cdh15

-4.6

Cxcr4
Des

-4.5
-1.7

0.0005
6.09E49
5.74E12
7.80E09
3.75E05
0.0004

Pax7

-1.5

0.05

Spry1

-17.6

Met

-1.8

0.001

Myod1

-5.9

Tenm4

-1.5

0.03

Itga7

-10.9

Calcr

1.0

1.0

Cdh15

-2.6

Cav1

1.1

0.6

Des

-4.2

Foxk1

1.2

0.5

Nes

-2.4

Hey1

1.0

0.9

Six4

-3.0

Itgb1
Mef2c
Myf5
Myf6
Mustn1
Ncam1
Nes
Pax3
Sdc3
Sdc4
Six1
Six4
Spry1
Srf
Vcam1

1.1
1.1
1.2
1.4
1.5
1.0
1.1
1.0
1.0
1.0
1.0
1.1
1.1
1.1
1.0

0.6
0.7
0.4
0.2
0.1
0.9
0.6
0.9
0.9
0.9
0.9
0.6
0.7
0.6
1.0

Met
Six1
Mef2c
Mustn1
Cxcr4
Hey1
Ncam1
Myf6
Pax3
Cav1
Sdc3
Itgb1
Foxk1
Pax7
Srf

-2.0
-3.0
-1.9
-1.8
-1.5
-1.3
1.6
1.4
1.2
1.2
1.1
1.1
1.0
1.0
1.3

Gene

Fold
Change

Vcam1

2.6

Sdc4

3.6

Cav1

3.0

padj
5.12E06
1.54E05
2.02E05

0.0001 Ncam1

2.0

0.003

0.001
0.01
3.29E77
5.37E32
3.72E17
5.75E16
4.01E11
1.85E10
7.99E06
8.29E06
0.002
0.01
0.00
0.02
0.08
0.1
0.2
0.2
0.3
0.4
0.7
0.8
1.0
0.1

Pax3
Met

2.2
1.6

0.03
0.03

Calcr

-3.6

Myod1

-7.6

Hey1

-3.4

Cdh15

-4.7

0.0004
4.05E11
1.53E06
4.54E06

Tenm4

-2.0

0.008

Mef2c

-1.8

0.01

Nes

-1.8

0.01

Cd34
Spry1
Itgb1
Six1
Myf5
Foxk1
Itga7
Six4
Myf6
Pax7
Cxcr4
Sdc3
Des
Srf
Mustn1

-1.4
-1.4
1.3
1.4
1.4
1.2
1.2
1.1
1.1
1.1
1.0
1.0
1.0
1.4
1.0

0.04
0.05
0.08
0.09
0.2
0.2
0.3
0.5
0.6
0.7
0.9
0.9
0.9
0.06
1.0
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Green is upregulated genes, red is downregulated genes, adj p-value cutoff <0.05 for
significance.
Supplemental Table 3.2 Top 50 differentially expressed genes in dKO cells by adjusted pvalue
Uninjured
Gene

Myod1
Wisp2
Dcn
Chrna1
Sgca
Pdgfra
Jsrp1
Pcsk6
Cilp
Ank1
Smoc2
Sfrp4
Gsn
Olfml3
Meox1
Cxcl14
Smoc1
Lepr
Cmklr1
Kng2
Mfap5
Kcnc1
Lrrn4cl
Ecm1
Thbs4
Dpep1
Clec3b
Myh8
Colgalt2
Pcolce

3 dpi
Fold

Adjusted

Change

p-value

-15.1
23.2
9.5
-79.9
-25.2
10.1
-17.9
12.3
8.2
-5.8
11.0
7.5
4.8
5.6
15.0
12.0
5.8
8.2
6.3
30.6
6.1
15.7
8.0
7.3
6.5
8.6
9.6
-80.2
8.4
5.1

6.09E-49
1.25E-41
3.83E-36
2.53E-35
1.93E-33
5.55E-31
3.60E-30
8.59E-29
8.36E-26
1.20E-24
1.16E-23
1.41E-23
1.58E-23
3.61E-23
7.13E-23
6.83E-22
8.96E-21
1.59E-20
1.61E-20
1.87E-20
1.87E-20
2.60E-20
5.15E-20
5.32E-20
5.85E-20
1.27E-19
5.74E-19
1.24E-18
1.36E-18
1.99E-17

Gene

Acta1
Atp2a1
Mylpf
Lrrn1
Scn5a
Myh3
Synpo2l
Srl
Myom2
Ttn
Tnnt2
Arpp21
Col6a2
Chrng
Lmo7
Chrnd
Xirp2
Pdgfra
Tnni1
Col6a3
Myl1
Aif1l
Col6a1
Scara5
Smyd1
Pnmal2
Serpine1
Chrna1
Myod1
St8sia2

12 dpi

Fold

Adjusted

Change

p-value

-148.9
-171.7
-109.9
-184.6
-81.3
-3452.4
-162.8
-32.1
-69.6
-640.3
-89.4
-105.6
19.5
-362.4
-24.0
-224.8
-130.6
20.3
-143.6
11.2
-149.6
-14.4
15.0
23.3
-104.9
-34.4
9.0
-76.5
-17.6
-14.4

8.41E-258
3.63E-190
1.81E-160
1.86E-157
1.87E-154
1.65E-134
2.45E-132
1.04E-123
3.27E-122
7.50E-117
7.95E-114
1.05E-113
1.14E-112
3.85E-104
3.70E-102
4.73E-100
4.18E-91
3.25E-89
2.99E-88
8.34E-87
5.18E-85
1.51E-84
1.22E-83
4.19E-83
1.32E-79
2.47E-79
5.63E-78
2.27E-77
3.29E-77
5.30E-76

Gene

Anxa8
Igfbp2
Nr4a2
Cd109
Myog
Tmem26
Pappa2
C1qtnf3
Nupr1
Actc1
Ano1
Mylk4
Kcnc1
Lmcd1
Tnn
Cgref1
Smoc1
Mymk
Otoa
Ptgis
Tiam2
Acp5
Chodl
Aqp1
Dlk1
Cemip
Gdnf
Sphk1
Nfatc2
Tnnt2

Fold

Adjusted

Change

p-value

23.7
144.1
9.0
8.4
-107.9
17.8
27.7
6.9
6.2
-61.1
19.0
-93.2
55.9
7.2
27.5
8.3
8.1
-57.8
-75.7
7.8
7.6
6.5
-4.8
12.4
-20.4
8.2
13.4
5.2
9.9
-36.5

3.07E-93
3.41E-91
5.47E-61
1.14E-60
1.12E-45
5.56E-44
1.55E-42
2.28E-42
2.28E-42
3.28E-40
1.23E-39
1.44E-37
1.64E-37
6.06E-37
3.13E-36
3.42E-36
1.95E-35
5.47E-35
1.32E-33
5.90E-33
3.01E-32
7.19E-32
7.26E-32
6.02E-30
1.29E-29
7.14E-29
1.29E-27
2.40E-27
5.10E-27
8.33E-27
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Bves
Dnm3os
Scn7a
Aebp1
Ces1d
Itga11
Ckap2
Hspb8
Col14a1
Cpxm2
Sema3c
C3
Otoa
Fst
Dpysl3
Ifi202b
Rassf2
Pamr1
Podn

-7.3
5.6
5.8
4.1
9.6
6.8
-11.3
4.7
7.1
5.3
6.2
8.5
-13.0
6.5
4.6
194.3
5.3
9.7
6.7

4.91E-17
6.30E-17
8.25E-17
2.16E-16
6.50E-16
2.46E-15
7.23E-15
1.41E-14
1.93E-14
2.45E-14
9.03E-14
1.75E-13
2.03E-13
2.07E-13
2.36E-13
2.40E-13
2.96E-13
4.52E-13
1.24E-12

Myl4
Adgra3
Mrc2
Cxcl5
E2f2
Jsrp1
Col16a1
Ryr1
Tnnt3
Smoc1
Tmem26
Klhl29
Cacng1
Iqsec3
Vegfa
Dynap
Rbm24
Tnni2
Medag

-32.8
11.4
9.7
25.0
-23.6
-262.8
11.4
-36.1
-19.3
57.8
19.4
24.9
-23.2
-9.7
7.5
-26.9
-57.3
-41.0
8.7

1.55E-75
1.41E-73
3.52E-69
3.27E-68
1.75E-65
6.42E-65
1.06E-64
2.74E-64
2.95E-64
5.17E-64
5.75E-64
8.43E-63
9.63E-63
5.31E-62
5.63E-62
7.30E-62
2.44E-61
4.28E-61
6.26E-60

Wisp2
Atp2a1
Rerg
Ereg
Sv2b
Cyp26b1
Nr4a3
Ryr1
Acta1
Slc9b2
Tnni1
Casr
Glis1
Mybpc2
Chst11
Dact2
Sfrp2
Pnmal2
S100a4

4.8
-20.4
10.5
14.9
24.5
4.9
8.5
-18.4
-26.4
16.2
-22.7
20.1
15.1
-43.1
5.0
-7.7
8.8
-22.3
6.1

1.12E-26
3.87E-26
5.86E-26
5.89E-26
9.04E-26
1.54E-25
1.57E-25
2.45E-25
3.27E-25
7.60E-24
1.43E-23
2.24E-23
2.57E-23
6.28E-23
6.93E-23
1.23E-22
2.35E-22
4.42E-22
5.27E-22

Supplemental Table 3.3 Top and bottom 10 differentially expressed genes by fold change
in dKO cells
Uninjured
Gene

Ifi202b
Arntl2
Col6a5
Gdf7
Kng2
Wisp2
Lmx1a
Sec14l4
Dio3os
Fam26e
Chrna4
Tmem181bps
Myog
Myh8

3 dpi
Fold

Adjusted

Change

p-value

Gene

194.3
71.4
39.6
32.5
30.6
23.2
22.7
18.3
16.4
15.8
-123.4

2.40E-13
3.68E-09
6.34E-07
1.97E-05
1.87E-20
1.25E-41
1.56E-4
3.27E-06
2.67E-08
3.33E-08
9.71E-08

Dnaic2
Cyp1a1
Serpina3c
Bhlhe22
Galnt13
C1s2
Aox3
C1qtnf7
Kcnip1
Nsun7
Myog

-102.3
-81.9
-80.2

9.09E-10 Myh3
3.87E-06 Trim55
1.24E-18 Gm7325

12 dpi

Fold

Adjusted

Change

p-value

330.9
310.5
218.4
145.8
132.8
100.8
96.9
95.2
90.7
71.6
-7488.7
-3452.4
-2943.8
-1294.0

3.28E-09
5.34E-09
7.83E-08
3.38E-06
3.84E-06
3.98E-06
2.26E-05
1.66E-05
2.46E-05
5.85E-07
2.65E-54

Gene

Fold

Adjusted

Change

p-value

Igfbp2
Kcnc1
Gjb4
Gjb3
Pappa2
P2rx2
Tnn
Myh13
Vtcn1
Ptprq
Myog

144.1
55.9
37.2
27.7
27.7
27.6
27.5
26.2
26.1
25.3
-107.9

3.41E-91
1.64E-37
5.50E-17
4.19E-14
1.55E-42
2.61E-07
3.13E-36
2.85E-08
4.80E-08
4.20E-20
1.12E-45

1.65E-134 Mylk4
1.24E-18 Trim55
8.31E-15 Otoa

-93.2
-84.0
-75.7

1.44E-37
1.80E-12
1.32E-33
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Chrna1
Rgs8
B3galt5
Gm4737
Sgca
Jsrp1

-79.9
-33.9
-28.4
-27.0
-25.2
-17.9

2.53E-35
3.14E-05
1.74E-05
5.97E-09
1.93E-33
3.60E-30

Lmod2
Ttn
Mymk
R3hdml
Klhl31
Chrng

-1069.2
-640.3
-614.4
-492.8
-398.2
-362.4

5.00E-14
7.50E-117
3.46E-11
1.91E-10
2.21E-16
3.85E-104

Ky
Pitx3
Actc1
Mymk
Plin5
Mybpc2

-67.7
-63.1
-61.1
-57.8
-54.1
-43.1
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2.15E-19
4.12E-07
3.28E-40
5.47E-35
2.13E-06
6.28E-23

Chapter 4 Conclusions and Future Directions
Here we have shown the absolute necessity of MyoD or Myf5 for adult myogenesis.
There are no other genetic or cellular factors that can substitute for them in vivo or in vitro. Mice
with at least a single allele of MyoD or Myf5 can undergo adult myogenesis. This is similar to
developmental myogenesis, where mice lacking both MyoD and Myf5 are born mostly devoid of
skeletal muscle. However, in those mice MRF4 can act as a determination factor and partially
drive developmental myogenesis by turning on Myog and creating some sparse myofibers, as
well as creating multinucleated myotubes in vitro.41 Thus far the only function found for MRF4 in
adult skeletal muscle is control of myofiber size, not in myogenic determination or
differentiation.169 It would be of interest to determine why MRF4 cannot rescue adult
myogenesis in dKO mice, perhaps by investigating its enhancers and chromatin landscape in
satellite cells, as well as potentially forcing its expression in the absence of other MRFs.40
We and other papers have documented in the absence of MyoD, Myf5 has a poor ability
to drive satellite cells to form myotubes in vitro, even though there is only a delay in adult
myogenesis in vivo.100 A recent paper showed that MyoD is much better than Myf5 at recruiting
Pol II at myogenic differentiation genes, but this does not address the large difference between
in vivo and culture.57 This suggests that other factors or cell types help Myf5 drive myogenesis.
We attempted to coculture Myf5-SA satellite cells and FAPs (a cell type crucial for muscle
regeneration), but results were inconclusive.77,220 Future experiments could further test different
cell types or secreted factors present in skeletal muscle after injury, e.g. macrophages and other
immune cells, and their effect on Myf5-SA satellite cells in vitro.
Additionally, we have shown that satellite cells lacking MyoD and Myf5 can
transdifferentiate into mature adipocytes. While this is not completely novel, we are the first to
demonstrate it in adult myogenesis without the use of adipogenic inducing media or
glycerol.43,197,211 Those papers found that MyoD upregulated mir-133, a microRNA responsible
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for inhibiting brown adipocyte programming. The results of our work were inconclusive with
respect to whether dKO satellite cells became brown or white fat, given the lack of specific
brown fat markers in vitro, but finding Prdm16 upregulated 3 dpi in vivo. Further experiments
need to determine the type of fat formed by dKO satellite cells, either by thermogenic testing, or
perhaps laser-capture RNA-seq of mature dKO fat cells, as such cells are lost during FACSisolation. Another issue to address is potential satellite cell heterogeneity. dKO satellite cell fat
formation was highly variable in vivo. This could be due to localized adipogenic inducing
factors, or, given that researchers propose subtypes of satellite cells, a potential intrinsic
difference in different satellite cell sub-populations.88,149,187 Experiments utilizing clonal analysis
and scRNA-seq could help resolve those issues.
dKO satellite cell conversion into fibroblast-like cells, as well as maintaining some
myogenic markers is a more perplexing issue. If dKO satellite cells are becoming fibroblasts
and highly expressing those genes, then are they secreting extracelluar matrix proteins like
tropocollagen? If not, what is preventing that? And given that dKO satellite cells isolated from
uninjured muscle have elevated fibroblast markers, why do aged mice with dKO satellite cells
have no increased fibrosis? Does satellite cell quiescence programming, e.g. Pax7 expression,
prevent that? It could be that these fibroblast-like dKO satellite cells are not really a distinct cell
type, but rather just weird and stuck between cell fates. Satellite cells could be considered
primed for myogenesis, they express three of the four MRFs during development, as well as
Pax7, a gene only found in satellite cells in skeletal muscle.41,87,88 Further experiments deleting
or efficiently knocking down Pax7 in dKO satellite cells could show a greater change of fate,
particularly since removal of Pax7 has been shown to reverse its chromatin remodeling in some
cell types.213
The creation and testing of the MyoDcKO allele gives us a remarkable tool to generate
animals and cells that would not be possible with a constitutive MyoD deletion. This allowed all
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of the experiments documented here, as well as given others in our lab the ability to delete
MyoD during fetal myogenesis or postnatal myogenesis to investigate the loss of MyoD during
those processes. It could also be possible to create other Cre or CreER systems to
preferentially delete MyoD in extraocular muscle with Cre under the control of Pitx2, or in fasttype muscles with Cre under the control of Tbx1.151,221
It would be remiss of me not to mention the following questions and experiments, given
the data I have collected. I ask the reader’s forgiveness, as this data needs to be mentioned,
but does not fit neatly into the chapter narrative I have written. We only studied the muscles of
the lower hind limbs. Skeletal muscle and satellite cells of the head have a different origin and
different behavior compared to the rest of the body.192 It would be interesting to perform similar
experiments on them. At 3 dpi, dKO satellite cells have much lower expression of mitotic
genes, as determined by GO (Table 3.3), their proliferation in culture is also lower at an early
timepoint. MyoD has been found to regulate certain cell cycle genes, both in terms of
stimulating proliferation and inhibiting it.222 The precise networks and mechanics behind
satellite cell activation are not well known. It could be interesting to perform a more detailed
study of cell cycle dynamics in the absence of it and Myf5, even just looking at the RNA-seq
data we generated could possibly elucidate satellite cell activation networks. Also, in culture, I
noticed a fair amount of binucleated dKO satellite cells. They were negative for MyHC and
Myog protein and did not have any myotube-like morphology. This requires further
investigation, as it could a failure of mitosis or mere just senescence as is seen in some Myodnull myoblasts.137 At last, I implore the able reader to further delve into the RNA-seq data, as I
have only scratched the surface. There could be many interesting genes that have novel effects
on adult myogenesis, as well as the potential to build genetic regulatory networks.
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Appendices
Appendix A
Satellite Cell Isolation via FACS and RNA Processing
Adapted from Liu et al. 2015 method.223 This protocol can be used for unlabeled mice, or those
with a GFP reporter. If you have other colors in your mice you need to speak with the Flow
Facilities Manager to ensure your color panel is optimal.
General Equipment and supplies:
Stereomicroscope with fluorescent capabilities
Tissue culture hood
Tissue culture incubator (37°C, 5% CO2)
Water bath (37°C)
Scale
Refrigerated centrifuge with swinging bucket rotor
Benchtop centrifuge dedicated to RNA samples
Clean dissection tools including sharp and blunt scissors and forceps
Sterile plastic culture dishes
Sterile 50 mL, 15 mL, and 2 mL tubes
Sterile microcentrifuge tubes (MCFTs)
Sterile serological pipettes
70 µm cell strainers
Sterile 5 mL FACS tubes with 35 µm cell strainer top
Flow Cytometer with appropriate lasers and detectors for fluors, e.g. BD FACSAria II
Qiashredder columns (Qiagen, 79654)
Agilent TapeStation 2200
Reagents:
Isoflurane
DNase I solution: Dissolve DNase I (Sigma, D4513) in HBSS (ThermoFisher, 14025) to a
concentration of 2000 U/mL, aliquot into MCFTs and store at -20°C.
-For optimal activity DNase I needs 5mM Mg2+. If you are having a lot of cells clumping
together you may try adding that to the digest media.
Sterile water
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Sterile 10X PBS
Make the following the day of:
Muscle dissociation buffer: 2 mg/mL of collagenase II (Gibco,17101-015), 0.3 mg/mL Dispase
(14105-041), 225 µL DNase I solution/per 10 mL, all dissolved in DMEM [high glucose, high
pyruvate] (ThermoFisher, 11995-065)
NOTE: The above is only a starting point as there is significant lot to lot variation for
collagenase II and Dispase activity. Calculate weights to have a final concentration of ~700-800
U/mL of collagenase II, and 11 U/mL of Dispase.
Cold Media: 20% Fetal Bovine Serum [FBS] (HyClone, SH30071.03 [or equivalent]) in DPBS
(Gibco, 14190-250)
Blocking Media: 10% FBS in DPBS
Antibodies:
1° Ab
V-Cam
α-7 integrin
Sca1
CD31
CD45

Manuf.
eBioscience
AbLab
eBioscience
eBioscience
eBioscience

Cat.
13-1061
N/A
12-5981
12-0311
12-0451

Conc.
0.5 mg/mL
1.0 mg/mL
0.2 mg/mL
0.2 mg/mL
0.2 mg/mL

host
rat
rat
rat
rat
rat

clone
429
R2F2
D7
390
30-F11

2°

Manuf.

Cat.

Conc.

host clone

IgG
IgG2a, k
IgG2b, k
IgG2a, k
IgG2a, k
IgG2b, k

Conj.
biotin
647
PE
PE
PE

dilution
1:100
1:1000
1:500
1:500
1:800

IgG

Conj.

dilution

Streptavidin
& Brilliant
V-Cam
Biolegend
405226 0.1 mg/mL N/A N/A
N/A
Violent 421
1:100
The above are only guidelines as dilutions must be determined by titrating the individual
antibodies for every batch/lot before satellite cell isolation. For that see:
https://cancer.wisc.edu/research/wp-content/uploads/2017/03/Flow_TechNotes_AntibodyTitrations_20170918.pdf224
Throughout this protocol samples should be kept cold and on ice, unless otherwise noted. This
is to prevent cell death and slow transcriptional changes.
RNeasy Microkit (Qiagen, 74004)
β-mercaptoethanol (Sigma, M3148-25ML)
High Sensitivity RNA ScreenTape Kit (Agilent)

Sample Prep
1. Anesthetize mouse in isoflurane-containing chamber being careful not to have isoflurane
in direct contact with mouse.
2. Euthanize by cervical dislocation.
a. Handle mice per approved IACUC protocols.
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3. For each sample, aliquot 10 mL of muscle dissociation media in 50 mL sterile conical
tubes.
4. Coat mouse with 70% ethanol to prevent fur from contaminating samples.
5. Remove the skin from the bottom half of the mouse by gently lifting skin away from belly.
and making an incision. Pull the skin until it completely tears away from the top half.
Then pull down past the feet of the mouse and cut the tail off with the blunt scissors.
Finally pull the skin all the way off the feet.
6. Check fluorescence under fluorescent stereomicroscope
a. We use a lot of fluorescent reporters in the Goldhamer lab, so check even if you
are not expecting your mouse to be fluorescently labeled.
7. Dissect total hind limb muscles.
a. Remove the fascia over the tibialis anterior muscles by gently scraping. After
removal of the fascia, gently scrape between the muscles and bone to better
separate them. Finally, cut the muscles as close to the tendon or bone and place
in a 10 mm culture dish containing a small amount of DPBS to maintain muscle
moistness.
8. Mince the muscle with forceps and sharp scissors for 10 min.
a. Try to remove as much connective tissue and fat as possible during mincing.
9. Place samples in individual 50 mL tubes prepared in step 3.
10. Places tubes in clean 37°C water bath for 1.5 hr, making sure that water level is above
the muscle dissociate solution level.
a. Gently swirl samples every 5-10 min.
11. Add 5 mL of cold media to samples to quench digestion.
a. If you are planning on culturing cells do steps 11 through the end in a cell culture
hood or in sterile conditions.
12. Filter samples through 70 µm strainers into new 50 mL conical tubes.
a. If you are having difficulty filtering through the 70 µm strainer, filter it through a
100 µm strainer first.
13. Rinse old sample tube with 10 mL cold media and filter rinse into new sample tubes.
14. Centrifuge samples at 800 g/4°C/5 min and carefully aspirate supernatant.
15. Resuspend in 40 mL DPBS and repeat step 14
a. Be gentle during resuspensions, so as to not lyse cells
16. Perform red blood cell (RBC) lysis by resuspending the sample pellet in 9 mL of sterile
water for ~6 sec and quickly add 1 mL of sterile 10X PBS
a. Perform step 16 quickly, as prolonged exposure to sterile water has potential to
lyse other cells besides RBCs.
b. RBC lysis is not necessary, but will speed up your sort by eliminating events. I
noticed no negative affect on RIN or cultured cells when performed.
17. Add 30 mL of DPBS to samples and repeat step 14.
a. If you have a satellite cell reporter, e.g. the Pax7CreER/+; R26NG/+ mouse, then you
can skip the antibody staining, as you are able to isolate satellite cells efficiently
without other markers.
b. Depending on your experimental aims, you may want to use a reporter mouse,
e.g. after injury satellite cell marker expression may shift.
18. For antibody staining resuspend the samples in 1 mL block and let incubate on ice for 15
min.
a. While samples are incubating prepare and label the following MCFTs:
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Name
Contains
Volume of Sample (µL)
WT
No antibodies
80
PI
No antibodies
80
PE
Sca1, CD31, CD45
80
A647
α-7 integrin
80
BV421
V-Cam
80
PE-FMO
α-7 integrin, V-Cam
80
A647-FMO
Sca1, CD31, CD45, V-Cam
80
BV421-FMO
α-7 integrin, Sca1, CD31, CD45
80
Sample-All
α-7 integrin, Sca1, CD31, CD45, V-Cam
Remaining Sample Vol
FMO stands for fluorescence minus one. It is an important control that must be used in order to
set appropriate gates. The volume of sample is a suggestion, you merely need to have enough
cells in those controls to set the lasers/voltages, compensations, and gates
19. Add samples to the labeled MCFTs as indicated above and add antibodies per dilutions
mentioned under reagents.
a. It is easier to have intermediate stock solutions of most of the antibodies, as the
dilutions can be very large. In that case make the intermediate stock solutions in
block.
b. Use non-fluorescent mice for the above single color controls. If you are using a
mouse with a fluorescent reporter you need to add Reporter-only and ReporterFMO controls for every color in your mouse.
c. If you are only sorting fluorescent mice, you still need an unlabeled mouse to set
area scaling on the flow cytometer.
d. Controls need only be done on one mouse if all mice to be analyzed/sorted are
similar. In the case of analyzing significantly different mice, e.g. a 18 month old
mouse vs. a newborn, then FMOs should be prepared for both conditions.
e. DO NOT USE ISOTYPE CONTROLS! They are 100% useless for isolating and
analyzing satellite cells.
20. Incubate samples in antibodies for 30 min on ice with gentle mixing at 15 min.
21. Add DPBS up to 1 mL in all MFCTs.
22. Centrifuge samples at 800 g/4°C/5 min and aspirate supernatant.
23. Resuspend all MCFTs up to 1 mL with DPBS and repeat step 22.
24. Resuspend samples to original volumes from step 19.
25. Add V-Cam “2°” to all V-Cam containing samples.
a. Do not add to V-Cam FMO!
26. Repeat steps 20-23.
27. Resuspend samples in 2% FBS in DPBS to a final volume of ~400 µL for the controls
and ~800 µL for samples to be sorted or analyzed.
28. Filter samples through 35 µm blue capped FACS filter tubes and bring to Flow
Cytometry Facility.
a. If samples are difficult to filter, dilute them with 2% FBS solution.
29. Add 1:20 by volume dilution of 100 µg/mL PI (propidium iodide) for cell viability to FMOs,
and Sample-All.
a. PI is made by flow facility
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Cell Gating and Sorting
1. Make sure settings on flow cytometer are set for what you want to do.
a. General rule: nozzle size should be no smaller than 5X diameter of the cell.
Uninjured satellite cells are 10-12 µm in diameter in suspension. I’ve used 85 µm
nozzle with success. Smaller nozzles exert more pressure on cells but allow for
faster sorting.
b. Sorting cells for RNA analysis should be done with a relatively low threshold in
FSC to ensure that only cells of interest are collected, and not debris. Culturing
of cells does not require such a low threshold, as debris will be washed away
when cultures are fed, and a higher threshold will make the sort faster. I used a
5,000 FSC threshold when sorting cells for RNA-seq samples.
c. When sorting there is a balance between flow rate and sample collection time.
The faster the flow rate the faster the sort, but your cells could be damaged, and
the sorter can have difficulties sorting cells.
d. If samples are clogging instrument, dilute and refilter.
2. Run single color controls and compensate before sorting.
a. If only analyzing samples, compensation can be done after data collection.
b. See here for more information about compensation:
https://www.bdbiosciences.com/documents/Compensation_Multicolor_TechBullet
in.pdf225
3. Run FMOs.
a. Collect enough events to see populations emerge. I collected ~30-50k for this.
b. Gates should be set to exclude (or include in Lin- case) the negative population.
4. Set gates in this order (See below for progression):
a. Live gate: PI vs FSC-A
i. Collecting cells that exclude PI, have intact membranes and are alive
b. Single Cells gate: FSC-H vs FSC-W
i. Collecting only single cells, not cells aggregates/doublets.
c. Scatter gate: SSC-A vs FSC-A
i. This gate is determined by back gating and allows for cleaner gates
downstream.
1. You would initially skip this gate and then add via backgating.
d. Lin- gate (CD31-/CD45-/Sca-1-): PE-A vs SSC-A
i. This gate selects cells negative for non-satellite cell markers.
1. However, Sca-1 protein is found on some satellite cells. So you
might be able to get away without staining for it.
e. ++ gate (α7-integrin+/V-Cam+): BV421 vs A647
i. These are satellite cells.
5. Sort cells in sterile 5 mL tube containing ~0.5 mL and coated with 10% FBS in DPBS.
a. Plate cells as soon as possible after sorting to maintain their viability.
i. Centrifuge samples at 800 g/4°C/5 min aspirate supernatant and
resuspend in GM before plating.
b. Alternatively, cells can be sorted directly into Matrigel-coated plates containing
GM.
i. This must be done when performing single cell cultures.
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c. I was able to get upwards of 80-90k satellite cells from a single uninjured adult
wildtype mouse with this method. However, sorting that many cells took over an
hour per mouse, and that was on a good day.
6. For RNA analysis cells can be sorted as per step 5.
a. Sorting directly into lysis buffer was recommended, but collecting cells in 10%
FBS and processing them in lab gave RINs over 8.0, good enough for RNA-seq.
b. As soon as enough cells are collected for a sample, process the sample.
Someone else can supervise the instrument while your next sample is sorting.
c. Always determine the RIN of a test sort of unimportant samples before you move
to your experimental samples. There are many places RNA
contamination/degradation can happen.
d. Collect as many cells as possible for RNA-analysis. The more RNA you have, the
better. Depending on the number of cells per sample, you may have to use a
different RNA processing kit. See kit guidelines for details.

Gating Progression:

FMOs:
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Appendix B
RNA Processing of FACS-Isolated Cells
1. Perform all RNA steps in a clean RNase-free environment. Do not talk or dawdle when
processing RNA samples. RNA is easily degraded and that can affect your results.
2. Centrifuge sample at 800 g/4°C/5 min and aspirate supernatant.
3. Resuspend in 700 uL DPBS and transfer to MCFT for easier pipetting and repeat step 2.
4. Resuspended in 700 uL of RLT lysis buffer from RNeasy Microkit.
a. efore resuspension add 10 µL of β-mercaptoethanol to every 1 mL of RLT lysis
buffer to reduce and denature RNases.
5. Transfer samples to Qiashredder columns and centrifuge in RNA-only tabletop
centrifuge at 16.1 g/2 min
a. Samples can be stored in -80°C freezer for future processing.
6. Follow the rest of the steps in the RNeasy Microkit manual.
a. Perform the DNase step to eliminate gDNA.
7. Purified RNA can be stored at -20°C for several weeks.
8. Analyze RNA on Agilent TapeStation 2200 following High Sensitivity RNA ScreenTape
manual.
a. May have to use other ScreenTape kit based on RNA amount. Though this
worked well for me with FACS-isolated cells.
b. See below for examples of low-quality and high-quality RNA.
9. RNA-seq requires RINs > 8.0, qRT-PCR requires RINs > 4.0
Gel with high (>8.0) and low (<4.0) quality RNA:
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High and low quality

Appendix C
Bulk RNA-seq Analysis
In life there are many ways to skin a cat, and many ways to analyze bulk RNA-seq data. They
all have their pros and cons, so read up on them before performing your analysis. READ THE
MANUAL OR VIGNETTE FOR EACH PROGRAM BEFORE ANALYZING YOUR DATA! I
cannot stress this enough. There are many details that are important in analyzing RNA-seq
data, e.g. single-end vs paired-end, strandedness, reference genome used, etc. That said, if
you can increase the number of biological replicates, then do it. All methods in RNA-seq work
better when your n is larger. I performed my analysis in Galaxy (https://usegalaxy.org/), a free
online graphical user interface, and RStudio, but you can use command line and R to do the
same thing. You need access to a cluster for computing and storage purposes, because
sample file sizes are very large and processing them generates more large files. UConn has
several options for that. My data was generated by pooling samples and using the Illumina
TruSeq Stranded mRNA sample preparation kit Set A. If you meet me and tell me what page
this is on I will buy you a drink [Must be claimed by 01/2025]. The samples were sequence on
an Illumina NextSeq 500, averaging ~130 million paired-end reads per sample. The library prep
and sequencing were performed by the Center for Genome Innovation at UConn. The general
analysis workflow is as follows:

1. Run FASTQC on samples. (FASTQ file input, webpage output)
a. (FASTQ Galaxy Version 0.72)226
b. If sample files are from different lanes, then run FASTQC on individual files to
determine if there any lane-specific issues.
c. Look at each QC item to determine if there are any issues.
d. Can concatenate sample lanes after this step or after mapping to genome.
2. Trim adapters and low-quality bases using Trimmomatic (FASTQ file input and output)
227
.
a. Illumina usually trims adapters for you when your samples are uploaded to their
BaseSpace platform after a run.
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b. There are many ways to do this, and you may have to try several methods to
eliminate low-quality bases without trimming too much good data.
c. My settings (Trimmomatic Galaxy Version 0.36.5):
i. Paired-end (two separate input files)
ii. R1 and R2
iii. Perform Illuminaclip Step:
1. No
iv. Trimmomatic Operation
1. Select Trimmomatic operation to perform:
a. Trim reads adaptively, balancing read length and error rate
to max the value of each read (MAXINFO)
i. Target read length:
1. 50
ii. Strictness:
1. 0.8
3. Run FASTQC on trimmed reads to ensure quality
4. Align paired-trimmed reads to reference genome with RNA STAR.180 (FASTQ input,
BAM output)
a. There are many other options for this, e.g. HISAT2. Read and find what is best
for your work.
b. You need a reference genome for this, there are again several options, but be
consistent with your reference genome for all steps. I used mm10 from UCSC.
c. Optional: you can use a gene model (gtf file) as a guide. I used Illumina’s
IGenomes.gtf for mouse, which can be found on Illumina’s website.
d. My settings (STAR Galaxy Version 2.5.2b-0):
i. Single-end or Paired-end:
1. Paired-end
ii. Custom or built-in reference genome:
1. Built-in:
a. mm10
i. Gene model (gff3, gtf) for splice junctions
1. IGenomes.gtf (from Illumina)
ii. Length of the genomic sequence around annotated
junctions
1. 100
iii. Count number of reads per gene:
1. No
iv. Would you like to set output parameters?
1. Yes
a. Extra SAM attributes to include
i. Standard
b. Include strand field flag XS:
i. No
c. Filter alignments containing non-canonical junctions
i. Remove alignments with non-canonical junctions
d. Would you like to set additional output parameters:
(format/filter)
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i. No
v. Other Parameters (seed, alignment, and chimeric alignment)
1. Use Defaults
e. Check the results of this step to see what percent of reads were mapped. You
should have >85% reads mapped uniquely.
5. If you want to quantify your samples for something like transcripts per million (TPM) you
can use a program like Salmon, otherwise go to step 6 to generate counts for differential
gene expression.228 (FASTQ input, TSV output)
a. For this you need a reference transcriptome, I used UCSC’s version.
i. You must normalize the reference genome in Galaxy.
b. You also require a file that maps transcripts to genes in order to get TPMs. You
can get this from UCSC as well.
c. My settings (Salmon Galaxy Version 0.8.2):
i. Select reference transcriptome:
1. Normalized UCSC ref
ii. Is this library mate-paired:
1. Paired-end
iii. Relative orientation of reads within a pair:
1. Mates are oriented toward each other (I = inward)
iv. Specify the strandedness of the reads:
1. Read 1 comes from the forward strand (SF)
v. Type of index:
1. Quasi
vi. Perfect Hash:
1. No
vii. Suffix Array:
1. 1
viii. Perform sequence-specific bias correction:
1. No
ix. Perform fragment GC bias correction:
1. No
x. File containing a mapping of transcript to genes:
1. UCSC mapping file (.txt file)
6. Assign mapped reads to genomics features with featureCounts.181 (BAM input, TSV
output)
a. HTSeq is another option for this. Downstream coding is different between the
two.
b. My settings (featureCounts Galaxy Version 1.4.6.p5):
i. Alignment file: output of RNA STAR
ii. Gene annotation file
1. IGenomes.gtf (mm10)
iii. Output format
1. Gene-ID “\t” read-count (DESeq2 IUC wrapper compatible)
iv. Create gene-length file
1. Doesn’t matter (maybe yes)
v. Options for paired-end reads
1. Count fragments instead of reads
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a. Enabled; fragments (or templates) will be counted instead
of reads
i. Check paired-end distance
1. No
ii. Only allow fragments with both reads aligned
1. No
iii. Orientation of the two read from the same pair
1. Forward, Reverse (fr)
iv. Exclude chimeric fragments
1. Yes
vi. Advanced options
1. GFF feature type filter
a. Exon
2. GFF gene identifier
a. Gene_id
3. On feature level
a. NO
4. Allow read to contribute to multiple features
a. No
5. Strand specificity of the protocol
a. Stranded (reverse)
6. Count multi-mapping reads/fragments
a. Disabled; multi-mapping reads are excluded
7. Minimum mapping quality per read
a. 12
8. Largest overlap
a. No
9. Minimum overlap
a. 1
10. Read 5’extension
a. 0
11. Read 3’ extension
a. 0
12. Only count primary alignments
a. No
13. Ignore reads marked as duplicate
a. No
14. Ignore unspliced alignments
a. No
7. Perform differential gene expression with DESeq2.182 (TSV input, CSV+++ output)
a. EdgeR is another option. Both will give good results but use different methods to
determine differentially expressed genes (DEGs).
b. This can be done on a personal computer, it is not computationally intensive and
does not involve large files. I used RStudio (Version 3.5.0) for this and followed
the DESeq2 (Version 1.20.0) Vignette:
https://www.bioconductor.org/packages/devel/bioc/vignettes/DESeq2/inst/doc/DE
Seq2.html
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c. The following is the code I used for DESeq2 DGE analysis. # represent
comments.
d. You should perform quality control steps like PCA analysis or making a heatmap
of sample correlations to see how closely your biological replicates are to one
another. This is all covered in the vignette.

#Install and load the following package:
library(DESeq2)
#Load featureCounts intro RStudio as a variable. It should be a text file.
countdata <- read.table("featureCountsoutput.txt", header=TRUE, row.names=1)
#Check your data
head(countdata)
#convert data.table into matrix
countdata <- as.matrix(countdata)
head(countdata)
#Set what you want to compare as the condition with the number of replicates
condition <- factor(c(rep("dHET", 2), rep("dKO", 2)))
#Set sample information
coldata <- data.frame(row.names=colnames(countdata), condition)
#Create DESeqDataSet
dds <- DESeqDataSetFromMatrix(countData = countdata, colData = coldata, design=
~condition)
dds <- estimateSizeFactors(dds)
#Can generate DESeq2 normalized counts for data visualization and interpretation
normalized_counts <- counts(dds, normalized=TRUE)
write.table(normalized_counts, file="normalized_counts.txt", sep="\t", quote=F, col.names=NA)
#Perform actual DGE
et <- DESeq(dds)
#Generate results
res <- results(et))
#Can also do log fold change shrink of results to visualize and rank genes. I got good results
with the ashr method.
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resLFC <- lfcShrink(et, coef="condition_dKO_vs_dHET", type="ashr", res = res)
#Write results as CSV files that you can look up in Excel
write.csv(as.data.frame(res), file="norm 12 dpi results.csv")
write.csv(as.data.frame(resLFCashr), file="12 dpi resultsLFCashr.csv")

There are many ways to visualize the data from DESeq2. Read the vignette and other protocols
online for more information.

RNA-seq analysis flowchart:
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Galaxy flowchart:

Integration of ChIP-seq and RNA-seq data with BETA
-ChIP-seq data was preprocessed (QC, aligned to mm10 genome, and peaks called with
MACS2) by the Cistrome database.229
-Peak bed files and RNA-seq DESeq2 results were uploaded onto Galaxy/Cistrome GUI and
analyzed thusly:
-BETA-basic: Used for binding and expression target analysis
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Notes:
-Distance from the gene TSS is set to 100kb
-Looking for genes that have adjusted p-values < 0.05
-Looking at all the genes listed
-However, I did not include genes whose fold changes were < 2-fold
-Output files are Predicted direct targets both upregulated and downregulated, and upregulated
and downregulated associated peaks. All are text files and contain the genes of interest and
their scores.
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